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I. 1) TYPE I INTERFERONS SUPERFAMILY 
  
In 1957, Alick Isaacs and Jean Lindenmann discovered interferon (IFN). In 
their experiment they showed that a supernatant, derived from chick 
chorioallantoic membranes and incubated with inactivated influenza virus, 
was capable of protecting other membranes from infection by active virus (1). 
This supernatant contained soluble protein factors capable of inducing a 
variety of biological functions, called IFNs. The classical function of these 
proteins is the protection against viral infections. Exposure of cells to viruses 
and doublestranded RNAs induces the production of IFN-α and IFN-β. 
However, it emerged soon the ability of IFNs to be involved in other 
biological processes: cell differentiation, cell growth control, modulation of 
immune system, and anti-tumor defense (2-5). 
There are two major categories of IFNs: type I and type II. IFN-γ is the only 
type II IFN, whereas the type I IFNs consist of four major classes: IFN-α, 
IFN-β, IFN-τ and IFN-ω. This thesis will focus on human type I IFNs, in 
particular the antitumor role of IFN-α and IFN-β in endocrine and non-
endocrine cancers. IFN-α comprises a family of different cytokines. There are 
at least 14 human IFN-α non allelic functional genes found on the short arm 
of the chromosome 9. They encode for 13 different human IFN-α proteins 
(IFN-α1, IFN-α2, …) with IFN-α1 and IFN-α13 resulting in the identical 
final protein. All proteins have 166 amino acids except IFN-α2, which 
contains 165 subsequent to a deletion at position 44. Some of these subtypes 
have variant forms (6). The various human IFN-α species have 75-99% amino 
acids sequence identity and are also highly species-specific with regard to 
biological properties (6). The human IFN-β gene is present as a single copy 
also on chromosome 9. The protein is composed of 166 amino acids and there 
is only approximately 30% amino acid sequence identity between IFN-α and 
IFN-β (6). A three dimensional, high resolution structure of IFN-α2a (fig.1) 
has been generated using heteronuclear NMR spectroscopy (7). In addition, 
X-ray crystallographic structures have been determined for human IFN-α2b 
(fig.2) (8) and natural IFN-β (fig.3) (9). The tertiary structure of type I IFNs 
contains multiple helices (fig.1-3). However, unlikely the four helices 
commonly found in other α-helical cytokines, all type I IFNs display a 
conserved core of five helices (A-E) and one long connection (AB2 loop). 
The most conserved feature of type I IFNs is the disulfide bond. In IFN-α and 
IFN-β there are two and one disulfide bonds, respectively. These have an 
important role in the stabilization of the molecule (7-9). Human IFN-α2b and 
IFN-β (fig.2,3) exist in the crystal as a noncovalent dimer, through extensive 
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interactions mediated by a zinc ion (Zn2+). The IFN-β dimer is different from 
the IFN-α2b dimer in that the two molecules are not related by a twofold axis, 
but by a rotation of about 44° along an axis approximately perpendicular to 
the plane defined by helices C, B, and D. Thus whereas IFN-α2b dimerizes 
with the same contact surface (helix D and AB loop), IFN-β dimerizes with 
contact surfaces from opposite sides of the molecule. However, the biological 
significance of these dimers and the different interactions with the receptor 
are unclear (8,9). 
 
 
Figure 1: Three dimensional structure of 
human IFN-α2a (ref 7) 
 
Figure 2: Three dimensional structure of human IFN-α2b. Extensive interactions in 
the dimmer interface are mediated by a zinc ion (Zn2+) (ref.8). 
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Finally, unlike IFN-α, natural human IFN-β (fig.3) contains a single site, 
asparagine 80, through which N-linked glycosylation can occur and which has 
been shown to vary according to the cells in which IFN-β is synthesized (10-
11). It is thought that glycosylation plays important roles in facilitating IFN-β 
secretion from cells, in increasing its solubility and stability, and in its 
metabolism in vivo (11-16). 
At present, only two recombinant alpha IFNs (IFN-α2a and IFN-α2b) are 
available as registered drugs; both appear to have equal activity. Similarly, 
two types of recombinant human IFN-β are currently in clinical use. IFN-β1b 
is produced in Escherichia coli bacteria, and as bacteria lack the ability to 
glycosylate proteins, it is not glycosylated. Furthermore, IFN-β1b has an 
amino acid sequence different from the natural human IFN-β; it has a 
cysteine-to-serine substitution at position 17 and a deletion of the N-terminal 
methionine residue. In contrast, IFN-β-1a is produced in mammalian cells, 
with an amino acid sequence and glycosylation identical to that of natural 
IFN-β. It has been observed that non-glycosylated IFN-β1b is much more 
susceptible to aggregation and is more immunogenic (17). When the protein is 
not glycosylated, the hydrophobic domain is exposed and the protein will 
have a tendency to form aggregates as an alternative way to shield this 
surface, and formation of aggregates is one of the more effective ways to 
increase the immunogenicity of proteins (18). However, non-glycosylated 
Figure 3: Three dimensional structure of human IFN-β. The modeled 
portions of the carbohydrates and zinc ion (Zn2+) are also shown (ref.9) 
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IFN-β1b, although more hydrophobic than glycosylated IFN-β1a, retains 
biological activity but with lower specific activity (19,20). 
 
 
 
I. 2) TYPE I INTERFERON RECEPTOR 
 
All the cellular effects of type I IFNs appear to be modulated by a common 
receptor complex, present in low numbers (100-5000 molecules/cell) on the 
surface of all vertebrate cells examined and composed by two chains (IFNAR-
1 and IFNAR-2) that dimerize following the interaction with the ligand (fig.4) 
(6). 
 
 
 
 
Figure 4: Signal transduction pathways activated by type I IFNs. 
IFNα/β, after the interaction with its receptor (AR-1 + AR-2c), activates the tyr kinase Jak-1 
and Tyk-2 that are responsible for the activation of the cytoplasmic targets of type I IFNs. 
The tyr phosphorylation of the targets causes the translocation to the nucleus of STAT-1 and 
STAT-2 hetero and homodimers, that migrate to the nucleus and bind to DNA mediating the 
transcription of several genes. Receptors consisting in AR-1 + AR2-b interact with type I 
IFNs, without transducing signals. 
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Mature human IFNAR-1, resulting from removal of the peptide sequence 
leader, is a 530 amino acid residue integral membrane protein. IFNAR-1 is 
considered the signaling subunit and it exists as the full chain. The IFNAR-2 
is the subunit responsible for the interaction with the ligand. Three forms of 
IFNAR-2 have been isolated, as differentially spliced products of the same 
gene (fig.4): the soluble (IFNAR-2a), short (IFNAR-2b) and long (IFNAR-2c) 
form (21-23). The full length receptor chain (IFNAR-2c), comprised of 487 
amino acids, together with IFNAR-1 subunit constitute the predominantly 
active form of the type I IFN receptor complex (fig.4). IFNAR-2c is capable 
of binding ligand, but with a lower affinity (20-fold less) than the dimeric IFN 
receptor complex itself (24). Therefore, both receptor chains are required to 
form a high affinity binding site and initiate signal transduction. The short 
form (IFNAR-2b), consisting of 303 amino acids of which only 67 residues 
are in cytoplasmic portion of the molecule, is able to bind type I IFNs, but 
does not couple to signal transduction because it lacks the signal transducing 
tail of IFNAR-2c (25). The soluble form (IFNAR-2a), lacking of the 
transmembrane and cytoplasmic portions, may act as a regulator of free IFNs 
and, depending on concentration, lead to the neutralization or enhancement of 
IFN bioactivity (26,27).  
After the IFNAR-1 and IFNAR-2c dimerization (fig.4) two intracytoplasmic 
receptor-associated kinases (Tyk-2, associated with IFNAR-1, and JAK-1, 
associated with IFNAR-2c) are activated and their activation induces the 
tyrosine phosphorylation of the receptor itself. In this way the tyrosine 
phosphorylated sites of the IFN receptor become docking elements for Src 
homology 2 (SH2) and phosphotyrosyl-binding domain-containing proteins 
present in the membrane or the cytoplasmic compartment (6). Prominent 
among these are the Signal Transducer and Activator of Transcription 
(STATs). These are a family of latent cytoplasmic transcription factors 
involved in cytokine, hormone, and growth factor signal transduction (28-32). 
STAT proteins mediate broadly diverse biological processes, including cell 
growth, differentiation, apoptosis, fetal development, transformation, 
inflammation, and immune response. Receptor-recruited STATs are 
phosphorylated on a single tyrosine residue in the carboxyl terminal portion. 
The modified STATs are released from the cytoplasmic region of the receptor 
subunits to form homodimers or heterodimers through reciprocal interaction 
between the phosphotyrosine of one STAT protein and the SH2 domain of 
another. Following dimerization, STATs rapidly translocate to the nucleus 
and interact with specific regulatory elements to induce target gene 
transcription (28-32). 
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IFN receptor activation classically leads to the phosphorylation and activation 
of STAT-1 and STAT-2 (fig.4). STAT-1 and STAT-2 form a heterodimer that 
associates with another cytoplasmatic protein, p48, resulting in the formation 
of the mature interferon-stimulated gene factor 3 (ISGF3) complex that 
translocates to the nucleus to initiate gene transcription by binding to 
interferon-stimulated response elements (ISRE) (33). STAT 1:1 homodimers, 
STAT 3:3 homodimers, STAT 1:3 heterodimers, STAT 5:5 homodimers, and 
CrkL:STAT-5 heterodimers are also activated during engagement with type I 
IFN receptor/IFN-α/β complex. These dimers move to the nucleus where they 
bind to gamma-activated sequence (GAS) regulatory elements in the 
promoters of IFN-activated genes (33,34). Thus, signalling specificity via the 
IFN-activated Jak/STAT pathway is established by the formation of multiple 
different complexes that activate distinct regulatory elements in the promoters 
of IFN-regulated genes. This is the most intriguing aspects of the function of 
type I receptor: its ability to discriminate the various types and subtypes of 
IFN and to elicit different biological responses. This could be partially 
explained by the different interactions of IFN-α/β with the common receptor 
complex. IFN-β induces a real association between IFNAR-1 and IFNAR-2, 
while IFN-α1, -α2, -α6, -α7 and -α8 do not (35). However, in spite of 
intensive studies, the interactions between IFNs and their receptor complex 
and the molecular mechanisms underlying the functional biological 
differences among the IFNs are still largely unknown. More clear are the 
direct biological effects inducing growth inhibition: stimulation of apoptosis, 
translational and posttranslational modifications of the proteins and cell cycle 
arrest. The variability in these direct responses may be influenced by cell type 
specific differences in STAT complement, availability of coactivators and 
oncogenic alterations present in the target cell (36). 
 
 
 
I. 3) INDUCTION OF APOPTOSIS 
 
Apoptosis plays an important role in the control of many normal physiological 
processes, such as embryonic development, immune regulation and 
maintenance of tissue homeostasis (37). Decreased sensitivity to apoptotic 
stimuli is a trait commonly shared by cancer cells. This feature provides the 
tumour cells with a survival advantage, facilitating the out-growth of 
malignant clones and may also explain a variable susceptibility to various 
anti-cancer drugs (38,39). Type I IFNs induce apoptosis in different ways 
(fig.5), influencing the death receptor (extrinsic pathway) and the 
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mitochondrial pathway; in this way, it could play a role in the antitumor 
activity and clearing of virus-infected cells (40, 41). 
 
 
Figure 5: The regulation of apoptosis and cell cycle by the type I IFNs. Activation of STAT 
pathways by the type I IFN/tyrosine kinases (Jak/Tyk-2) complex leads to induction of 
proapoptotic machinery through caspase cascade activation depending upon Fas system up-
regulation, Jnk1/p38 stimulation or still unidentified mechanisms; inhibition of cell cycle 
progression via p21/p27 increased expression, suppression in the phosphorylation of pRb, 
p130 and p107. 
 
 
 
The Extrinsic Pathway 
Apoptosis can be mediated by the activation of death receptors belonging to 
the tumor-necrosis factor (TNF) receptor family (fig.5). Members of the TNF 
receptor family share a common internal domain, the so-called death domain, 
and are activated by several ligands, including TNF-α, Fas ligand and TRAIL 
(TNF-related apoptosis-inducing ligand). The interaction between receptor 
and ligand recruits FADD (Fas-associated death domain protein) and pro-
caspase-8 to the death domain forming the DISC (death-inducing signaling 
complex). At the DISC, cleavage of procaspase-8 yields the active form of 
this protease. In type I cells, the amount of activated caspase-8 is sufficient to 
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initiate apoptosis via direct activation of the central effector caspase-3 
(40,41). 
In myeloma, as well as in glioma cell lines, long term treatment with IFN has 
been suggested to sensitive the cells to Fas-induced apoptosis (42,43). 
Moreover, the Fas ligand/receptor system may mediate effects of IFN-α2 in 
basal cell carcinoma (44). In fact, after injection of IFN-α2 into basal cell 
carcinomas, Fas receptor and apoptosis were induced, and tumours regressed. 
However, Chawla-Sarkar et al. have recently demonstrated that IFN-β is a 
stronger Fas system and apoptosis inducer than IFN-α in melanoma cells (45). 
Similar data were obtained by Sanceau et al. in sarcoma cell lines in which 
IFN-β induces p38 MAPK-mediated Ser 727 STAT-1 phosphorylation and 
apoptosis more efficiently than IFN-α (46). Studies on T cells have shown a 
downregulation of FLICE-like inhibitory protein (FLIP) and inhibitor 
apoptosis proteins (IAP), both inhibitor regulators of apoptosis process, 
following treatment with IFN-β (fig.5) (41). Despite these biological 
differences the molecular basis of the diversity between IFN-α and IFN-β in 
the induction of apoptotic events is still unknown. 
 
The Mitochondrial Pathway 
In type II cells, the signal enhancing-effect of mitochondria is needed to 
induce the full apoptotic process. The detailed molecular background to IFN-
induced apoptosis remains unclear, but it was demonstrated that it also 
involves an ordered activation of mitochondrial pathway, as shown by the 
release of cytochrome c (cyt c) and the association with apoptosis-activating 
factor 1 (Apaf-1) and procaspase-9 to form the apoptosome complex. This 
leads to the activation of caspase-9, which induces in turn executioner 
caspases (caspases-3, -6, -7) (fig.5) (47). 
Moreover, Thyrrell et al. have demonstrated that IFN-α-induced apoptosis is 
not inhibited by antagonistic antibodies to the Fas-receptor and, thus, it is a 
Fas-independent effect (32). 
In a similar experimental model, Panaretakis et al. have showed that IFN-α-
induced apoptosis occurs together with the activation of the pro-apoptotic 
Bcl-2 related proteins Bak and Bax (48). However, Bak activation occurred 
early in the apoptotic response, prior to the cytochrome c release and loss of 
mitochondrial membrane potential, whereas Bax activation followed these 
events (49). The same authors showed a transient initial increase of two 
inhibitors of apoptosis (Bcl-xL and Mcl-1), that could explain the late onset of 
the apoptosis induced by IFN-α (49). Taken together these results suggest a 
mitochondrial involvement in the apoptosis triggered by type I IFNs (50). 
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The Stress Kinase Cascade Involvement 
There are indications that other pathways affecting the regulation of apoptosis 
can also be modulated by type I IFNs. In eukaryotic cells enzymatic isoforms 
of MAPK, such as Jun kinase-1 (JNK1) and p38 kinase, mediate 
antiproliferative stimuli and apoptosis. They have large sequence homology, 
but are functionally different from proliferative pathway-associated Erk-1/2. 
In fact, JNK1 and p38 kinase are part of enzymatic cascades activated by anti-
proliferative agents such as ionizing and ultraviolet rays and cytokines.  
In this regard, there are several evidences that type I IFNs activate members 
of the MAPK family, including Erk (51), the p38 MAPK (that belongs to the 
stress-activated kinases) and JNK-1 (52-54). In addition, p38 seems to be 
essential for the transcription of IFN-dependent genes, independently of 
activation of STAT protein (52-55). 
It was, moreover, found that p38 MAPK pathway is engaged in type I IFN 
signalling in primary human hematopoietic progenitors and its function is 
required for the generation of the suppressive effects of IFNs on normal 
hematopoiesis (56). Moreover, p38 MAPK, is involved in the generation of 
the antileukemic effects of IFN-α in break cluster region (BCR)-ABL-
expressing cells of acute myeloid leukemia (57).  
Another gene involved in the IFN-mediated apoptosis is the tumour 
suppressor gene p53. Takaoka et al. (58) have recently shown that 
transcription of the p53 gene is induced by IFN-α/β, accompanied by an 
increase in p53 protein level. IFNα/β signalling itself does not activate p53; 
rather, it contributes to boosting p53 responses to stress signals. In these 
experimental conditions p53 gene induction by IFN-α/β contributes to tumour 
suppression, is activated in virally infected cells to evoke an apoptotic 
response and is critical for antiviral defence of the host (58). 
Finally, the role of NF-kB in the apoptosis induced by IFN-α is controversial. 
In fact, it has been demonstrated that IFN-α a can activate NF-kB through 
STAT-3 and via phosphatidylinositol 3 kinase (PI3K) and Akt activation in 
lymphoma cells and promotes survival of human primary B-lymphocytes via 
PI3K (59). Other studies demonstrate that IFN-α sensitizes human hepatoma 
cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kB 
inactivation or suppresses the antiapoptotic effect of NF-kB and sensitizes 
renal cell carcinoma cells in vitro to chemotherapeutic drugs (60,61). 
For a summary see Table 1. 
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Table 1. Modes by which type I IFNs induce apoptosis 
 
   
General Mechanism Molecular target Ref 
 
  
 
  
 
Fas Receptor/Ligand 42-45 
Cyt-c release and loss of mitochondrial 
membrane potential 
 
47 
 
Death receptor and 
mitochondrial involvement 
 
Fas-independet Caspase 9 activation 
 
32 
 Bak and Bax activation 48 
   
 P38 kinase and consequent activation of 
MapKapK-2 
 
52-54 
   
 JNK-1 and P38 kinase 55 
Stress kinase cascade P53 58 
 STAT-3->NF-kB->Akt 59 
 -Sensitization to TRAIL 
- DR5 increase->NF-kB inactivation 
 
60-61 
   
 
 
 
I. 4) TRANSLATIONAL AND POST-TRANSLATIONAL MODIFICATIONS OF 
PROTEINS 
 
Protein kinase dependent from double-stranded RNA (PKR) 
IFNs regulate at the transcriptional level more than 200 gene products that 
determine their responses. The protein kinase dependent from double-stranded 
RNA (PKR), involved in protein synthesis regulation, is one of gene 
stimulated by type I IFNs. Human PKR is a serine-threonine kinase of 551 
amino acid residues, implicated in the promotion of cell death mediated by 
double-stranded RNA. Once activated, PKR phosphorylates exogenous 
substrates. The best characterized substrate of PKR is the small subunit of the 
eukaryotic initiation factor 2 (eIF2). PKR inhibits translational initiation by 
phosphorylating eIF2 on serine (62). Additionally, PKR also regulates the 
action of several transcription factors such as NF-kB, IRF-1, p53, STAT-1 
and NF-90. Modulation of all of these different targets allows PKR to control 
diverse cellular processes, such as cell growth (63), differentiation (64) and to 
exert antitumour activity (65), by induction of cell cycle arrest and, mainly, of 
apoptosis. In fact, PKR activation regulates translational and transcriptional 
pathways (eIF-2a and NF-kB-dependent) resulting in the specific expression 
of selected proteins (Fas, p53, Bax and others) that trigger cell death by 
engaging with the caspase pathway (66). 
 
The eukaryotic initiation factor-5A of protein synthesis (eIF-5A) 
The eIF5A belongs to a family of translational factors that are involved in the 
regulation of cell growth. eIF5A is peculiar because its activity is modulated 
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by a series of post-translational modifications that culminates in the formation 
of the unusual amino acid hypusine. Hypusine [Nε-(4-amino-2-
hydroxybutyl)lysine] is formed by the transfer of the butylamine portion from 
spermidine to the ε-amino group of a specific lysine residue of eIF-5A 
precursor and by the subsequent hydroxylation at carbon 2 of the incoming 4-
aminobutylmoiety (67). eIF-5A probably acts in the final stage of the 
initiation phase of protein synthesis by promoting the formation of the first 
peptide bond (68). Hypusine plays a key role in the regulation of eIF-5A 
function. In fact, only the hypusine-containing eIF-5A form is active and, 
consequently, the dosage of intracellular hypusine content measures also the 
activity of eIF-5A, since hypusine is contained only in this factor (69). The 
correlation between hypusine, eIF-5A activity, and cell proliferation suggests 
that activated eIF-5A might play a role in cell growth and differentiation (70). 
The cell proliferation regulatory properties of eIF-5A could be correlated by 
its reported mRNA chaperon functions since eIF-5A is involved in the 
transport of mRNAs from the nucleus to the cytoplasm (fig.5) (71). It has 
been also proposed that these mRNAs could encode for proteins involved in 
the regulation of cell proliferation (72).  
Caraglia et al. reported that IFN-α induces growth inhibition and reduction of 
the activity of eIF-5A in human epidermoid cancer KB cells (fig.5) (73). The 
activity of eIF-5A was evaluated through the determination of hypusine levels 
since this amino acid is essential for the function of this translational factor 
that is involved in the regulation of cell proliferation and transformation. IFN-
α is able to induce a strong inhibition of eIF-5A activity (fig.5) since a 
reduction of hypusine synthesis was recorded with a parallel increase of eIF-
5A protein expression. This finding suggests a further reduction of the active 
fraction of eIF-5A (hypusine-containing eIF-5A:total eIF-5A ratio) (73). 
Moreover IFN-α induces cell growth inhibition and apoptosis in human 
epidermoid cancer cells and these effects are antagonized by EGF. On the 
other hand, when EGF antagonized the apoptosis induced by IFN-α, a 
restoration of hypusine synthesis caused by the cytokine and an increase of 
extracellular signal regulated kinase (Erk) activity are recorded in cancer cells 
(73). All these data support the hypothesis of an involvement of eIF-5A, 
another protein synthesis regulator, in the apoptosis induced by IFN-α, at 
least in human epithelial cells. 
 
The modulation of protein degradation 
The proteasome is a multisubunit enzyme complex that plays a central role in 
the regulation of proteins that control cell-cycle progression and apoptosis, 
and has therefore become an important target for anticancer therapy. In fact, 
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the expression of proteins essential for the regulation of cell growth and 
survival can be also controlled at post-transcriptional and post-translational 
levels, the latter through the regulation of protein degradation. Before a 
protein is degraded, it is first flagged for destruction by the ubiquitin 
conjugation system, which ultimately results in the attachment of a 
polyubiquitin chain on the target protein. The proteasome’s 19S regulatory 
cap binds the polyubiquitin chain, denatures the protein, and feeds the protein 
into the proteasome’s proteolytic core. The proteolytic core is composed of 2 
inner beta rings and 2 outer alpha rings. The 2 beta rings each contain 3 
proteolytic sites named for their trypsin-like, post-glutamyl peptide hydrolase-
like (i.e., caspase-like), or chymotrypsin-like activity. Inhibition of the 
proteasome generally results in cell-cycle arrest and apoptosis (74). 
It has been demonstrated that type I IFNs can regulate this complex system. 
Since 1996 it has been demonstrated that type I IFNs can regulate the 
expression of a 16-kDa protein that is produced by the bovine endometrium 
during early pregnancy and that shares epitopes with ubiquitin and ubiquitin 
cross-reacting proteins (75). In addition, IFN-α induces the expression of an 
ubiquitin cross-reactive protein (ISG15) and two ubiquitin-conjugating 
enzymes (UbcH5 and UbcH8) in T cells. A molecular target of these enzymes 
is the inhibitor of kB (IkB) protein, a cytoplasmic protein that binds and 
inactivates NF-kB. IkB degration activates Rel/NF-kB that triggers the 
transcription of genes involved in the apoptotic/antiapoptotic process. (76) 
More recently, it was demonstrated that administration of interleukin-1β (IL-
1β) in vivo attenuates IFN-α-induced STAT-1 tyrosine phosphorylation in the 
liver but not in the spleen. The inhibitory action of IL-1β in vivo is not 
affected by depleting hepatic Kupffer cells, suggesting that IL-1β may 
directly target IFN-α signalling in hepatocytes. Indeed, pretreatment of 
human hepatocellular carcinoma HepG2 cells with IL-1β suppresses IFN-α-
induced antiviral activity and protein MxA mRNA expression. Furthermore, 
IL-1β attenuated IFN-α-induced STAT-1 binding and tyrosine 
phosphorylation without affecting the level of STAT-1 protein. This 
inhibitory effect can be reversed by pretreatment with either proteasome 
inhibitors or transfection of dominant negative NF-kB inducing kinase 
mutants. Taken together, these findings suggest that IL-1β attenuates IFN-α-
induced STAT-1 activation by a proteasome-dependent mechanism (77). 
In human epidermoid lung cancer cells IFN-α induces apoptosis through, at 
least in part, the increase of the expression and activity of tTGase, a 
ubiquitous member of the transglutaminase enzyme family, that has been 
reported to play a role in apoptosis (78). The increase of the expression of 
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tTGase was not due to the induction of its transcription, but to a decrease of 
its degradation via a proteasome-dependent pathway. 
Therefore, type I IFNs could modulate apoptosis through the regulation of the 
degradation of intracellular proteins involved in the triggering of apoptotic 
process. However, not only the target of the type I IFN-dependent signalling 
but also the components of the pathway activated by the cytokine itself can be 
subjected to regulation via proteasome-dependent degradation. In fact, 
Mumps virus, a common infectious agent of humans, causing parotitis, 
meningitis, encephalitis, and orchitis, induces degradation of STAT-3 
mediated by the ubiquitination and subsequent proteasome-dependent 
degradation (79). The latter could be a mechanism by which viruses protect 
themselves by the anti-viral action of type I IFNs. Finally, the suppressors of 
cytokine signalling (SOCS) are a family of physiological regulators of 
cytokine responses, including the type I IFNs. One of the modes used by 
SOCS to turn off the IFN-α-dependent signalling is the delivery of the 
transductional components to the degradative proteosomal machinery (80). 
For a summary see Table 2. 
 
 
Table 2. Correlations between the protein degradation and the type I IFNs-dependent 
pathways 
 
 
     
Proteasome 
component 
Target Source Biological Effect Ref 
     
   
 
 
16kD protein similar to 
ubiquitin and ubiquitin 
cross-reacting protein 
Unknown Bovine 
endometrium 
during 
pregnancy 
Unknown 75 
     
• Ubiquitin cross-
reactive protein 
• Ubiquitinating 
enzymes (UbcH5 and 
UbcH8) 
Unknown T cells Unknown 76 
     
Unknown STAT-1 Hepatocellular 
carcinoma cells 
Attenuation of IFN-α 
activity by IL1β 
77 
     
Unknown TTG Epidermoid 
cancer cells 
Mediates apoptosis 
induced by IFN-α 
78 
     
Unknown STAT-3 Epithelial cells Attenuation of IFN-α 
activity by Mumps 
virus 
79 
     
Unknown IFN-AR, 
JAK-1, 
Tyk-2, 
STATs 
Epithelial cells Attenuation of IFN-α 
activity by the 
inactivator  SOCS 
80 
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I. 5) CELL CYCLE ARREST 
 
The arrest of cell cycle is another antitumor mechanism described in several 
cancers after treatment with type I IFNs. IFN-α and IFN-β can affect all 
phases of the mitotic cell cycle (81). Infact, type I IFNs have been described 
to induce a G0-G1 arrest, to prolong S-phase transition or to block cells in 
G2/M. 
Temporal order and continued passage through cell cycle is dependent on the 
sequential formation and activation of series of serine/threonine protein 
kinases. These protein complexes consist of a regulatory subunit, termed 
cyclin, and a catalytic subunit, the cyclin-dependent kinases (cdks) (fig.6). 
From G1, following mitosis, cells may also enter a stable “resting state” called 
quiescence, or G0. As cells enter the cycle following mitosis (or alternatively 
from quiescence), the D-type cyclins (D1, D2 and D3) and cyclin E are 
synthesized sequentially, leading to the formation of cyclin D-cdk4/6 and 
cyclin E-cdk2 complexes. Other cdk-complexes, such as cyclin A-cdk2, 
operate in S and G2, whilst cyclin B-cdk1 functions in G2/M phase. To ensure 
fine-tuning in the regulation of proliferation, the activity of these complexes is 
regulated at multiple levels, including the synthesis and destruction of the 
regulatory cyclin, and by phosphorylation and dephosphorylation on specific 
residues of the kinase subunit by the enzymes CAK and Cdc25A, 
respectively. In addition, a new level of regulation of these complexes has 
been elucidated by the identification of two families of low molecular weight 
cdk inhibitors. This inhibitors include the Ink4 family (p15, p16, p18 and p19 
proteins), which binds specifically to cdk4 and cdk6, thereby interfering with 
cyclin D-cdk interactions; and Cip/Kip family (p21, p27 and p57 proteins), 
inhibiting the kinase activity of cyclin E-cdk2, cyclin A-cdk2 and cyclin D-
cdk4/6 complexes (82). 
Many proteins have been suggested as substrates for the different cyclin/cdk 
complexes. A main substrate of cyclin D-cdk4/6 is the pRb protein that 
influences the transcription of genes necessary for G1 progression through 
binding and regulating the activity of members of the E2F family of 
transcription factors as well as histone deacetylases (HDAC:s). The 
phosphorylation of pRb by cyclin D-cdk4/6 induces a conformational change, 
which disrupts its binding to HDAC and causes de-repression of some genes 
with E2F sites in their promoters. Further phosphorylation of pRb, and the 
two other pocket proteins p107 and p130 by cyclin E-cdk2 leads to release of 
E2F and transactivation of E2F-responsive genes required for S phase 
progression, such as DNA polymerase alpha, dihydrofolate reductase, and c-
myc. Therefore, the phosphorylation of the pRb protein by cyclin/cdk 
complexes is a rate limiting step in G1 progression (83). 
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Figure 6: The proposed model for type-I IFNs induced G0-like arrest. Addition of type I IFN 
to exponentially growing cells can cause a G0-like arrest. This is associated with a down-
regulation of Cdk4 and Cdk2 activity, presumably leading to activation of the pocket proteins. 
This effect is thought to be brought about through a primary response involving the 
transcriptional induction of the Cdk inhibitors p15 and p21. This is followed by a secondary 
response involving a post-translationally regulated increase in p27 levels, down-regulation of 
cyclins D and A, as well as down-regulation of the Cdk-activating phosphatase Cdc25A. The 
binding of Cip/Kip inhibitors to the G1 Cdks also leads to a blockage of their phosphorylation 
by the CAK enzyme. In parallel with the above-mentioned processes the levels of c-myc are 
rapidly downregulated (modified from Sangfelt O. et al., ref. 82). 
 
 
IFN-α induced a cell accumulation in a G0-like state and a cell cycle arrest in 
G1 phase in Daudi cells and in U-266 cells, respectively (83). These effects 
seem to be modulated by the suppression in the phosphorylation of pRb, p130 
and p107 (82,83). 
Since pocket protein phosphorylation is regulated by the cdk-complexes, 
several groups have addressed the issue of whether IFN acts by down-
regulating cdk activity. Indeed, type I IFNs have been shown to strongly 
repress the activity of the cdk2 –4 and 6-complexes in a number of different 
cell types. There are several possible explanations for this effect, as there are 
many ways of regulating cdk activity. First, IFN could act by decreasing the 
levels of the cdks or their regulatory cyclin subunits. Second, it could increase 
the expression of one or several cdk-inhibitory proteins, or, thirdly, influence 
the phosphorylation status of the cdks by affecting CAK activity or expression 
of Cdc25A (fig.6) (82,83). Experimental data have shown that, indeed, IFN 
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influences cdk activity through all of these mechanisms (82). In fact, long 
incubation with IFN-α decreases cyclin D3 and cyclin A expression and 
activity in the Burkitt lymphoma cell line Daudi (82). The induction of several 
cdk-inhibitory proteins (p21, p15, p27) in parallel to the decrease in the 
activity of G1 cdks has been detected during IFN-α treatment. In particular, 
the increase in p27 levels induced a dissociation of cyclin E/Cdk2-p130 or 
p107 complexes to yield cyclin E/Cdk2-p27 complexes (83, 84). As 
mentioned above, full cdk activity is only acquired if the kinase subunit is 
dephosphorylated at certain residues and phosphorylated on others. This 
requires both the phosphatase CDC25a and the cdk-complex CAK. Type I 
IFNs seem also to down-regulate the expression of Cdc25A and to block the 
activity of CAK. The overall reduction in activities of cyclins and cdk, 
resulted in decreased pRb phosphorylation, thereby preventing cell cycle 
progression into S phase (85). 
Another involved pathway could be the activation of the double-stranded 
RNA-activated protein kinase (p68 PKR), inducing cell cycle arrest in G1 
through the proto-oncogene c-myc suppression (86,87). 
Other studies revealed S-phase accumulation in response to IFN-α and IFN-β, 
as a failure to complete DNA replication. In hepatocellular carcinoma, where 
IFN-α induced an accumulation in S-phase, the cell cycle-dependent induction 
of cyclin A and cyclin B was impaired, resulting in reduced activity of cdk2 
and cdc2 kinases. Because cyclin A expression is absolutely required for 
passage through S phase, while cyclin B is synthesized to function as a 
regulatory subunit in cdc2 kinase complexes as cells progress from S- into 
G2/M, the decrease of cellular cyclin A and B content represents a likely 
cause for IFN-α-dependent growth inhibition (88). Similar results were 
observed by Detjen et al. in neuroendocrine tumor cells (89). Qin et al. 
reported the loss or inactivation of the normal G1 checkpoint conferred by the 
Rb protein as a mechanism of IFN-α and IFN-β–mediated accumulation of the 
cells in the S phase. The increase appeared to be due to a continued S phase 
entry and subsequently a failure of S phase cells to transit efficiently into G2 
and M phases (90).  
Finally, few papers reported a blockage at the G2/M phase after type I IFNs 
treatment, but the involved mechanisms are not completely clear (91,92).  
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I. 6) THE AIMS OF THE PRESENT THESIS: 
 
The current thesis has been designed with the following aims: 
1. To compare the anti-tumor effects of IFN-α and IFN-β and the 
involved mechanisms in: pancreatic carcinoid (BON cell line), human 
pancreatic adenocarcinoma (BxPC-3, MiaPaCa-2 and Panc-1 cell 
lines) and adrenocortical cancer (H295 and SW-13 cell lines). 
2. To evaluate the mechanisms of tumor cell resistance to IFN-α, related 
to the up-regulation of epidermal growth factor receptor (EGF-R) in 
epidermoid cancer cells (KB cell line). 
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Abstract 
Interferon (IFN)-α controls hormone secretion and symptoms in human 
gastroenteropancreatic neuroendocrine tumors (GEP-NETs), but it rarely 
induces a measurable tumor size reduction. The effect of other type I IFNs, 
i.e. IFN-β, has not been evaluated. We compared the antitumor effects of 
IFN-α and IFN-β in BON cells, a functioning human GEP-NET cell line. As 
determined by quantitative RT-PCR analysis and immunocytochemistry, 
BON cells expressed the active type I IFN receptor mRNA and protein 
(IFNAR-1 and IFNAR-2c subunits). After 3 and 6 days of treatment, IFN-β 
significantly inhibited BON cell growth in a time- and dose-dependent 
manner. IC50 and maximal inhibitory effect on day 6 were 8 IU/ml and 98%, 
respectively. In contrast, the effect of IFN-α resulted significantly in a less 
potent effect (IC50: 44 IU/ml, maximal inhibition: 26%). IFN-α induced only 
cell cycle arrest, with an accumulation of the cells in S phase. IFN-β, apart 
from a more potent delay in S-G2/M phase transit of the cell cycle, also 
induced a strong stimulation of apoptosis, evaluated by flow cytometry 
(annexin V and 7-AAD) and measurement of the DNA fragmentation. 
Besides, only IFN-β severely suppressed chromogranin A levels in the 
medium from BON cells after 6 days of treatment.  In conclusion, IFN-β is 
much more potent, compared to IFN-α, in its inhibitory effect on GEP-NET 
cell proliferation in vitro through the induction of apoptosis and cell cycle 
arrest. Further studies are required to establish whether IFN-β has comparable 
potent tumor growth inhibitory effects in vivo.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 28 
Introduction 
Gastroenteropancreatic-neuroendocrine tumors (GEP-NETs) are a 
heterogeneous category of tumors and represent the largest group of all NETs 
(1). GEP-NETs frequently synthesize several biologically active substances, 
(bioamines and neuropeptides), leading to disease characterized by diarrhea, 
abdominal cramps and pain, cardiac valve disease, bronchoconstriction, 
flushing, telangiectasias and pellagra-like dermatitis, often debilitating for 
patients (1-3). In the liver, monoamine oxidases can detoxify the amines 
released by the tumor and prevent the occurrence of the tumor-associated 
hypersecretion syndrome. However, the presence of hepatic and occasionally 
large retroperitoneal and ovarian metastases, where secreted products by-pass 
the liver detoxification, is commonly associated to this syndrome (4).  
In addition to the impaired quality of life, patients with advanced GEP-NETs 
have a dismal prognosis with a 5-year survival of about 20-30% (5). In these 
cases there are relatively few therapeutic options, most of them are palliative. 
Surgery is indicated only for conservative resections of the intestine, 
mesenteric tumors and fibrotic areas, in order to improve symptoms and 
quality of life (6). Hepatic resection in selected patients with metastatic 
functioning GEP-NETs is safe, provides temporary relief of symptoms, and 
may prolong survival (6,7). As alternative to hepatic resection in patients with 
liver metastases, local ablative procedures may also be considered including 
chemoembolization, laser and radiofrequency ablation, as palliative support to 
control symptoms of hypersecretion syndrome (6). The use of 
chemotherapeutic regimens is limited to fast growing or undifferentiated 
tumors (8). Few studies suggest the use of targeted radiotherapy with 
somatostatin analogues coupled to β- or Auger electron emitters in the 
management of GEP-NETs, but its definitive role has yet to be defined (9-11). 
The most common medical treatment in advanced GEP-NETs includes the 
use of somatostatin analogs and interferon (IFN)–α, alone or in combination. 
Somatostatin analogs are used in the treatment of clinical symptoms, but 
tachyphylaxis is frequently recorded and these drugs are unable to control 
tumor progression (12-13). IFN-α induces a 42% biochemical and 14% tumor 
response in carcinoid, and a 51% biochemical and 12% tumor response in 
neuroendocrine pancreatic tumors (14-15). However, also after the treatment 
with IFN-α a measurable tumor reduction is only reported occasionally (16).  
Therefore, therapeutic options to inhibit the growth of metastatic GEP-NET 
tumors are still unsatisfactory, and many patients become refractory to the 
conventional palliative therapy. For all these reasons, novel treatment 
strategies appear mandatory. Few authors reported that IFN-β has greater 
antitumor effects than IFN-α on melanoma, squamous carcinoma, glioma, 
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breast and hepatocellular cancer (17-21). On these bases, IFN-β appears to be 
of potential interest in the treatment of tumors. 
To further explore the possibilities of new medical therapies in GEP-NETs, 
we compared in this study the role and mechanism of action of IFN-α and 
IFN-β in the regulation of cell growth in BON cells, a functioning human 
NET cell line, derived from a lymph node metastasis of a pancreatic 
carcinoid. 
 
 
Materials and methods 
Cell lines and culture conditions 
Human pancreatic carcinoid BON cells were obtained from Dr Townsend (The University of 
Texas Medical Branch, Galveston, Texas, USA). The cells were cultured in a humidified 
incubator containing 5% CO2 at 37°C. The culture medium consisted of a 1:1 mixture of 
Dulbecco’s modified Eagle’s medium (DMEM) and F12K medium, supplemented with 10% 
FCS, penicillin (1x105 U/l), fungizone (0.5 mg/l) and l-glutamine (2 mmol/l). Periodically, 
cells were confirmed as Mycoplasma-free. Cells were harvested with trypsin EDTA 10% and 
resuspended in medium. Before plating, cells were counted microscopically using a standard 
hemocytometer. Trypan Blue staining was used to assess cell viability, which always 
exceeded 95%. Media and supplements were obtained from GIBCO Bio-cult Europe 
(Invitrogen, Breda, The Netherlands).  
 
Drugs and Reagents 
Human recombinant IFN-α-2b (Roferon-A) was obtained from Roche (Mijdrecht, The 
Netherlands). Human recombinant IFN-β-1a was obtained from two preparations: Serono Inc. 
(Rebif, Rockland, MA) and GIBCO Brl (Paisley, UK). All compounds were stored at -20°C, 
and the stock solution was constituted in distilled water according to the manufacturer 
instructions. Anti-human IFN-β neutralizing antibody was purchased from Sigma-Aldrich (St. 
Louis, MA). 
 
Quantitative RT-PCR 
The expression of type I IFN receptors (IFNAR-1, IFNAR-2 total, the short form IFNAR-2b, 
and the long form IFNAR-2c) and housekeeping gene hypoxanthine-phosphoribosyl-
transferase (HPRT) mRNA was evaluated by quantitative RT-PCR in BON cells. Poly A+ 
mRNA was isolated using Dynabeads Oligo (dT)25 (Dynal AS, Oslo, Norway) from cell 
pellets containing approximately 5x105 cells. The cells were lysed for 2 minutes on ice in a 
buffer containing 100 mM Tris-HCl (pH 8), 500 mM LiCl, 10 mM EDTA (pH 8), 1% LiDS, 
5 mM DTT and 5 U/100 ml of RNAse inhibitor (HT Biotechnology Ltd. Cambridge, UK). To 
the lysate 30µl prewashed Dynabeads Oligo (dT)25 were added, and the mixture was 
incubated for 10 minute on ice. Thereafter, the beads were collected with a magnet, washed 
three times with 10 mM Tris-HCl (pH 8), 0.15 M LiCl, 1 mM EDTA, 0.1% LiDS, and two 
times with a similar buffer from which LiDS was omitted. Messenger RNA was eluted from 
the beads in 2 x 20µl of H2O for 2 min at 65°C. Complementary DNA (cDNA) was 
synthesized using the poly A+ mRNA in a Tris-buffer (50 mM Tris-HCl, pH 8.3; 100 mM 
KCl; 4 mM DTT; 10mM MgCl2) together with 1mM of each deoxynucleotide triphosphate, 
10 U RNAse inhibitor, and 2 U AMV Super Reverse Transcriptase (HT Biotechnology Ltd., 
Cambridge, UK) in a final volume of 40 µl. This mixture was incubated for 1 h at 42°C. One 
tenth of the cDNA library was used for quantification of IFN receptors and HPRT mRNA 
levels. A quantitative PCR was performed by AmpliTaq Gold® DNA Polymerase and the 
ABI PRISM 7700 sequence detection system (Perkin-Elmer Applied Biosystems, Groningen, 
The Netherlands) for real-time amplifications, according to manufacturer’s protocol. The 
assay was composed by 15 µl TaqMan Universal PCR Master Mix (Applied Biosystems, 
Capelle aan de Ijssel, The Netherlands), forward primer (500 nmol HPRT and IFNAR-2c; 
300 nmol IFNAR-1, IFNAR-2 total and IFNAR-2b), reverse primer (500 nmol HPRT and 
IFNAR-2c; 300 nmol IFNAR-1, IFNAR-2total, and IFNAR-2b), probe (100 nmol HPRT, 
 30 
IFNAR-1 and IFNAR-2total; 200 nmol IFNAR-2b and IFNAR-2c) and 10 µl cDNA template, 
in a total reaction volume of 25 µl. PCR amplification started with a first step for 2 min at 
50°, followed by an initial heating at 95°C for 10 min, samples were subjected to 40 cycles of 
denaturation at 95°C for 15 sec and annealing for 1 min at 60°C. The primer and probe 
sequences were purchased from Biosource (Nivelles, Belgium) and are indicated in Table 1.  
 
Table 1: Primers and probes used for the quantitative RT-PCR. 
 
 
IFNAR-1  
Forward 5’-CCCAGTGTGTCTTTCCTCAAA-3’ 
Reverse 5’-AAGACTGGAGGAAGTAGGAAAGC-3’ 
Probe 5’-FAM-TCCGCGTACAAGCATCTGATGGA-TAMRA-3’ 
  
IFNAR-2 (total form)  
Forward 5’-AGTCAGAGGGAATTGTTAAGAAGCA-3 
Reverse 5’-TTTGGAATTAACTTGTCAATGATATAGGTG-3’ 
Probe 5’-FAM-AAACCCGAAATAAAGGAAACATGAGTGGAAATT-TAMRA-3’ 
  
IFNAR-2b (short form)  
Forward 5’-GCTTAAGAAATAGCCTCCCCAAA-3’ 
Reverse 5’-CTGTGAATAGCCACTGCATTCC-3’ 
Probe 5’-FAM-TCTTGAGGCAAGGTCTCGCTAAGGGC-TAMRA-3’ 
  
IFNAR-2c (long form)  
Forward 5’-TGACAAGCACCATAGTGACACTGA-3’ 
Reverse 5’-TAGGAAATGGCCAGGCTAAAAA-3’ 
Probe 5’-FAM-TGGATTGGTTATATATGCTTAAGAAATAGCCTCCCCA-
TAMRA-3’ 
  
HPRT  
Forward 5’-TGCTTTCCTTGGTCAGGCAGTAT-3’ 
Reverse 5’-TCAAATCCAACAAAGTCTGGCTTATATC-3’ 
Probe 5’-FAM-CAAGCTTGCGACCTTGACCATCTTTGGA-TAMRA-3’ 
 
The detection of HPRT mRNA was used for normalization of IFN receptor mRNA levels. 
Expression of IFNAR-2a mRNA, the soluble form of IFNAR-2 subunit, was determined 
indirectly by subtracting IFNAR-2b and IFNAR-2c from IFNAR-2 total. Several controls 
were included in the RT-PCR experiments. To exclude contamination of the PCR reaction 
mixtures, the reactions were also performed in the absence of DNA template in parallel with 
cDNA samples. As a positive control for the PCR reactions of HPRT and type I IFN receptors 
human cDNA was amplified in parallel with the cDNA samples. 
 
Immunocytochemistry 
Cytospin preparations of BON cells were fixated with acetone and subsequently incubated for 
30 minutes at room temperature with antibodies to human IFNAR-1 (rabbit polyclonal 
antibody, Santa Cruz Biotechnology, Inc., Santa Cruz, California, USA), IFNAR-2b (rabbit 
polyclonal antibody, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and IFNAR-2c 
(monoclonal antibody, Dr E. Croze, Berlex Biosciences, Richmond, CA) subunits. Finally, a 
peroxidase complex (IL Immunologic, Duiven, The Netherlands) for IFNAR-1 and IFNAR-
2b, or standard streptavidin-biotinylated alkaline phosphatase (IL Immunologic, Duiven, The 
Netherlands) for IFNAR-2c, were used according to the manufacturer’s recommendations to 
visualize the bound antibodies. Negative controls for the immunohistochemistry included: 1) 
omission of the primary antibody; and 2) preabsorbtion of the antibody for IFNAR-2b with 
the respective immunizing receptor peptide. 
 
Cell proliferation assay 
After trypsinization, the cells were plated in 1 ml of medium in 24-well plates at a density of 
5x103 cells/well. The plates were then placed in a 37°C, 5% CO2 incubator. Three days later 
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the cell culture medium was replaced with 1ml/well medium containing various 
concentrations (0, 1, 5, 10, 50, 100, 1000 IU/ml) of IFN-α or IFN-β (Serono Inc.). 
Quadruplicates of each treatment were performed. Plates were further incubated at 37°C and 
5% CO2. After 3 and 6 days of treatment cells were harvested for DNA measurement. Plates 
for 6 days were refreshed after 3 days and compounds were added again. Measurement of 
total DNA-contents, representative for the number of cells, was performed using the 
bisbenzimide fluorescent dye (HoechstTM 33258) (Boehring Diagnostics, La Jolla, CA), as 
previously described (22).  
To evaluate the specificity of the effects of IFN-β on cell growth, we exposed type I IFNs 
with anti-human IFN-β neutralizing antibody. Cells (5x103 cells/well) were plated in 24-well 
plates and after 3 days of incubation at 37°C and 5% CO2, the medium containing IFN-β (0, 
5, 50 IU/ml) or IFN-α (100 IU/ml) in the absence or in presence of anti-human IFN-β 
neutralizing antibody (4 µg/ml), was changed. Plates were refreshed after 3 days and 
compounds were added again. After 6 days of treatment plates were collected for DNA 
measurement. Both IFNs, alone or in combination with anti-human IFN-β neutralizing 
antibody, have been incubated for 1 day at 4°C prior to be added to BON cells, in order to 
antagonize the IFN-β activity. 
 
Apoptosis assays 
After trypsinization BON cells were plated in 6-well plates at a density of 0.5-1x105 
cells/well. These plates were placed in a 37°C, 5% CO2 incubator. Three days later the 
medium was refreshed in the presence and absence (control group) of IFN-α or IFN-β 
(Serono Inc.) at the concentration of 100 IU/ml. After 1, 2 and 3 days of incubation cells were 
gentle trypsinized and washed with ice-cold PBS. Cells were resuspended in 100 µl of 1 x 
binding buffer (Nexins Research B.V., Hoeven, The Netherlands), and stained with 5 µl of 
FITC-annexin V (25 µg/ml) and 10 µl of 7-amino-actinomycin D (7-AAD) (1 mg/ml). Cells 
were incubated for 15 min on ice in the dark. Every sample was diluted with 385 µl of 1 x 
binding buffer and immediately analyzed by FACScalibur flow cytometer (Becton Dickinson, 
Erembodegem, Belgium). At least 20000 cells were detected for each sample. With the use of 
CellQuest Pro Software, three subsets of cells, based on intensity of staining with annexin and 
7-AAD, were identified: annexin–/7-AAD– (live cells), annexin+/7-AAD– (early apoptotic 
cells) and annexin+/7-AAD+ (late apoptotic and necrotic cells) (23). Subsequently, the 
percentage of each population was calculated. Annexin and binding buffer were obtained 
from Nexins Research (Kattendijke, The Netherlands), while 7-AAD from Becton and 
Dickinson.  
Apoptosis was further confirmed by the analysis of the DNA fragmentation. After plating 
5x104 cells/well on 24 well plates, cells were incubated at 37°C. Three days later the cell 
culture medium was replaced with 1ml/well medium containing various concentrations (0, 1, 
5, 10, 50, 100, 1000 IU/ml) of IFN-α or IFN-β (Serono Inc.). Quadruplicates of each 
treatment were performed. After an additional incubation of 1 day, apoptosis was assessed 
using a commercially available ELISA kit (Cell Death Detection ELISAPlus, Roche 
Diagnostic GmbH, Penzberg, Germany). The standard protocol supplied by the manufacturer 
was used, as previously described (24).  
 
Cell cycle analysis 
Cells (0.8-2x106) were plated in 75cm2 flasks. After 3 days medium was changed with fresh 
medium (control group) and with fresh medium plus IFN-α or IFN-β (Serono Inc.) at the 
concentration of 100 IU/ml. After 1, 2 and 3 days of incubation (with a confluence of about 
60-70%), cells were harvested by gentle trypsinization, washed with cold PBS (calcium and 
magnesium free), and collected by centrifugation. For cell cycle analysis, approximately 106 
cells were re-suspended in 200µl of PBS and fixed in 70% ice-cold ethanol with an overnight 
incubation at -20°C. After brief centrifugation, cells were washed once with PBS and 
incubated for 30 minutes at 37°C in PBS containing 40µg/ml of propidium iodide (Sigma 
Aldrich, The Netherlands) and 10µg/ml of DNase-free RNase (Sigma Aldrich, The 
Netherlands). For each tube 20000 cells were immediately measured on a FACScalibur flow 
cytometer (Becton Dickinson, Erembodegem, Belgium) using CellQuest Pro Software. 
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Chromogranin A determinations 
BON cells (5x103 cells/well) were cultured in 24-well plates and placed in a 37°C, 5% CO2 
incubator. Three days later the culture medium was replaced with 1ml/well medium 
containing various concentrations of IFN-α or IFN-β (Serono Inc.) (0, 1, 5, 10, 50, 100 
IU/ml). Plates were further incubated at 37°C and 5% CO2, refreshed after 3 days and 
compounds were added again at escalating concentrations. After 6 days of treatment the 
supernatant and the plates were collected for chromogranin A and DNA measurements, 
respectively. Human chromogranin A was measured in the conditioned media by a solid-
phase two-site immunoradiometric assay based on monoclonal antibodies that bind to two 
distinct contiguous epitopes within the 145-245 region of chromogranin A (Cromogranin A-
RIA CT, CIS bio international, Gif-sur-Yvette, France), according to the manufacturer 
procedures (25).  
 
Effects of two different preparations of IFN-β-1a on cell growth and chromogranin A 
production.    
After trypsinization, the cells were cultured in 24-well plates at a density of 5x103 cells/well. 
The plates were then placed in a 37°C, 5% CO2 incubator. Three days later the cell culture 
medium was replaced with 1ml/well medium containing various concentrations (0, 1, 5, 10, 
50, 100 IU/ml) of IFN-β-1a from 2 different preparations: Serono Inc. and GIBCO Brl. Plates 
were refreshed after 3 days and compounds were added again. After 6 days of treatment cells 
and conditioned medium were harvested, as indicated above, for DNA and chromogranin A 
measurement.  
 
Statistical analyses 
All experiments were carried out at least three times and gave comparable results. For 
statistical analysis GraphPad PrismTM 3.0 (GraphPad Software, San Diego, USA) was used. 
Relative 50% growth-inhibition concentrations (IC50) and maximal inhibitory effect were 
calculated using nonlinear regression curve-fitting program. The comparative statistical 
evaluation among groups was firstly performed by ANOVA test. When significant 
differences were found, a comparison between groups was made using the Newman-Keuls 
test. The unpaired Student t-test was chosen to analyze the differences in concentration-effect 
curves (IC50 and maximal inhibitory effect) and effects in cell cycle modulation between 
different types or preparations of IFNs, and the differences of the growth inhibitory effects of 
IFNs after 3 and 6 days of treatment. Correlation analyses were performed using Pearson’s 
coefficients. In DNA fragmentation analyses, the means of quadruplicates for each treatment 
with the same dose of IFN-β have been correlated to the corresponding means of 
quadruplicates in the corresponding plates for the cell proliferation assay after 6 days of 
treatment with IFN-β. In addition, in one experiment DNA measurements after 6 days of 
treatment with IFN-β have been correlated to the corresponding chromogranin A 
concentrations, evaluated in the corresponding conditioned medium.In all analyses, values of 
p<0.05 were considered statistically significant. Data are reported as mean + SEM. 
 
 
 
Results 
Expression of type I IFN receptors mRNA and proteins in BON cells 
Since the activity of type I IFNs is modulated by a common receptor, we 
analyzed the expression of IFNAR-1 and IFNAR-2 (total, short and long 
form) mRNA in BON cells by quantitative RT-PCR (fig.1A). 
Using sequence specific primers against the type I IFN receptor subunits, we 
detected the presence of IFNAR-1, IFNAR-2 total, IFNAR-2b and IFNAR-2c 
mRNA. IFNAR-1 mRNA expression, normalized for the amount of the 
housekeeping gene HPRT, was higher than IFNAR-2 total. Among IFNAR-2 
subunits, IFNAR-2c was the form expressed at a relatively low level. 
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Specific immunoreactivity for IFN receptor subunits (IFNAR-1, IFNAR-2b 
and IFNAR-2c) was found in BON cells at immunocytochemistry (fig.1B-D). 
It was strongly positive for IFNAR-1 on the membrane and cytoplasm 
(fig.1B), moderately positive for IFNAR-2b on the membrane and cytoplasm 
(fig.1C) and weakly positive for IFNAR-2c on the membrane (fig.1D). 
Therefore, quantitative RT-PCR study demonstrated the presence of type I 
IFN receptor subunit transcripts and immunocytochemistry confirmed the 
presence of activable receptor proteins on BON cell membrane. 
 
 
 
Figure 1. A: Relative expression of type I IFN receptor (AR-1, AR-2 total, AR-2b, AR-2c) 
mRNA in the human carcinoid BON cell line, evaluated by quantitative RT-PCR. The 
amount of IFN receptor mRNA was calculated relative to the amount of HPRT mRNA and is 
given in arbitrary units. The soluble form of IFNAR-2a subunit was determined indirectly by 
subtracting IFNAR-2b and IFNAR-2c from IFNAR-2 total. Values represent the mean ± 
SEM. B-D: Immunocytochemical detection of IFNAR-1 (B), IFNAR-2b (C) and IFNAR-2c 
(D) receptors in human BON carcinoid cells. A strong IFNAR-1 immunostaining is evident in 
the membrane and cytoplasm. A moderate positivity for IFNAR-2b was detected in the 
membrane and cytoplasm, whereas a weak immunostaining is evident for IFNAR-2c along 
the cell membrane. Magnification, x 400. 
 
Effects of type I IFNs on cell growth 
After 6 days of incubation, IFN-α and IFN-β significantly suppressed the 
growth of BON cells in a dose-dependent manner, with an IC50 of 44 IU/ml 
and 8 IU/ml, respectively (fig.2A-B). The growth-inhibitory effect of IFN-β 
was significantly more potent than that of IFN-α, as shown by the higher 
maximal inhibition of proliferation induced by IFN-β, compared with IFN-α 
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after 3 (74.8% + 2 and 16.3% + 1.3, respectively, p<0.0001; fig.2A) and 6 
days (97.6% + 4.3 and 25.8% + 2.6, respectively, p<0.0001; fig.2B) of 
treatment, as well as by the lower logIC50 of IFN-β compared with IFN-α 
after 3 (1.1 + 0.1 and 1.6 + 0.1, respectively, p<0.05) and 6 days (0.9 + 0.1 
and 1.6 + 0.2, respectively, p<0.0001). Note that after 6 days of incubation 
IFN-β induced a statistically significant cell growth inhibition already at very 
low concentrations (1 IU/ml). The antiproliferative effects of IFN-α and IFN-
β were time-dependent. In fact, the maximal inhibition of cell proliferation, 
induced by both cytokines, resulted to be higher after 6 days compared with 3 
days of incubation (IFN-α: p<0.05, IFN-β: p<0.0001). No statistically 
significant difference was observed between the values of IC50 of inhibition 
after 3 and 6 days for either IFN-α or IFN-β. 
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Figure 2. A-B: Dose-dependent inhibition of cell proliferation after 3 (A) and 6 (B) days of treatment with 
IFN-α and IFN-β in BON cell line. Measurement of total DNA-contents was performed using HoechstTM 
33258. The mean DNA contents in controls were: 3278 ng/well (IFN-α, 3 days), 3592 ng/well (IFN-β, 3 
days), 8941 ng/well (IFN-α, 6 days), 8497 ng/well (IFN-β, 6 days).   : IFN-α   : IFN-β. *: p<0.001, **: 
p<0.01, ***: p<0.05 vs control. C-D: Effects of IFN-β (C) and IFN-α (D) on cell growth, alone and 
following pre-absorption with neutralizing antibodies against IFN-β (IFN-beta Ab). *:p<0.001, **:p<0.05 
vs relative controls. Measurement of total DNA-contents was performed using HoechstTM 33258. Values 
are expressed as the percentage of control (untreated cells) and represent the mean ± SEM of at least 3 
independent experiments in quadruplicate.  
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To clarify the specificity of action of IFN-β we evaluated the effects on cell 
growth after a pre-absorption of IFN-α and IFN-β with neutralizing antibodies 
against IFN-β. As shown in fig.2C, the anti-tumor activity of 50 IU/ml IFN-β 
was significantly weakened by immuno-neutralization, whereas the effect of 5 
IU/ml IFN-β was completely abolished. Moreover, these antibodies were 
unable to counteract the inhibitory effects of IFN-α on cell growth (fig.2D). 
 
Effects of type I IFNs on apoptosis 
The effects of IFN-α (100 IU/ml) and IFN-β (100 IU/ml) on the induction of 
apoptosis in BON cells were examined by flow cytometry. Using annexin V 
and 7-AAD, 2-color flow cytometric analysis detected 3 populations: viable, 
early apoptotic, and both late apoptotic and necrotic cells. Percentages of 
these populations, compared to the untreated control after 1, 2 and 3 days of 
treatment with IFN-α or IFN-β are shown in fig.3A, B, C. We observed 
(fig.3A) a significant decrease in the fraction of viable cells during the 
incubation with IFN-β (1, 2 and 3 days: p<0.01). The percentage of early 
apoptotic cells significantly increased after 1, 2 and 3 days (all p<0.01) of 
treatment with IFN-β (fig.3B). In the same way, IFN-β induced a significant 
increase (p<0.01) in the fraction of late apoptotic/necrotic cells (fig.3C). It is 
noteworthy that, after 2 days of treatment with IFN-β (100 IU/ml) about 20% 
of cells showed signs of apoptosis or necrosis, which is 2.3 times higher than 
the control. In contrast, IFN-α did not significantly modify the fractions of 
life cells, early apoptotic and late apoptotic/necrotic cells in comparison to the 
untreated group. 
During the treatment with IFN-α and IFN-β the measurement of the DNA 
fragmentation was further used to investigate the effect on the apoptosis 
(fig.4A-B). After 1 day of incubation, IFN-α had no remarkable stimulatory 
effects on DNA fragmentation at any concentration up to 1000 IU/ml in BON 
cell line. On the other hand, a dose-dependent induction of apoptosis was 
observed after IFN-β treatment, with a maximal increase of DNA 
fragmentation of about 3 times compared to the untreated control in BON 
cells. This cytokine stimulated apoptosis already at very low concentrations (1 
IU/ml). These data were also confirmed by morphological observations. Only 
the treatment with IFN-β induced morphological alterations consistent with 
apoptosis, such as cell shrinkage, picnotic nucleus and detachment from the 
plate after 1-3 days (not shown). The inhibitory effects of IFN-β on the cell 
growth of BON cells appeared to be mainly due to an early pro-apoptotic 
activity, as shown by the highly significant positive correlation between the 
cell proliferation inhibition after 6 days of treatment and DNA fragmentation 
variation after 1 day of incubation (r2 = 0.82, p<0.001; fig.4C).  
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Figure 3A-C: Effects of IFN-α (100 
IU/ml) and IFN-β (100 IU/ml) on the 
induction of apoptosis in BON cells, 
evaluated by flow cytometry for 
annexin V and 7-AAD. 
Values of viable cells, early apoptotic 
cells and late apoptotic/necrotic cells 
are expressed as percentage compared 
to the untreated control. Data are 
reported as mean ± SEM. Control 
values have been set to 100%. The 
mean percentages ± SEM of viable 
cells in controls were: 89.2% ± 1.3 (1 
day), 88.1% ± 0.9 (2 days), 85.9% ± 
1.3 (3 days). The mean percentages ± 
SEM of early apoptotic cells in 
controls were: 4.5% ± 0.2 (1 day), 4.7 
± 0.9 (2 days), 4.2% ± 0.4 (3 days). 
The mean percentages ± SEM of late 
apoptotic/necrotic cells in controls 
were: 3.7% ± 0.2 (1 day), 3.3% ± 0.5 
(2 days), 7.4% ± 1.7 (3 days). 
 : IFN-α 
: IFN-β (Serono). 
*: p<0.01 vs control.  
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Effects of type I IFNs on the cell cycle 
We also evaluated the effect of treatment with IFN-α (100 IU/ml) and IFN-β 
(100 IU/ml) on cell cycle phase distribution after 1, 2 and 3 days of incubation 
(fig. 5). 
IFN-α treatment induced a slight, but significant accumulation of cells in S 
phase after 2 (p<0.05) and 3 days (p<0.001) of treatment compared to the 
control. In the same way, the incubation with IFN-β increased the fraction of 
BON cells in the S phase of the cell cycle already after 1 day (p<0.001 after 1, 
Figure 4A-B: DNA 
fragmentation after 1 day of 
treatment of BON cell line 
with IFN-α (A) and IFN-β 
(B). Values are absorbance 
units and are expressed as 
percent control. Data are the 
mean ± SEM. *:p<0.001, 
**:p<0.01, ***:p<0.05 vs 
control. 
C: Correlation between DNA 
fragmentation and cell 
proliferation inhibition after 
IFN-β treatment in BON cell 
line. Data correspond to the 
means of four wells for each 
treatment point with IFN-β in 
DNA fragmentation analysis 
after 1 day (on the abscissa) 
and to the means of 
quadruplicate for each 
treatment point in the 
respective plates for cell 
proliferation assay after 6 
days of treatment with IFN-β 
(on the ordinate).  
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2 and 3 days), whereas the proportion of cells in G1 phase decreased in 
comparison with the control (p<0.001 after 24h, 48h and 72h). These data 
suggested that BON cells in S phase failed to transit into G2 and M phases 
efficiently and exhibited a prolonged stay in S phase after treatment with type 
I IFNs.Of note, the cell cycle arrest induced by IFN-β was more potent than 
that of IFN-α, as showed by the statistically significant difference in 
percentage of cells in S phase compared to the control after 1, 2 and 3 days of 
incubation with IFN-β and IFN-α (all p<0.001).   
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 Biochemical effects of type I IFNs. 
The chromogranin A levels in the media, collected from BON cells during the 
interval 3-6 days of incubation with IFN-β, were significantly suppressed, 
also using low dose (fig. 6B). This effect was dose dependent, with IC50 
values of 6 IU/ml (comparable with the IC50 of IFN-β on cell proliferation 
inhibition). On the other hand, IFN-α (fig. 6A) induced only a slight 
suppression of chromogranin A even at high dose (100 IU/ml). It is interesting 
to observe that, chromogranin A values, detected after 6 days of treatment 
with IFN-β, highly correlated with the relative values of DNA quantification 
(r2 = 0.98, p<0.0001). 
Figure 5: Cell cycle distribution after 1, 2 and 3 days of incubation with 100 IU/ml IFN-α 
and 100 IU/ml IFN-β in BON cells. Data are expressed as mean ± SEM of the percentage of 
cells in the different phases, compared with untreated control cells. Control values have been 
set to 100%. The mean percentages of control cells in G1 phase were: 60% ± 0.8 (1 day), 
64.8% ± 0.9 (2 days), 65.4% ± 0.6 (3 days). The mean percentages of control cells in S 
phase were: 23.9% ± 0.9 (1 day), 20.6% ± 0.9 (2 days), 21% ± 0.6 (3 days).  : IFN-α   : 
IFN-β. *: p<0.001, **: p<0.05 vs control. 
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Effects of two different preparations of IFN-β-1a on cell growth and 
chromogranin A production.    
The potencies of IFN-β-1a preparations from two different sources (Serono 
Inc. and GIBCO Brl) on cell proliferation and chromogranin A production 
were superimposable (IC50 on cell growth: 6 IU/ml for both preparations; IC50 
on chromogranin A: 4 IU/ml and 3 IU/ml, respectively). For IFN-β Serono 
and IFN-β GIBCO no statistically significant difference was observed 
between the values of logIC50 (on cell growth: 0.79 + 0.04 and 0.75 + 0.06, 
respectively; on chromogranin A: 0.65 + 0.08 and 0.44 + 0.12, respectively) 
and maximal inhibition of proliferation (on cell growth: 98% + 1.6 and 99% + 
2.7, respectively; on chromogranin A: 86 + 2.8 and 85 + 3.4, respectively). 
Figure 6: Effect of IFN-α (A) 
and IFN-β (B) on the 
production of chromogranin A 
in human BON cells after 6 
days of incubation. Plates were 
refreshed after 3 days of 
treatment and compounds 
added again. Values are 
expressed as the percentage of 
control chromogranin A release 
and represent the mean ± SEM. 
The mean chromogranin A 
levels in controls were: 3554 
ng/well (panel A), 3759 ng/well 
(panel B). *: p<0.001, **: 
p<0.01 vs control. 
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Discussion 
IFN-α is currently used as a therapeutic agent in several malignancies, 
including GEP-NETs (14-16,26-29). This cytokine belongs to the class of 
type I IFNs (e.g. IFN-α, IFN-β, IFN-ω, IFN-κ and IFN-τ), which modulate a 
variety of biological responses through the activation of a common receptor, 
composed by two subunits: IFNAR-1 and IFNAR-2 (30,31). IFNAR-1 is 
considered the signaling subunit and it exists as the full chain. The IFNAR-2 
is the subunit responsible for the interaction with the ligand. There are three 
forms of IFNAR-2, which are differentially spliced products of the same gene, 
e.g. the soluble (IFNAR-2a), short (IFNAR-2b) and long (IFNAR-2c) form 
(26,31,32). The chain IFNAR-2c with its long cytoplasmic domain and the 
IFNAR-1 subunit constitute the predominantly active form of the type I IFN 
receptor complex. IFNAR-2c is capable of binding ligand, but with a lower 
affinity (20-fold less) than the dimeric IFN receptor complex itself (33). 
Therefore, both receptor chains are required to form a high affinity binding 
site and initiate signal transduction. The short form is able to bind type I IFNs, 
but does not couple to signal transduction because it lacks the signal 
transducing tail of IFNAR-2c (34). The soluble form may act as a regulator of 
free IFNs and, depending on concentration, lead to the neutralization or 
enhancement of IFN bioactivity (35,36). 
Whereas the role of IFN-α has been extensively studied, the effect of other 
type I IFNs on neuroendocrine cell proliferation has not been evaluated. IFN-
β is a multifunctional cytokine binding to the same receptor of IFN-α, but 
with higher affinity (37). It seems to be an essential mediator not only for the 
host defense in the innate immune responses against microbial infections, but 
also for a host defense system against oncogenesis (28). Few studies showed 
that IFN-β has greater antitumor effects than IFN-α, via the activation of 
apoptosis (17-21). Therefore, IFN-β represents a promising drug in the 
treatment of cancer. 
In the present study, we compared the anti-tumor effects of IFN-β-1a and 
IFN-α-2b in human GEP-NETs, as well as the mechanisms that are involved 
in the growth inhibition. The expression of mRNA and protein for the active 
subunits of type I IFN receptor (IFNAR-1 and IFNAR-2c) was detected by 
quantitative RT-PCR and immunocytochemistry in the human BON cell line. 
Both IFNs showed an inhibitory effect on the cell proliferation of these cells, 
but the antitumor activity of IFN-β-1a was significantly higher than that of 
IFN-α-2b. This difference could be explained by the potent pro-apoptotic 
activity of IFN-β-1a, as shown by the increase in apoptotic cells, evaluated by 
flow cytometry and the increase in DNA fragmentation. On the other hand, 
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IFN-α-2b did not stimulate apoptosis in BON cells, but it was able to induce a 
cell cycle arrest with an accumulation of the cells in S phase. These results are 
consistent with previous studies, which demonstrated a delay in S-G2/M 
phase transit of the cell cycle after treatment with IFN-α in the human GEP-
NETs cells (38,39). The present study shows that apart from the potent 
induction of apoptosis, IFN-β-1a can induce a cell cycle arrest as well, 
resulting in increasing the fraction of cells in the S phase. Moreover, this latter 
effect was significantly more potent and earlier than that of IFN-α-2b. The 
specificity of the effects of IFN-β on BON cell growth is shown by the 
abolishment of the inhibitory effect of IFN-β after incubation with 
neutralizing antibodies against IFN-β in BON cells. 
Although, IFN-α and IFN-β interact with the same receptor, the induction of 
differential pathways can be explained by the differences in the structure 
between both cytokines (40,41), generating differential interactions with the 
same receptor. In fact, although both IFNs induce tyrosine phosphorylation of 
the receptor subunits, IFN-β, but not IFN-α, induces the association of 
IFNAR-1 and IFNAR-2c chains, indicating that the specificity of signaling for 
distinct type I IFN subtypes could be established by differential conformation 
of the receptor complex (34,42). Moreover, it was demonstrated that IFN-α 
can trigger survival pathways in human tumor cells that could, at least in part, 
explain its poor effects on apoptosis onset if compared with that one caused 
by IFN-β (43). On the basis of these results, studies on the pathways activated 
by the two IFNs isoforms are warranted. However, we cannot exclude that 
apoptosis induced by IFN-β was likely due to the strong lack of transition of 
BON cells from S to G2/M phase of cell cycle. In fact, apoptosis could arise as 
a consequence of inefficient cell cycle progression, culminating in apoptosis 
(44).  
In addition, we evaluated the effects of IFN-α and IFN-β on chromogranin A 
production. Chromogranin A is the most sensitive and specific marker in 
GEP-NETs (45,46) and BON cells are able to release this substance. In 
patients, circulating chromogranin A levels are dependent by several factors: 
tumor mass, secretory activity and granule density of tumor cells (45,46). This 
may render the use of chromogranin A in monitoring the response of tumor 
mass during medical treatment difficult. In fact, several drugs (e.g. 
somatostatin analogs) induced a decrease in plasma chromogranin A levels, 
through an inhibitory effect on synthesis and secretion, without any effect on 
tumor growth (46). We detected a very potent dose dependent suppression of 
the chromogranin A levels in the conditioned media collected from BON cells 
in the interval 3-6 days of incubation with IFN-β, whereas the biochemical 
effect of IFN-α was minor and statistically present only at high dose. On the 
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basis of a strong positive correlation between chromogranin A concentrations 
and DNA quantification after 6 days of treatment with IFN-β, we hypothesize 
that the suppression of this tumor marker results from the decrease in the 
number of the cells, rather than from an inhibition in synthesis and secretion. 
This observation suggests that, in patients the determinations of plasma 
chromogranin A could give important information about the effect on tumor 
growth during the treatment of GEP-NETs with IFN-β, also considering that 
the estimation the total tumor mass in disseminated GEP-NETs is not easy 
(46).  
Finally, our findings support the clinical attractiveness to use IFN-β in the 
treatment of GEP-NETs, considering that IFN-β inhibited cell proliferation 
and stimulated apoptosis already at very low concentrations (1-10 IU/ml). 
These concentrations can be achieved in vivo, since 12.3 IU/ml is the maximal 
IFN-β serum concentration reported in healthy subjects after subcutaneous 
administration of this cytokine (47,48). Translation of these findings into a 
clinical application is, however, not easy, considering the short half life of 
IFN-β. But new promising strategies (PEGylated form, carrier proteins like 
IFNAR-2a, or gene therapy) can improve pharmacokinetic and 
pharmacodynamic properties of IFN-β, bringing its real clinical application in 
cancer closer (36,49,50).  
In conclusion, this is the first study showing that the antitumor activity of 
IFN-β in GEP-NETs is considerably more potent than IFN-α. This seems to 
be related to the fact that IFN-α induced cell cycle arrest only, whereas both 
apoptosis and cell cycle arrest were responsible for IFN-β-mediated growth 
suppression even at very low doses. These data provide rationales for future 
preclinical and clinical trials using IFN-β in GEP-NETs. 
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Abstract 
Chemotherapy and radiotherapy have only a marginal role in the management 
of pancreatic adenocarcinoma. 
We evaluated the role of type I interferons (IFNs) and their receptors in the 
regulation of cell growth in 3 human pancreatic adenocarcinoma cell lines 
(BxPC-3, MiaPaCa-2 and Panc-1). 
The treatment with IFN-β showed a very potent inhibitory effect on the 
proliferation of BxPC-3 (IC50: 14 IU/ml) and MiaPaCa-2 (IC50: 64 IU/ml) 
after 6 days. The inhibitory effect of IFN-β was dose- and time dependent and 
significantly stronger than IFN-α. This antitumor effect is mainly modulated 
by the stimulation of apoptosis, which was earlier and more potent than IFN-
α, although cell cycle arrest was induced as well. Panc-1 was the most 
resistant cell line to both IFNs, showing a stimulation of apoptosis only at 
very high doses, and cell cycle arrest at moderate dose. As determined by real 
time quantitative RT-PCR and immunocytochemistry, all 3 cell lines 
expressed type I IFN receptor (IFNAR-1 and IFNAR-2 subunits) mRNA and 
protein. The expression of active subunits (IFNAR-1 and IFNAR-2c) was 
significantly higher in BxPC-3 and mainly localized on the membrane, 
whereas in Panc-1 the staining for IFNAR-1 and IFNAR-2c was mainly 
cytoplasmatic and about 60-70% of cells were negative for IFNAR-2c 
In conclusion, IFN-β is much more potent than IFN-α in its anti-proliferative 
effect on pancreatic cancer cell lines through the induction of an early 
apoptosis, particularly in BxPC-3. The relative high expression of IFNAR-1 
and IFNAR-2c subunits in BxPC-3 and membranous distribution could 
explain the major sensitivity of this cell line to IFN treatment. 
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Introduction 
Pancreatic adenocarcinoma is a highly aggressive malignancy (1). Surgery is 
the only curative therapy. Unfortunately, due to a lack of specific symptoms, 
limitations in diagnostic methods and the biologically aggressive nature of 
this tumor, only 5% to 15% of patients are surgical candidates at the time of 
the diagnosis (1). In this selected group of patients, adjuvant chemotherapy 
has a significant survival benefit but the 5-year survival of 21 % remains poor 
(2). The role of chemoradiotherapy in the management of pancreatic 
adenocarcinoma is unclear (3). However, it has been showed that interferon 
(IFN)-α in combination with adjuvant chemoradiotherapy improved overall 5-
year survival rates of 55% despite advanced tumors resected (4). 
In vitro and in vivo studies have showed the efficacy of type I IFNs (e.g. IFN-
α, IFN-β, IFN-ω, IFN-κ and IFN-τ), in the treatment of several tumors (5-9). 
Although the antitumor effects of IFN-α have been studied in detail, those of 
IFN-β are not well clarified. IFN-β is a multifunctional cytokine binding the 
same receptor of IFN-α, but with higher affinity (10). It seems to be an 
essential mediator not only for the innate immune responses against microbial 
infections, but also for a host defense system against oncogenesis (6,11). 
Besides, few studies showed that IFN-β has greater antitumor effects than 
IFN-α (10, 12-16). On the basis of these observations, IFN-β represents a 
promising drug in the treatment of cancer.  
Importantly, several chromosomal aberrations have been detected in 
pancreatic adenocarcinoma, including a frequent loss of chromosome arm 9p, 
observed in more than 80% of human pancreatic cancer (17). Together to the 
tumor-suppressor genes p16INK4a, p15INK4b and p14ARF also the IFN-α 
and IFN-β genes are located on chromosome 9p (18). Therefore, in relation to 
the defensive role of IFNs against tumors (11), the absence of IFNs 
expression may have an important role in the pathogenesis of pancreatic 
adenocarcinoma.   
To further explore the possibilities of new medical treatments in pancreatic 
cancer, we evaluated in the present study the antitumor activity of IFN-α and 
IFN-β in 3 human pancreatic adenocarcinoma cell lines (BxPC-3, MiaPaCa-2 
and Panc-1) and the role of their receptors in the responsiveness to type I 
IFNs. 
 
 
 
 
Methods 
Cell lines and culture conditions 
The human pancreatic cell lines, BxPC-3, MiaPaCa-2 and Panc-1 were purchased from 
American Type Culture Collection. The cells were cultured in a humidified incubator 
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containing 5% CO2 at 37°C. The culture medium consisted of RPMI 1640 supplemented with 
10% FCS, penicillin (1x105 U/l) and L-glutamine (2 mmol/l). Periodically, cells were 
confirmed as Mycoplasma-free. Cells were harvested with trypsin (0.05%), EDTA (0.02%) 
and resuspended in medium. Before plating, cells were counted microscopically using a 
standard hemocytometer. Trypan Blue staining was used to assess cell viability, and always 
exceeded 95%. Media and supplements were obtained from GIBCO Bio-cult Europe 
(Invitrogen, Breda, The Netherlands).  
 
Drugs and Reagents 
Human recombinant IFN-α-2b (Roferon-A) was obtained from Roche (Mijdrecht, The 
Netherlands), while human recombinant IFN-β-1a was acquired from Serono Inc. (Rebif, 
Rockland, MA). Polyinosic:polycytidylic acid (poly I:C) was obtained from Sigma-Aldrich 
(Leiden, The Netherlands). All compounds were stored at -20°C, and the stock solution was 
constituted in distilled water according to the manufacturer instructions. 
 
Cell proliferation assay 
After trypsinization the cells were plated in 1 ml of medium in 48-well plates at a density of 
5x103 – 4x104 cells/well, depending on the length of the incubation period. The plates were 
then placed in a 37°C, 5% CO2 incubator overnight. The next day the cell culture medium 
was replaced with 1ml/well medium containing increasing concentrations (0-10000 IU/ml) of 
IFNα or IFNβ. Quadruplicates of each treatment were performed. Plates were further 
incubated at 37°C and 5% CO2. After 1, 3 and 6 days of treatment cells were harvested for 
DNA measurement, at approximately 70-80% confluence. Plates for 6 days were refreshed 
after 3 days and compounds were added again. Measurement of total DNA-contents, 
representative for the number of cells, was performed using the bisbenzimide fluorescent dye 
(HoechstTM 33258) (Boehring Diagnostics, La Jolla, CA), as previously described (19).  
 
Cell Death Detection (DNA fragmentation) 
After plating 104 – 4x104 cells/well, depending on the length of the incubation period, on a 48 
well plate cells were left overnight to adhere. The next day the cell culture medium was 
replaced with 1ml/well medium containing increasing concentrations (0-10000 IU/ml) of 
IFNα or IFNβ. Quadruplicates of each treatment were performed. After an additional 
incubation of 1 and 3 days, apoptosis was assessed using a commercially available ELISA kit 
(Cell Death Detection ELISAPlus, Roche Diagnostic GmbH, Penzberg, Germany). The 
standard protocol supplied by the manufacturer was used, as previously described (20). 
Relative apoptosis was determined by a ratio of the average absorbance of the treatment wells 
to the average absorbance of the control wells. The data were corrected for the effect on cell 
number after 1 and 3 days of treatment.  
 
Cell cycle analysis 
Cells (1-4 x 106), depending on the length of the incubation period, were plated in 75cm2 
culture flasks (Corning Costar, Amsterdam). After 1 day medium was changed with fresh 
medium (control group) and with fresh medium plus IFN-α or IFN-β at the concentration of 
1000 IU/ml. Duplicates of each treatment were performed. After 1, 2 and 3 days of 
incubation, cells were harvested by gentle trypsinization and prepared for cell cycle 
determination using propidium iodide for DNA staining, as previously described (17). The 
stained cells were analyzed by FACScalibur flow cytometer (Becton Dickinson, 
Erembodegem, Belgium) and CellQuest Pro Software. Cell cycle progression was measured 
with corresponding absorbances for G0/G1, S and G2-M phases, whereas apoptosis was 
measured by quantifying the sub-G0 peak. 
 
Quantitative RT-PCR 
The expression of type I IFN receptors (IFNAR-1, IFNAR-2 total, the short form IFNAR-2b, 
and the long form IFNAR-2c), IFN-β and housekeeping gene hypoxanthine-phosphoribosyl-
transferase (HPRT) mRNA was evaluated by quantitative RT-PCR in all 3 pancreatic cancer 
cell lines, as previously described (17). Briefly, poly A+ mRNA was isolated using 
Dynabeads Oligo (dT)25 (Dynal AS, Oslo, Norway) from cell pellets containing 
approximately 5x105 cells or from cells previously plated on 48 well plates, as reported in 
poly I:C section. Complementary DNA (cDNA) was synthesized using the poly A+ mRNA in 
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a Tris-buffer together with 1mM of each deoxynucleotide triphosphate, 10 U RNAse 
inhibitor, and 2 U AMV Super Reverse Transcriptase (HT Biotechnology Ltd., Cambridge, 
UK) in a final volume of 40 µl. This mixture was incubated for 1 h at 42°C. One fifth of the 
cDNA library was used for quantification of IFN receptors, IFN-β and HPRT mRNA levels. 
A quantitative PCR was performed by AmpliTaq Gold® DNA Polymerase and the ABI 
PRISM 7700 sequence detection system (Perkin-Elmer Applied Biosystems, Groningen, The 
Netherlands) for real-time amplifications, according to the manufacturer’s protocol. Each 
sample was assayed in duplicate. The assay was performed using 15 µl TaqMan Universal 
PCR Master Mix (Applied Biosystems, Capelle aan de Ijssel, The Netherlands), forward 
primer, reverse primer, probe and 10 µl cDNA template, in a total reaction volume of 25 µl. 
PCR amplification started with a first step for 2 min at 50°, followed by an initial heating at 
95°C for 10 min, samples were subjected to 40 cycles of denaturation at 95°C for 15 sec and 
annealing for 1 min at 60°C.   
The primer and probe sequences that were used for the detection of IFNAR-1, IFNAR-2 total, 
IFNAR-2b, IFNAR-2c and HPRT have been previously described (19). In addition, we also 
evaluated IFN-β mRNA expression in the present study using the following primers and 
probe: 
IFN-β forward, 5’-CAGCAATTTTCAGTGTCAGAAGCT-3’; 
IFN-β reverse, 5’-TTCATCCTGTCCTTGAGGCAG-3’; 
IFN-β probe, 5’-FAM-TGTGGCAATTGAATGGGAGGCTTGAAT-TAMRA-3’. 
All the primer and probe sequences were purchased from Biosource (Nivelles, Belgium). 
The detection of HPRT mRNA was used for normalization of IFN receptor mRNA levels. 
Expression of IFNAR-2a mRNA, the soluble form of IFNAR-2 subunit, was determined 
indirectly by subtracting IFNAR-2b and IFNAR-2c from IFNAR-2 total. Several controls 
were included in the RT-PCR experiments. To ascertain that no detectable genomic DNA was 
present in the poly A+ mRNA preparation (because the IFN-β gene is intron-less), the cDNA 
reactions were also performed without reverse transcriptase and amplified with each primer-
pair. To exclude contamination of the PCR reaction mixtures, the reactions were also 
performed in the absence of DNA template in parallel with cDNA samples. As a positive 
control for the PCR reactions of HPRT and type I IFN receptors human cDNA was amplified 
in parallel with the cDNA samples. 
 
Polyinosinic-polycytidylic acid (poly I:C) stimulation 
Cells were plated at 6x104-8x104 cells/well, depending on the length of the incubation period, 
on 24 well plates and left to adhere overnight. After this period the medium was replaced. 
Poly I:C, double stranded RNA, a potent activator of IFN-β expression, was added at a 
concentration of 100µg/ml in quadruplicates and samples were collected after 2, 4, 6 and 24 
hours of incubation, as described in the quantitative RT-PCR section. Samples were kept on 
ice and directly stored at -80°C. 
 
Immunocytochemistry 
Cytospin preparations of BxPC3, MiaPaCa-2 and Panc-1 cells were fixed with acetone for 10 
minutes. After washing two times with PBS, the cells were incubated for 30 minutes at room 
temperature with antibodies to human IFNAR-1 (rabbit polyclonal antibody, Santa Cruz 
Biotechnology, Inc., Santa Cruz, California, USA) and IFNAR-2c (monoclonal antibody, Dr 
E. Croze, Berlex Biosciences, Richmond, CA) subunits, and for overnight with antibodies to 
IFNAR-2b (rabbit polyclonal antibody, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, 
USA). Finally, a peroxidase complex for IFNAR-1 and IFNAR-2b, or standard streptavidin-
biotinylated alkaline phosphatase (both from IL Immunologic, Duiven, The Netherlands) for 
IFNAR-2c, were used according to the manufacturer’s recommendations to visualize the 
bound antibodies. Negative controls for the immunohistochemistry included: 1) omission of 
the primary antibody; and 2) preabsorbtion of the antibody for IFNAR-2b with the respective 
immunizing receptor peptide. 
 
Statistical analyses 
All experiments were carried out at least three times and gave comparable results. For 
statistical analysis GraphPad PrismTM 3.0 (GraphPad Software, San Diego, USA) was used. 
Fifty percent growth-inhibition concentrations (IC50) and maximal inhibitory effect were 
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calculated using nonlinear regression curve-fitting program. The comparative statistical 
evaluation among groups was firstly performed by the ANOVA test. When significant 
differences were found, a comparison between groups was made using the Newman-Keuls 
test. The unpaired Student t-test was chosen to analyze the differences in concentration-effect 
curves (IC50 and maximal inhibitory effect) and effects in cell cycle modulation between 
different types of IFNs, and the differences of the growth inhibitory effects of IFNs after 3 
and 6 days of treatment. Correlation analyses were performed using Pearson’s coefficients.  
In all analyses, values of p<0.05 were considered statistically significant. Data are reported as 
mean + SEM. Statistical analysis was made after logarithmic transformation. 
 
 
 
Results 
Antiproliferative effects of type I IFNs  
After 6 days of incubation, IFN-α and IFN-β significantly suppressed the 
growth of all three pancreatic cancer cell lines in a dose-dependent manner 
(Fig. 1), with a mean IC50 of 606 IU/ml and 14 IU/ml in BxPC-3, 
respectively; 1531 IU/ml and 64 IU/ml in MiaPaCa-2, respectively; 1250 
IU/ml and 112 IU/ml in Panc-1, respectively. 
The growth-inhibitory effect of IFN-β was significantly more potent than that 
of IFN-α, as shown by the higher maximal inhibition of proliferation induced 
by IFN-β compared with IFN-α (96.7% ± 2 and 72% ± 5.7, respectively, 
p<0.0001 in BxPC-3; 87.5% ± 3.2 and 69.1% ± 6.1, respectively, p<0.0001 in 
MiaPaCa-2; 70.7% ± 1.4 and 53% ± 5.7, respectively, p<0.0001 in Panc-1) 
after 6 days of treatment, as well as by the lower logIC50 of IFN-β compared 
with IFN-α (1.15 ± 0.06 and 2.78 ± 0.15, respectively, p<0.00001 in BxPC-3; 
1.8 ± 0.07 and 3.18 ± 0.13, respectively, p<0.00001 in MiaPaCa-2; 2.05 ± 
0.05 and 3.1 ± 0.17, respectively, p<0.0001 in Panc-1). It is interesting to note 
that in BxPC-3 and MiaPaCa-2 IFN-β induced a statistically significant cell 
growth inhibition already at very low concentrations (5-10 IU/ml). 
In all 3 pancreatic cell lines the effects of IFN-α and IFN-β were time 
dependent. In fact, the maximal inhibition of cell proliferation, induced by 
both cytokines, resulted to be higher after 6 days compared with 3 days of 
incubation (both p<0.0001 in BxPC3; p<0.005 and p<0.0001, respectively for 
IFN-α and IFN-β in MiaPaCa-2; both p<0.0001 in Panc-1). In addition, in 
none of the cells a statistically significant difference was observed between 
the values of IC50 after 3 and 6 days of incubation with IFN-α or IFN-β. 
The cell lines exhibited different sensitivities to the treatment, particularly 
with IFN-β.  BxPC-3 resulted to be the most sensitive and Panc-1 the most 
resistant. The maximal inhibition of proliferation for IFN-β was higher in 
BxPC-3 than in MiaPaCa-2 (p<0.05) and in Panc-1 (p<0.001), while it was 
lower in Panc-1 compared with MiaPaCa-2 (p<0.01). Similarly, the IC50 of 
IFN-β was significantly lower in BxPC-3 than in MiaPaCa-2 and Panc-1 
 52 
(both p<0.001), and higher in Panc-1 compared with MiaPaCa-2 (p<0.05). 
The maximal inhibition of proliferation for IFN-α was higher in BxPC-3 
compared with Panc-1 (p<0.05), while no difference in IC50 values of IFN-α 
was observed between the 3 cell lines. 
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Effects of type I IFNs on apoptosis 
A crucial step in apoptosis is DNA fragmentation, a process that results from 
the activation of endonucleases, which degrade chromatin into smaller 
fragments. The measurement of DNA fragmentation was used to investigate 
the effect of treatment with IFN-α and IFN-β on apoptosis (Fig. 2 and 3). 
After 1 day of incubation, IFN-α had no remarkable stimulatory effects on 
DNA fragmentation at any concentration up to 1000 IU/ml in all 3 cell lines, 
only at the dose of 10000 IU/ml IFN-α induced a significant increase in DNA 
fragmentation (Fig.2 A-C). On the other hand, a dose-dependent induction of 
apoptosis was observed after IFN-β treatment in BxPC-3 and MiaPaCa-2, 
already at a very low concentration (5-10 IU/ml), with a maximal increase of 
DNA fragmentation of about 3.5 times compared to the untreated control 
(Fig.2 D, E). In Panc-1 a stimulating effect on apoptosis has been observed 
only for high doses of IFN-β (> 500 IU/ml) (Fig. 2 F). 
After 3 days of treatment with IFN-α an increase in DNA fragmentation has 
been detected in BxPC-3 and MiaPaCa-2 at a moderate to high dose (Fig 3 
A,B). At this time the induction on apoptosis was still present after IFN-β 
with a maximal stimulation of about 4 and 10 times, compared to the control, 
respectively in MiaPaCa-2 and BxPC-3 (Fig 3 D, E). Also after 3 days of 
incubation the stimulating effects on apoptosis persisted in Panc-1 only at 
high doses of IFN-α (10.000 IU/ml, Fig. 3 C) and IFN-β (>500 IU/ml, Fig. 3 
F). 
These data were also confirmed by morphological observations. In all three 
cell lines the treatment with IFN-β induced clear structural alterations 
consistent with apoptosis, such as cell shrinkage, picnotic nucleus and 
detachment from the plate after 1-3 days, also at very low doses in BxPC-3 
cell line (not shown). These morphological changes are evident only at high 
doses of IFN-α treatment.  
The inhibitory effects of IFN-β on the cell growth of BxPC-3 and MiaPaCa-2 
cell lines appeared to be mainly due to an early pro-apoptotic activity, as 
shown by the highly significant positive correlation between the cell 
proliferation inhibition after 6 days of treatment and DNA fragmentation 
variation after 1 day (r2 = 0.95, p<0.0001, both for BxPC-3 and MiaPaCa-2) 
and 3 days of incubation (r2 = 0.95, p<0.0001, for BxPC3; r2 = 0.90, 
p<0.0001, for MiaPaCa-2). At early stage, apoptosis seems to be not involved 
in the antiproliferative effect of IFN-α on pancreatic cancer cells, in fact no 
significant correlation has been observed between cell proliferation inhibition 
after 6 days and DNA fragmentation variation after 1 day of treatment with 
IFN-α. Only after 3 days of treatment with IFN-α, we observed a positive 
correlation between DNA fragmentation variation and the 6 days cell 
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proliferation inhibition (r2 = 0.74, p<0.0001, for BxPC3; r2 = 0.71, p<0.0001, 
for MiaPaCa-2).  
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Figure 4: Cell cycle distribution after 1, 2 and 3 days of incubation with 1000 IU/ml IFN-α 
and 1000 IU/ml IFN-β in BxPC-3 (A-C), MiaPaCa-2 (D-F) and Panc-1 (G-I) cells. Data are 
expressed as mean ± SEM of the percentage of cells in the different phases, compared with 
untreated control cells. Control values have been set to 100%. 
∆: IFN-α   ▲: IFN-β. *: p<0.05, **: p<0.01, ***:p<0.001 vs control. 
 
 
 
Effects of type I IFNs on the cell cycle 
We also evaluated the effect of treatment with IFN-α (1000 IU/ml) and IFN-β 
(1000 IU/ml) on cell cycle phase distribution after 1, 2 and 3 days of 
incubation in BxPC-3, MiaPaCa-2 and Panc-1 (Fig. 4A-I). 
IFN-α treatment induced a significant accumulation of all 3 cell lines in S 
phase compared to the control and a decrease in proportion of cells in G0/G1 
phase in MiaPaCa-2 and Panc-1. In addition, the histograms of cell cycle 
revealed a late and slight increase in cells with subdiplod DNA content (sub-
G0 phase) only in BxPC-3 and MiaPaCa-2, confirming the induction of 
apoptosis after IFN-α treatment, as previously shown by the DNA 
fragmentation analyses. In the same way, the incubation with IFN-β increased 
the fraction of all 3 cell lines in the S phase of the cell cycle, whereas the 
proportion of cells in G0/G1 phase decreased in comparison with the control. 
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An accumulation of cells in sub-G0 phase has been observed in BxPC-3, 
MiaPaCa-2 and Panc-1 after IFN-β treatment. These data suggested that 
pancreatic cancer cells in S phase failed to transit into G2 and M phases and 
exhibited a prolonged stay in S phase after treatment with type I IFNs.The cell 
cycle arrest induced by IFN-β was more potent than that of IFN-α, 
considering that the percentage of cells in S phase compared to the control 
resulted to be higher after 3 days of incubation with IFN-β than after IFN-α 
(BxPC-3: p<0.05, MiaPaCa-2: p<0.001, Panc-1: p<0.001).  
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Expression of type I IFN receptors and IFN-β mRNA 
Since the susceptibility of cells to IFNs could reflect the different amount of 
corresponding receptors, we analyzed the expression of type I IFN receptors 
Figure 5A-F: Relative expression of type I IFN receptor (AR-1, AR-2 total, AR-2a, AR-2b, 
AR-2c) and IFN-β mRNA in human pancreatic cancer cell lines (BxPC-3, MiaPaCa-2, Panc-
1), evaluated by quantitative RT-PCR. The amount of IFN receptor and IFN-β mRNA was 
calculated relative to the amount of HPRT mRNA and is given in arbitrary units. The soluble 
form of IFNAR-2a subunit was determined indirectly by subtracting IFNAR-2b and IFNAR-2c 
from IFNAR-2 total. Values represent the mean ± SEM 
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(IFNAR-1 and IFNAR-2, short and long form) mRNA by real time 
quantitative RT-PCR in BxPC-3, MiaPaCa-2 and Panc-1 cell lines. Using 
sequence specific primers against the type I IFN receptor subunits, we 
detected the presence of IFNAR-1, IFNAR-2 total, IFNAR-2b and IFNAR-2c 
mRNA, normalized for the amount of the housekeeping gene HPRT. As 
shown in figure 5, the expression of IFNAR-1 mRNA was significantly 
higher in BxPC-3 and MiaPaCa-2 compared with Panc-1 (both p<0.001), 
while no difference was observed between BxPC-3 and MiaPaCa-2. In 
addition, the number of IFNAR-2a, IFNAR-2b and IFNAR-2c mRNA copies 
was higher in BxPC3 than in MiaPaCa-2 and Panc-1 (p<0.001).  
Low expression of mRNA encoding for IFN-β was detected in BxPC-3, while 
it was undetectable in MiaPaCa-2 and Panc-1. We also investigated whether 
the potent IFN inducer, poly I:C, was able to stimulate pancreatic cancer cells 
to produce endogenous IFN-β. Treatment with poly I:C at the concentration of 
100 µg/ml strongly up-regulated the expression of IFN-β mRNA in only 
BxPC-3 (Fig. 6). The peak of IFN-β stimulation was detected after 2 hours of 
incubation with poly I:C, with an increase of about 80-fold compared to the 
control. After 24 hours the levels of IFN-β mRNA returned to the normality. 
In contrast, in the MiaPaCa-2 and Panc-1 cell lines, IFN-β mRNA was absent 
in normal baseline condition as well as after stimulation with poly I:C (100 
µg/ml). 
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Figure 6: Relative expression of IFN-β mRNA after 2h, 4h, 6h and 24h of incubation with poli 
I:C (100µg/ml) in BxPC-3 cell line, evaluated by quantitative RT-PCR. The amount of IFN-β 
mRNA was calculated relative to the amount of HPRT mRNA and is given in arbitrary units. 
Data (mean ± SEM) are presented as percentage change over the control. *: p<0.001; **:p<0.05. 
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Figure 7: Immunocytochemical detection of IFNAR-1 (A,D,G), IFNAR-2b (B,E,H) and 
IFNAR-2c (C,F,I) receptors in BxPC-3 (A-C), MiaPaCa-2 (D-F) and Panc-1 (G-I). 
Magnification, x 400. The espressions of IFNAR-1 and IFNAR-2c are mainly membranous in 
BxPC-3 (A; C see solid arrow), while in Panc-1 both receptors are localized in the cytoplasm 
(G; I see solid arrow) and 60-70% of the cells are negative for IFNAR-2c (I, see dash arrow) 
 
 
 
 
Immunocytochemistry 
Specific immunoreactivity for IFN receptor subunits (IFNAR-1, IFNAR-2b 
and IFNAR-2c) was found in all 3 pancreatic cancer cell lines (Fig. 7A-I). It 
was strongly positive for IFNAR-1 in BxPC3 (Fig. 7A) and the staining was 
predominantly at the plasma membrane. On the other hand, MiaPaCa-2 (Fig. 
7D) and in Panc-1 (Fig. 7G) the expression of IFNAR-1 was lower and 
particularly distributed in the cytoplasm. IFNAR-2b showed a comparable 
expression in BxPC-3 (Fig. 7B) and Panc-1 (Fig. 7H). In BxPC3 the 
immunostaining of IFNAR-2b was localized on the cytoplasm and on the 
membrane, while in Panc-1 the expression of IFNAR-2b is preferentially on 
the cytoplasm. In MiaPaCa-2 (Fig. 7E) the expression of this subunit was 
cytoplasmic and lower compared with the other 2 cell lines. IFNAR-2c is 
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mainly expressed on the plasma membrane and in the cytoplasm in BxPC-3 
(Fig. 7C) and in MiaPaCa-2 (fig. 7F), respectively. In addition, in Panc-1 
(Fig. 7I) this subunit is mainly expressed in cytoplasm, but the IFNAR-2c 
pattern is heterogeneous, in fact the staining is negative in about 60-70% of 
the cells. 
 
 
 
Discussion 
Although few trials criticized the intense toxicity of IFNs (21,22), several 
studies showed that combination of IFN-α with adjuvant chemoradiation 
therapy might increase response rates and achieve prolonged survival in 
patients with pancreatic cancer (4,23). In addition, the administration of IFN-
α in combination with 13-cis retinoic acid or with 5-fluorouracil, leucovorin 
and cisplatin seems to have an increased antiproliferative effect in advanced 
pancreatic carcinoma (24-26). Interestingly, recent reports showed that 
regional adenovirus-mediated IFN-α gene transfer significantly suppressed 
the growth of subcutaneous xenografts of human pancreatic cancer cells in 
nude mice (27,28).  
Whereas the role of IFN-α has been extensively studied, the effect of other 
type I IFNs on pancreatic cancer has been less evaluated. Preliminary reports 
suggested the possibility to use IFN-β in the treatment of pancreatic cancer 
(29-32). A high local production of IFN-β seems to have a strong antitumor 
effect on PANC02-H7, a highly metastatic mouse pancreatic carcinoma cell 
line successfully transfected with a vector containing a murine IFN-β gene. 
The IFN-β-secreting cells drastically lose their capacity to growth and 
metastasize in syngenic mouse, whereas the same cells transfected with a 
control vector remain highly tumorigenic and metastatic (29). A recent paper 
showed that the treatment of human pancreatic cancer cell lines with 
gemcitabine and human IFN-β gene entrapped in liposomes was more 
effective than each treatment alone (30). Busch et al. described the 
stabilization of the disease in a patient with incomplete resection of a 
pancreatic cancer, treated with IFN-β in combination with gemcitabine, 
cisplatinum and radiotherapy (31). On the other hand, Recchia et al. showed 
few long-lasting responses and disease stabilization in patients with advanced 
pancreatic cancer by combining IFN-β with chemotherapy (5-fluorouracil, 
folinic acid, epirubicin, mitomycin C) and retinoids (32). However, the 
efficacy of IFN-β in the treatment of pancreatic cancer, the potential 
differences in antitumor activity with IFN-α and the involved mechanisms of 
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action are still poorly understood. Besides, in clinical practice one of the main 
limits of therapy with type I IFNs is the absence of molecular predictors, 
potentially useful in deciding whether a patient should be treated. This is a 
crucial point, considering that several tumours are completely or partially 
resistant even to high doses of IFNs. While, the loss of type I IFNs genes has 
been excluded to be a predictor factor of response to the treatment with IFN-α 
and IFN-β treatment (18), the role of the IFN receptor has not been reported 
so far. 
Therefore, in the present study, we compared the anti-tumor effects of IFN-α 
and IFN-β, as well as the mechanisms that are involved in the growth 
inhibition of 3 human pancreatic cancer cell lines (BxPC-3, MiaPaCa-2 and 
Panc-1). Moreover, for the first time we evaluated the cellular distribution of 
type I IFN-receptor subtypes in these cell lines. We found that IFN-β potently 
inhibits cell proliferation already at very low concentrations (5-10 IU/ml), at 
least in BxPC3 and MiaPaCa-2. These concentrations can be achieved in vivo, 
since 12.3 IU/ml is the maximal IFN-β serum concentration reported in 
healthy subjects after subcutaneous administration of this cytokine (33,34). 
The direct anti-tumor effects of IFN-α and -β are associated with the 
induction of apoptosis and cell cycle arrest. In BxPC-3 and MiaPaCa-2 both 
cytokines are able to induce apoptosis, but the increase in DNA fragmentation 
after IFN-β treatment occurred earlier and was  considerably more potent than 
IFN-α. It is well known that type I IFNs induce apoptosis by activating the 
caspase cascade, releasing cytochrome-c from mitochondria, inducing tumor 
necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and 
promoting DNA fragmentation. However, this activation occurs late (after at 
least 48-72h) (35,36). Surprisingly, in BxPC-3 and MiaPaCa-2, a significant 
induction of apoptosis is already evident after 1 day of treatment with low 
dose IFN-β, while this effect is present only after 3 days of treatment with a 
moderate to high dose of IFN-α. Panc-1 results to be the most resistant cell 
line to both IFNs, showing a stimulation of apoptosis only at very high doses 
(IFN-α > 10000 IU/ml, IFN-β > 500 IU/ml). However, also in Panc-1 the 
induction of apoptosis is already observed after 1 day of incubation with IFN-
β. In all 3 pancreatic cancer cell lines both IFNs induce a significant 
accumulation of cells in S phase compared to the control, suggestive of a cell 
cycle arrest in the late S phase. The block induced by IFN-β is more potent 
and earlier than that of IFN-α.  
The differential expression and distribution of IFN receptor subunits could 
partially explain the different susceptibility of all 3 cell lines to IFN treatment. 
All type I IFNs activate a common receptor complex composed of two major 
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subunits, IFNAR-1 and IFNAR-2 (37,38). IFNAR-1 is considered the 
signaling subunit, as it is absolutely required for signal transduction. The 
IFNAR-2 is the subunit responsible for the interaction with the ligand. There 
are three forms of IFNAR-2, which are differentially spliced products of the 
same gene, e.g. the soluble (IFNAR-2a), short (IFNAR-2b) and long (IFNAR-
2c) form (6, 39-41). The IFNAR-2c and IFNAR-1 subunits constitute the 
predominantly active form of the type I IFN receptor complex. IFNAR-2c is 
capable of binding ligand, but with a lower affinity (20-fold less) than the 
dimeric IFN receptor complex itself (42). Therefore, both receptor chains are 
required to form a high affinity-binding site and initiate signal transduction 
leading to the induction of IFN-responsive genes. The short form is able to 
bind type I IFNs, but does not couple to signal transduction because it lacks 
the signal transducing tail of IFNAR-2c (43). The soluble form may act as a 
regulator of free IFNs and, depending on concentration, lead to the 
neutralization or even enhancement of IFN bioactivity (44,45). 
Quantitative RT-PCR study and immunocytochemical analysis demonstrate 
the presence of type I IFN receptor subunit transcripts and proteins in BxPC-
3, MiaPaCa-2 and Panc-1 cells. The high expression of IFNAR-1 and IFNAR-
2c subunits in BxPC-3 could explain the major sensitivity of this cell line to 
IFN treatment. In fact, as shown by Wagner et al., increasing the cell surface 
levels of IFNAR2c in cancer cells enhances their sensitivity to the 
antiproliferative and apoptotic effects of type I IFNs (46). Besides, long-term 
cultures of IFNAR1-deficient mouse embryonic fibroblasts as well as IFN-β 
deficient cells result in the formation of transformed colonies, which could 
form tumors in nude mice (5). It is interesting to observe that, by 
immunocytochemistry we demonstrate striking differences in the subcellular 
localization and distribution of IFNs receptor subunits. While in BxPC-3 the 
staining for the active subunits of IFN receptor (IFNAR-1 and IFNAR-2c) are 
mainly membranous, in Panc-1 the expression of both subunits is 
preferentially in the cytoplasm. Besides, in Panc-1 about 60-70% of the cells 
exhibit no detectable levels of IFNAR-2c. This heterogeneity in IFNAR-2c 
expression may provide an additional explanation for the low sensitivity of 
these cells to IFN-α and IFN-β treatment. In Panc-1 it is possible a selection 
of cell type during type I IFNs treatment, with higher possibility to survive for 
IFNAR-2c negative cells. Therefore, all these data suggest that the high 
sensitivity of BxPC3 to IFNs treatment could be related to the strong 
expression of IFNAR-1 and IFNAR-2c and the main membranous 
localization. On the other hand, the low expression, cytoplasmic localization 
and heterogeneous staining of the active receptor in Panc-1 could explain the 
relative resistance of these cells to IFNs treatment. This is the first study, as 
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far as we know, showing the importance of expression, distribution and 
localization of type I IFNs receptor subtypes in the modulation of response to 
IFNs treatment in pancreatic cancer. Our data are also suggestive for a careful 
evaluation of IFNAR subtypes in pancreatic cancer before treatment with type 
I IFNs is considered.  
Finally, the expression of IFN-β was investigated. BxPc-3 is the only cell line 
able to produce IFN-β mRNA in normal condition or after the stimulation 
with poly I:C, a synthetic double-stranded RNA copolymer of inosinic and 
cytidylic acids able to mimic a viral infection. It is noteworthy, that BxPC-3 
has been described to be more differentiated than MiaPaCa-2 and Panc-1 (47). 
We cannot exclude a main role of the endogenous production of IFN-β in the 
differentiation of these cell lines, considering that IFNs are also differentiating 
factors (5,10). 
Although IFN-α and IFN-β interact with the same receptor, the induction of a 
differential response can be explained by the diversity in the structure 
between both cytokines. There is only 35% sequence identity between both 
IFNs, and unlike IFN-α, IFN-β is glycosylated and includes a zinc ion 
(48,49). These differences generate different interactions and affinities for the 
related receptor. In fact IFN-β has a higher affinity (10-fold) than IFN-α (9). 
However, this cannot completely explain the difference in potency of cell 
growth inhibition between both cytokines, particularly in BxPC-3, where the 
IC50 for IFN-β is 40 times lower than that of IFN-α. Differences in the 
interaction of these IFNs with their receptors might be also involved. In fact, 
although both IFNs induce tyrosine phosphorylation of the receptor subunits, 
IFN-β, but not IFN-α, induces the association of IFNAR-1 and IFNAR-2c 
chains, indicating that the specificity of signaling for distinct type I IFN 
subtypes is established by differential conformation of the receptor complex 
(43,50).  
In conclusion, our study shows that IFN-β is significantly more effective than 
IFN-α in inducing cell growth inhibition in pancreatic cancer, because it 
induces a more potent and earlier cell cycle arrest and apoptosis activation 
compared with IFN-α. Considering that IFN-β stimulates apoptosis already at 
very low dose, this cytokine could be a more promising agent than IFN-α for 
the treatment of human pancreatic cancer, particularly in tumors with a high 
expression of IFNAR1 and IFNAR2c, supporting its use in future clinical 
investigation. In addition, there is clear in vitro evidence that differential 
expression levels and distribution of the IFNs receptor subunits play a role in 
the regulation of the response to type I IFNs therapy in pancreatic cancer. 
Future studies should investigate in vivo whether the intensity, subcellular 
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localization and distribution of IFNAR-1 and IFNAR-2c at 
immunohistochemistry might predict the response to therapy with IFN-β in 
pancreatic cancer. 
 
 
 
References 
1. Sohn T, Yeo C, Cameron J, et al. Resected adenocarcinoma of the pancreas—616 patients: 
results, outcomes, and prognostic indicators.  J Gastrointest Surg 2000;4:567-79.  
2. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and 
chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-10. 
3. Klinkenbijl JH, Johannes J, Tarek S, et al. Adjuvant radiotherapy and 5-fluorouracil after 
curative resection of cancer of the pancreas and periampullary region: phase III trial of the 
EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230:776-82. 
4. Picozzi VJ, Kozarek RA, Traverso LW. Interferon-based adjuvant chemoradiation therapy 
after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 2003;185:476-
480. 
5. Lindner DJ, Borden EC, Kalvakolanu DV. Synergistic antitumor effects of a combination of 
interferons and retinoic acid on human tumor cells in vitro and in vivo. Clin Cancer Res 
1997;3:931-7. 
6. Takaoka A, Taniguchi T. New aspects of IFN-α/β signalling in immunity, oncogenesis and 
bone metabolism. Cancer Sci 2003;94:405-11. 
7. Mitchell MS. Combination of anticancer drugs and immunotherapy. Cancer Immunol 
Immunother 2003;52:686-92. 
8. Vitale G, Tagliaferri P, Caraglia M, et al. Slow release lanreotide in combination with 
interferon-α2b in the treatment of symptomatic advanced medullary thyroid carcinoma. J Clin 
Endocrinol Metab 2000;85:983-8. 
9. Vitale G, Caraglia M, Ciccarelli A, et al. Current Approaches in the therapy of Medullary 
Thyroid Carcinoma. Cancer 2001;91:1797-808. 
10. Johns TG, Mackay IR, Callister KA, Hertzog PJ, Devenish RJ, Linnane AW. 
Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher 
efficacy of interferon beta. J Natl Cancer Inst 1992;84:1185-90. 
11. Xie K, Bielenberg D, Huang S. Abrogation of tumorigenicity and metastasis of murine and 
human tumor cells by transfection with the murine IFN-beta gene: possible role of nitric 
oxide. Clin Cancer Res 1997;3:2283-94. 
12. Giandomenico V, Vaccari G, Fiorucci G, et al. Apoptosis and growth inhibition of squamous 
carcinoma cells treated with interferon-α, interferon-β and retinoic acid are associated with 
induction of the cyclin-dependent kinase inhibitor p21. Eur Cytokine Netw 1998; 9:619-31. 
13. Rosenblum MG, Yung WKA, Kelleher PJ, Ruzicka F, Steck PA, Borden EC. Growth 
inhibitory effects of interferon-β but not interferon-α on human glioma cells: correlation of 
receptor binding 2’,5’ –oligoadenylate synthetase and protein kinase activity. J Interferon Res 
1990;10:141-51. 
14. Coradini D, Biffi A, Pirronello E, Di Fronzo G. The effect of α-, β- and λ-interferon on the 
growth of breast cancer cell lines. Anticancer Res 1994;14:1779-84. 
15. Damdinsuren B, Nagano H, Sakon M, et al. Interferon-β is more potent than interferon-α in 
inhibition of human hepatocellular carcinoma cell growth when used alone and in 
combination with anticancer drugs. Ann Surg Oncol 2003:10:1184-90. 
16. Vitale G, de Herder WW, van Koetsveld PM, et al. Interferon-beta is a highly potent inhibitor 
of gastroenteropancreatic neuroendocrine tumor cell growth in vitro. Cancer Res 2006;66:(In 
Press). 
 65 
17. Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin 
Cancer Res 2000;6:2969-72. 
18. Chen ZH, Zhang H, Savarese TM. Gene deletion chemoselectivity: codelection of the genes 
for 16INK4, methylthioadenosine phosphorylase, and the α- and β-interferons in human 
pancreatic cell carcinoma lines and its implications for chemotherapy. Cancer Res 
1996;56:1083-90. 
19. Hofland LJ, van Koetsveld PM, Lamberts SW. Percoll density gradient centrifugation of rat 
pituitary tumor cells: a study of functional heterogeneity within and between tumors with 
respect to growth rates, prolactin production and responsiveness to the somatostatin analog 
SMS 201-995. Eur J Cancer 1990;26:37-44. 
20. Ferone D, Pivonello R, van Hagen PM, et al. Quantitative and functional expression of 
somatostatin receptor subtypes in human thymocytes. Am J Physiol Endocrinol Metab 
2002;283:E1056-66. 
21. John WJ, Flett MO. Continuous venous infusion of 5-fluorouracil and interferon-alpha in 
pancreatic carcinoma. Am J Clin Oncol 1998;21:147-50. 
22. Sparano J, Lipsitz S, Wadler S, et al. Phase II trial of prolonged continuous infusion of 5-
fluorouracil and interferon-alpha in patients with advanced pancreatic cancer: eastern 
cooperative oncology group protocol 3292. Am J Clin Oncol 1996;19:546-51. 
23. Nukui Y, Picozzi VJ, Traverso LW. Interferon-based adjuvant chemoradiation therapy 
improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 
2000; 179:367-371 
24. Brembeck FH, Schoppmeyer K, Leupold U, et al. A phase II pilot trial of 13-cis retinoic acid 
and interferon-α in patients with advanced pancreatic carcinoma. Cancer 1998;83:2317-23. 
25. Sporn JR, Buzaid AC, Slater D, Cohen N, Greenberg BR. Treatment of advanced pancreatic 
adenocarcinoma with 5-FU, leucovorin, interferon-alpha-2b, and cisplatin. Am J Clin Oncol 
1997;20:81-3. 
26. Bernhard H, Jager-Arand E, Bernhard G, et al. Treatment of advanced pancreatic cancer with 
5-fluorouracil, folinic acid and interferon alpha-2A: results of a phase II trial. Br J Cancer 
1995;71:102-5. 
27. Hatanaka K, Suzuki K, Miura Y, et al. Interferon-α and antisense K-ras RNA combination 
gene therapy against pancreatic cancer. J Gene Med 2004;6:1139-48. 
28. Ohashi M, Yoshida K, Kushida M, et al. Adenovirus-mediated interferon-α gene transfer 
induces regional direct cytotoxicity and possible systemic immunity against pancreatic 
cancer. Br J Cancer 2005;93:441-9. 
29. Wang B, Xiong Q, Shi Q, Le X, Abbruzzese JL, Xie K. Intact nitric oxide synthase II gene is 
required for interferon-β-mediated suppression of growth and metastasis of pancreatic 
adenocarcinoma. Cancer Res 2001;61:71-5. 
30. Endou M, Mizuno M, Nagata T, et al. Growth inhibition of human pancreatic cancer cells by 
human interferon-β gene combined with gemcitabine. Int J Mol Med 2005;15:277-83. 
31. Busch M, Wilkowski R, Schaffer M, Duhmke E. Combined chemotherapy, radiotherapy, and 
immunotherapy for pancreatic carcinoma. A case report. Adv Ther 2000;17:133-9. 
32. Recchia F, Sica G, Casucci D, Rea S, Gulino A, Frati L. Advanced carcinoma of the 
pancreas: phase II study of combined chemotherapy, beta-interferon, and retinoids. Am J Clin 
Oncol 1998;21:275-9. 
33. Buchwalder PA, Buclin T, Trinchard I, Munafo A, Biollaz J. Pharmacokinetics and 
pharmacodynamics of IFN-beta 1a in healthy volunteers. J Interferon Cytokine Res 
2000;20:857-66. 
34. Salmon P, Le Cotonnec JY, Galazka A, Abdul-Ahad A, Darragh A. Pharmacokinetica and 
pharmacodynamics of recombinant human interferon-beta in healthy male volunteers. J 
Interferon Cytokine Res 1996;16:759-64. 
35. Chawla-Sarkar M, Leaman DW, Jacobs BS, Borden EC. IFN-β pretreatment sensitizes 
human melanoma cells to TRAIL/Apo2 Ligand-Induced Apoptosis. J Immunol 
2002;169:847-55. 
36. Chawla-Sarkar M, Leaman DW, Borden EC. Preferential induction of apoptosis by interferon 
(IFN)-β compared with IFN-α2: correlation with  TRAIL/Apo2L induction in melanoma cell 
lines. Clin Cancer Res 2001;7:1821-31. 
 66 
37. Mogensen KE, Lewerenz M, Reboul J, Lutfalla G, Uze G. The type I interferon receptor: 
structure, function, and evolution of a family business. J Interferon Cytokine Res 
1999;19:1069-98. 
38. Deonarain R, Chan DCM, Platanias LC, Fish EN. Interferon-α/β-receptor interactions: a 
complex story unfolding. Curr Pharm Des 2002;8:2131-7. 
39. Domanski P, Witte M, Kellum M, et al. Cloning and expression of a long form of the beta 
subunit of the interferon alpha beta receptor that is required for signalling. J Biol Chem 
1995;270:21606-11. 
40. Domanski P, Colamonici OR. The type-I interferon receptor. The long and short of it. 
Cytokine Growth Factor Rev 1996;7:143-51. 
41. Pestka S. The interferon receptors. Semin Oncol 1997;24 (3 Suppl 9):S9-18-S9-40. 
42. Cohen B, Novick D, Barak S, Rubinstein M. Ligand-induced association of the type I 
interferon receptor components. Mol Cell Biol 1995;15:4208-14 
43. Croze E, Russell-Harde D, Wagner TC, Pu H, Pfeffer LM, Perez HD. The human type I 
interferon receptor. Identification of the interferon beta-specific receptor-associated 
phosphoprotein. J Biol Chem 1996;271:33165-8. 
44. Hardy MP, Owczarek CM, Trajanovska S, Liu X, Kola I, Hertzog PJ. The soluble murine 
type I interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both 
agonistic and antagonistic properties. Blood 2001;97:473-82. 
45. McKenna SD, Vergilis K, Arulanandam AR, Weiser WY, Nabioullin R, Tepper MA. 
Formation of human IFN-beta complex with the soluble type I interferon receptor IFNAR-2 
leads to enhanced IFN stability, pharmacokinetics, and antitumor activity in xenografted 
SCID mice. J Interferon Cytokine Res 2004;24:119-29 
46. Wagner TC, Velichko S, Chesney SK, et al. Interferon receptor expression regulates the 
antiproliferative effects of interferons on cancer cells and solid tumors. Int J Cancer 
2004;111:32-42.  
47. Sipos B, Moser S, Kalthoff H, Torok V, Lohr M, Kloppel G. A comprehensive 
characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in 
vitro research platform. Virchows Arch 2003;442:444-52. 
48. Klaus W, Gsell B, Labhardt AM, Wipf B, Senn H. The three-dimensional high resolution 
structure of human interferon alpha-2a determined by heteronuclear NMR spectroscopy in 
solution. J Mol Biol 1997;274:661-75. 
49. Karpusas M, Nolte M, Benton CB, Meier W, Lipscomb WN, Goelz S. The crystal structure of 
human interferon beta at 2.2-A resolution. Proc Natl Acad Sci U S A 1997;94:11813-8. 
50. Platanias LC, Fish EN. Signaling pathways activated by interferons. Exp Hematol 
1999;27:1583-92. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 67 
 
 
 
 
 
 
 
 
CHAPTER IV: 
 
DIFFERENTIAL EFFECTS OF TYPE I 
INTERFERONS ON THE TUMOR GROWTH OF 
HUMAN ADRENAL CARCINOMA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
van Koetsveld PM, Vitale G, van der Wansem K, Waaijers M,  de 
Herder WW, Croze E, van der Lely AJ, Lamberts SJW, Hofland LJ. 
(Submitted) 
 
 68 
Abstract 
Adrenocortical carcinoma (ACC) is a rare tumor with a poor prognosis. 
Despite efforts to develop new therapeutic regimens, surgery remains the 
mainstay of treatment. In the present paper, we evaluated the anti-tumor 
effects of type I interferons (IFN-α and IFN-β) on human ACC cell lines 
(H295 and SW13). 
As determined by quantitative RT-PCR analysis and immunocytochemistry, 
H295 and SW13 cells expressed the active type I IFN receptor mRNA and 
protein (IFNAR-1 and IFNAR-2c subunits). Both IFNs significantly inhibited 
ACC cell growth in a dose-dependent manner, but the effect of IFN-β1a (IC50: 
5 IU/ml, maximal inhibition: 96% in H295; IC50: 18 IU/ml, maximal 
inhibition: 85% in SW13) was significantly more potent than that of IFN-α 
(IC50: 57 IU/ml, maximal inhibition: 35% in H295; IC50: 221 IU/ml, maximal 
inhibition: 60% in SW13). Whereas in H295 cells both IFNs induced 
apoptosis and accumulation of the cells in S phase, in SW13 the anti-tumor 
mechanism is modulated by the cell cycle arrest only. Interestingly, only IFN-
β potently suppressed IGF-2 mRNA expression in H295. 
In conclusion, IFN-β is much more potent, compared to IFN-α, in its 
inhibitory effect on ACC cell proliferation in vitro via the induction of 
apoptosis and cell cycle arrest. Further studies are required to establish 
whether IFN-β has comparable potent tumor growth inhibitory effects in vivo.  
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Introduction 
Adrenocortical carcinoma (ACC) is a rare tumor with a dismal prognosis. The 
incidence of AAC in the population is 0.5 to 2 per million and about two-third 
of ACC are functional, producing cortisol, aldosterone, androgens, or 
estrogens (1, 2). 
Complete surgical resection is currently the only potentially curative therapy 
for localized adrenal cortical carcinoma (3). When complete resection is not 
possible, or in advanced disease, the treatment of choice is chemotherapy with 
mitotane (2). Mitotane is an adrenolytic compound with a specific activity on 
the adrenal cortex (4). The efficacy of the treatment is approximately 30%, 
dependent of the stage of the tumor. This drug gives several side effects in 
central nervous system, liver, kidney, and bone marrow and long-term therapy 
is indicated only in case of a clinical response (2). In addition, there are no 
conclusive data showing favourable effects on survival and quality of life 
after the treatment with mitotane alone or in combination with chemotherapy 
in ACC (5). Therefore, novel treatment strategies are clearly required for this 
carcinoma. 
In vitro and in vivo studies have shown the efficacy of type I interferons 
(IFNs) in the treatment of several tumors, alone or in combination with 
chemotherapy (6, 7). Type-I IFNs primarily include IFNs-α, IFN-β and IFN-
ω, that interact with same receptor complex, composed by two subunits: 
IFNAR-1 and IFNAR-2 (8, 9). These cytokines modulate anti-tumor activity 
through different mechanisms, e.g. cell cycle arrest, induction of apoptosis, 
activation of NK cells, T cells, monocytes and macrophages, induction of 
surface antigen expression on tumor cells, as well as inhibition of 
angiogenesis and the production of various growth factors (10). It has been 
described that type I IFNs are able to downregulate the expression of gene and 
protein release of insulin-like growth factor-2 (IGF-II) in some cancers (11, 
12). Considering that, IGF-II is highly expressed by more than 90% of the 
ACC and being involved in adrenal growth and tumorigenesis of this cancer 
(13), type-I IFNs could be of potential interest in the treatment of ACC.  
To further explore the possibilities of new medical therapies in ACC, we 
investigated the in vitro effects and the mechanism of action of type-I IFNs 
(IFN-α2b and IFN-β) on the growth of two established human ACC cell lines 
(H295, SW13). 
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Material and method 
Cell lines and culture conditions  
Human H295R cells, a human adrenocortical carcinoma cell line, were obtained from ATCC 
(Manassas (VA), United States). As previously shown, these cells produce several 
corticosteroid hormones (14). SW13 adrenal tumor cells were obtained from ECACC 
(Salisbury, Wiltshire, UK). 
The cells were cultured in a humidified incubator containing 5% CO2 at 37°C in  75 cm2 
culture flasks (Corning Costar, Amsterdam,The Netherlands). The culture medium consisted 
of a 1:1 mixture of Dulbecco’s modified Eagle’s medium (DMEM) and F12K medium, 
supplemented with 5% FCS, penicillin (1x105 U/l), fungizone (0.5 mg/l) and L-glutamine (2 
mmol/l). Periodically, cells were confirmed as Mycoplasma-free. Cells were harvested with 
trypsin EDTA 10% and resuspended in culture medium. Before plating, cells were counted 
microscopically using a hemocytometer. Trypan Blue staining was used to assess cell 
viability, and always exceeded 95%. Media and supplements were obtained from GIBCO 
Bio-cult Europe (Invitrogen, Breda, The Netherlands).  
 
Drugs and Reagents 
Human recombinant IFN-α-2b (Roferon-A) was purchased from Roche® (Almere, The 
Netherlands). Human recombinant IFN-β-1a was purchased from Serono Inc. (Rebif, 
Rockland, MA). Human recombinant IFN-β-1b was obtained from Schering (Mijdrecht, The 
Netherlands).  Anti-human IFN-β neutralizing antibody was purchased from Sigma-Aldrich 
(St. Louis, MA). Caspase inhibitors Devd-cho, Lehd-cho and Ietd-cho were purchased by 
Biosource (Brussel, Belgium). Mitotane ((1,1–dichloro-2(o-chlorophenyl)-2(p-
chlorophenyl)ethane), Lysodren) was obtained from Bristol-Myers Squibb (Sermoneta, Italy). 
All compounds were stored at -20°C, and the stock solution was diluted according to the 
manufacturer instructions. 
 
Quantitative RT-PCR 
Quantitative PCR was performed as described previously (15, 16). Briefly, for the detection 
of interferon receptors (IFNAR1, IFNAR2c, IFNar2b) and IGF-II total RNA was isolated 
using a commercially available kit (Roche®, Almere, The Netherlands) according the 
manufacture procedure. 
cDNA was synthesized using 10 µl (10 µg/µl) RNA, in a Tris buffer (50 mmol/L Tris-HCL 
(pH 8.3), 100 mmol/L KCL, 4 mmol/L DTT, and 10 mmol/L MGCL2), together with 5 ng 
Oligo(16)12-18 Primer (InVitrogen, Breda, The Netherlands), 1 mmol/L of each 
deoxynucleotide triphosphate, 10 units RNase inhibitor, and 2 units avian myeloblastosis 
virus Super Reverse Transcriptase (HT biotechnology) in a final volume of 40 µL. This 
mixture was incubated by 65oC for 10 min followed by 42oC for 60 min., (biometra, 
Westburg, The Netherlands). 
A quantitative PCR was performed using the TaqMan® Gold nuclease assay (Perkin Elmer 
Corporation, Foster City, CA, USA) and the ABI PRISM® 7700 sequence detection System 
(Perkin Elmer Applied Biosystems, Groningen, The Netherlands) for real-time 
amplifications, according to manufacturer’s protocol. The assay was performed using 12.5 µl 
TaqMan® Universal PCR Master Mix (Applied Biosystems, The Netherlands), 2.5 µl primer 
mix contain: forward primer (500 nmol for IFNAR-2c; 300 nmol for IFNAR-1, IFNAR-2 
total, IFNAR-2b and IGF-II), reverse primer (500 nmol for IFNAR-2c; 300 nmol IFNAR-1, 
IFNAR-2total, IFNAR-2b and IGF-II), probe (100 nmol for IFNAR-1 IFNAR-2total, and 
IGF-II; 200 nmol IFNAR-2b and IFNAR-2c) and 10 µl cDNA template. After an initial 
heating at 95°C for 8 min, samples were subjected to 40 cycles of denaturation at 95°C for 15 
sec and annealing for 1 min at 60°C. The primer and probe sequences were purchased from 
Biosource (Brussel, Belgium). The sequence of the primers IFNAR-1, IFNAR-2 total, 
IFNAR-2b and IFNAR-2c and IGF-2 were described in table 1 (17). 
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Table 1: Primers and probes used for the quantitative RT-PCR. 
 
 
IFNAR-1 
 
Forward 5-CCCAGTGTGTCTTTCCTCAAA-3’ 
Reverse 5’-AAGACTGGAGGAAGTAGGAAAGC-3’ 
Probe 5’-FAM-TCCGCGTACAAGCATCTGATGGA-TAMRA-3’ 
  
IFNAR-2 (total form)  
Forward 5’-AGTCAGAGGGAATTGTTAAGAAGCA-3’ 
Reverse 5’-TTTGGAATTAACTTGTCAATGATATAGGTG-3’ 
Probe 5’-FAM-AAACCCGAAATAAAAG 
GAAACATGAGTGGAAATT-TAMRA-3’ 
  
IFNAR-2c (long form)  
Forward 5’-TGACAAGCACCATAGTGACACTGA-3’ 
Reverse 5’-TAGGAAATGGCCAGGCTAAAAA-3’ 
Probe 5’-TGGATTGGTTATATATGCTTAAG 
AAATAGCCTCCCCA-TAMRA-3’ 
  
IFNAR-2b (short form)  
Forward 5’-GCTTAAGAAATAGCCTCCCCAAA-3’ 
Reverse 5’-CTGTGAATAGCCACTGCATTCC-3’ 
Probe 5’-TCTTGAGGCAAGGTCTCGCTAAGGGC-TAMRA-3’ 
  
IGF-2  
Forward 5’-CCAAGTCCGAGAGGGACGT-3’ 
Reverse 5’-TTGGAAGAACTTGCCCACG-3’ 
Probe 5’-FAM-ACCGTGCTTCCGGACAACTTCCC-TAMRA-3’ 
 
 
 
 
The estimated copy numbers were obtained according to the method described by Swillens et 
al. (18). IFNAR-1, IFNAR-2 total, IFNAR-b, IFNAR-2c and IGF-II were normalised by the 
amount of RNA. Several controls were included in the RT-PCR experiments. To ascertain 
that no detectable genomic DNA was present in the RNA the cDNA reactions were also 
performed without reverse transcriptase and amplified with each primer-pair. To exclude 
contamination of the PCR reaction mixtures, the reactions were also performed in the absence 
of cDNA template in parallel with cDNA samples. As a positive control for the PCR 
reactions of type I IFN receptors and IGF-2 human DNA was amplified in parallel with the 
cDNA samples. 
 
Immunocytochemistry 
Cytospins preparations of H295 and SW13 cells were fixed with acetone (10 min.) and 
incubated for 30 minutes at room temperature with antibodies to human IFNAR-1 (rabbit 
polyclonal antibody, Santa Cruz Biotechnology, Inc., Santa Cruz, California, USA) and 
human IFNAR-2c (monoclonal antibody, Dr. E. Croze, Berlex Biosciences, Richmond, CA). 
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Finally, a peroxidase complex (IL Immunologic, Duiven, The Netherlands) for IFNAR-1 or a 
standard streptavidin-biotinylated alkaline phosphatase detection system (IL Immunologic, 
Duiven, The Netherlands) for IFNAR-2c were used according to the manufacturer’s 
recommendations to visualize the bound antibodies. 
Negative controls for the immunohistochemistry included omission of the primary antibody. 
 
Cell proliferation assay 
After trypsinization, the cells were plated in 1 ml of medium in 24-well plates at a density of 
105 cells/well for H295 and of 5x103 SW13. The plates were then placed in a 37°C, 5% CO2 
incubator. Two days later the cell culture medium was replaced with 1ml/well medium 
containing various concentrations of drugs (IFN-α: 0-1000 IU/ml; IFN-β1a: 0-100 IU/ml; 
IFN-β1b: 0-100 IU/ml). Quadruplicates of each treatment were performed. Plates were 
further incubated at 37°C and 5% CO2. After 3 and 6 days of treatment the cells were 
harvested for DNA measurement. Plates for 6 days were refreshed after 3 days and 
compounds were added again. Measurement of total DNA-contents, representative for the 
number of cells, was performed using the bisbenzimide fluorescent dye (HoechstTM 33258, 
Boehring Diagnostics, La Jolla, CA), as previously described (19)  
To evaluate the specificity of the effects of IFN-β1a on cell growth, the cells were  exposed to 
IFN-β1a with an anti-human IFN-β neutralizing antibody. H295 cells (105 cells/well) were 
plated in 24-well plates and after 2 days of incubation  the medium containing IFN-β1a (5 
IU/ml), in the absence or in presence of anti-human IFN-β neutralizing antibody (4 µg/ml), 
was added. After 3 days the plates were collected for DNA measurement, as previously 
described. IFN-β1a alone or in combination with anti-human IFN-β neutralizing antibody, 
have been incubated for overnight at 4°C prior to be added to H295 cells, in order to 
antagonize the IFN-β activity. 
 
Apoptosis assay 
Apoptosis was evaluated by the analysis of the DNA fragmentation. After plating of 105 
cells/well for H295 and 2 x 104 cells/well for SW13 on 24 well plates, cells were incubated at 
37°C. After two days the cell culture medium was replaced with 1ml/well medium containing 
various concentrations of drugs (IFN-α: 0-1000 IU/ml; IFN-β1a: 0-100 IU/ml; IFN-β1b: 0-
100 IU/ml). Quadruplicates of each treatment were performed. After 1 day of incubation, 
apoptosis was assessed using a commercially available ELISA kit (Cell Death Detection 
ELISAPlus, Roche Diagnostic GmbH, Penzberg, Germany). The standard protocol supplied by 
the manufacturer was used, as previously described (20). Apoptosis was expressed as 
percentage to control. 
To evaluate the role of caspases involved in the induction of apoptosis after IFN-β1a 
treatment, we studied the effects of caspase inhibitors in combination with IFN-β1a in H295 
cells. Cells (105 cells/well) were plated in 24-well plates and after 1 day of incubation, 1ml of 
the medium containing 10µM of different caspase inhibitors: Devd-cho (blocks caspase 3), 
Ietd-cho (blocks caspase 8), Lehd-cho (blocks caspase 9) was added. After 1 day of 
incubation, IFN-β1a (5 IU/ml) in the absence or in the presence of the caspase inhibitors, was 
incubated for 24 hours. Plates were collected for DNA fragmentation detection, as previously 
described.  
 
Cell cycle analysis 
Cells 2 x105 for H295 and 5 x 105 for SW13 were plated on 12 well plates. After 1 day the 
medium was changed with fresh medium (control) or with fresh medium plus IFN-α2b (500 
and 1000 IU/ml) or IFN-β1a (50 and 100 IU/ml). After 3 days of incubation (confluency of 
about 60-70%), cells were harvested by gentle trypsinization, washed with cold phosphate-
buffered calcium and magnesium free saline (PBS), and collected by centrifugation. Cells 
were re-suspended in 200µl of PBS and fixed in 70% ice-cold ethanol with an overnight 
incubation at -20°C. After brief centrifugation, cells were washed once with PBS and 
incubated for 30 minutes at 37°C in PBS containing 40µg/ml of propidium iodide (Sigma 
Aldrich, Zwijndrecht, The Netherlands) and 10µg/ml of DNase-free RNase (Sigma Aldrich, 
Zwijndrecht, The Netherlands). For each tube 20000 cells were immediately measured on a 
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FACScalibur flow cytometer (Becton Dickinson, Erembodegem, Belgium) and analyzed 
using CellQuest Pro Software. 
 
Cortisol determination 
After trypsinization, the H295 cells were cultured in 24-well plates at a density of 105 
cells/well. The plates were then placed in a 37°C, 5% CO2 incubator. After two days later the 
cell culture medium was replaced with 1ml/well medium containing increasing various 
concentrations of drugs (IFN-α: 0-1000 IU/ml; IFN-β1a: 0-100 IU/ml). Medium were 
refreshed after 3 days and compounds were added again. On day 6, medium was removed and 
fresh medium and drugs with forskolin 10 µM was added to the cells for 24 hours.  Forskolin 
stimulates the adenylate cyclase system. In presence of foskolin, cortisol is the major protein 
secreted by the adrenal carcinoma cell line H295 in contrast to other steroids protein (14). 
After 24 hours the media were collected and stored at -20°C until the measurement of 
cortisol. 
Human cortisol concentrations were determined by a non-isotopic, automatic 
chemiluminescence immunoassay system (Immulite, DPC Inc., Breda, The Netherlands) 
according to the manufacturer procedures. Intra- and interassay CV’s were 5.6% and 7.8%, 
respectively.  
 
Statistical analysis 
All experiments were carried out at least three times and gave comparable results. For 
statistical analysis GraphPad PrismTM 3.0 (GraphPad Software, San Diego, USA) was used. 
Relative 50% growth-inhibitory concentrations (IC50) and maximal inhibitory effect were 
calculated using nonlinear regression curve-fitting program. The comparative statistical 
evaluation among groups was firstly performed by ANOVA test. When significant 
differences were found, a comparison between groups was made using the Newman-Keuls 
test. The unpaired Student t-test was chosen to analyze the differences in concentration-effect 
curves (IC50 and maximal inhibitory effect) and effects in cell cycle modulation between 
different types or preparations of IFNs, as well as the differences of the growth inhibitory 
effects of IFNs after 3 and 6 days of treatment. Correlation analyses were performed using 
Pearson’s coefficients. In all analyses, values of p<0.05 were considered statistically 
significant. Data are reported as mean + SEM. 
 
 
 
 
 
Results  
Expression of type I IFN receptor mRNA and proteins in H295 and SW13 
cells 
The activity of type I IFNs is modulated by a common receptor. We generated 
a set of specific primers to analyze the expression of IFNAR-1 and IFNAR-2 
(total, short and long form) mRNA in H295 and SW13 cells by quantitative 
RT-PCR. In both cell lines we detected the presence of IFNAR-1, IFNAR-2 
total, IFNAR-2b and IFNAR-2c (fig. 1). IFNAR-1 mRNA expression, 
normalized for the amount of the total RNA, was higher than IFNAR-2 total 
in both cell lines. Among the IFNAR-2 subunits, IFNAR-2c was the form 
expressed at the relatively lowest level. 
Specific immunoreactivity for the two active IFN receptor subunits (IFNAR-1 
and IFNAR-2c) was found in H295 and SW13 cells at immunocytochemistry 
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(fig. 2). It was positive for IFNAR-1 mainly localized on the membrane (fig.2 
A,C) and strongly positive  for IFNAR-2c on the membrane and cytoplasm 
(fig.2 B,D). 
 
 
 
 
 
 
 
Figure 1: Relative expression of type I interferon receptor (AR-1, AR-2 total, AR-2a, AR-2b, 
AR-2c) mRNA in the human adrenal cancer cell lines H295 and SW13, evaluated by 
quantitative RT-PCR. The amount of relative copies of IFN receptor RNA was calculated 
correcting for the amount of total RNA. The soluble form of IFNAR-2a subunit was 
determined indirectly by subtracting IFNAR-2b and IFNAR-2c from IFNAR-2 total. Values 
represent the mean ± SEM. 
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Figure 2: Immunocytochemical detection of the functional IFN receptor subunits IFNAR-1 (A, C) 
and IFNAR-2c (B, D) in human adrenal cancer H295 (A, C) and SW13 (B, D) cell lines. A strong 
IFNAR-1 and IFNAR-2c immunostaining is evident mainly in the membrane and lesser in the 
cytoplasm. Magnification, x 400. 
 
 
 
 
Effects of two different types of IFN-β on cell growth and apoptosis 
We evaluated the effect of two commercially available INF-β preparations on 
cell proliferation and apoptotic activity in H295 cells. IFN-β1a (Serono, 
amino acid sequence and glycosylation equal as native IFN-β) and IFN-β1b 
(Schering, one amino acid change and absence of glycosylation compared to 
the native IFN-β). 
The effect of IFN-β1a on cell proliferation was significantly more potent 
compared with IFN-β1b after 6 days of treatment (IC50: 9.7±2.7 IU/ml vs. 
87.0±3.8 IU/ml, p<0.01; maximal inhibition effect on cell proliferation 88 
±7% vs. 51±10%, respectively for IFN-β1a and IFN-β1b, P<0.01) (Fig.3 A). 
In H295 cells both types of INF-β preparations increased DNA fragmentation 
in a dose-dependent manner, but in concordance with the effect of cell 
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proliferation, IFN-β1a was more potent than IFN-β1b (IFN-β1a, EC50: 
5.0±1.4 IU/ml, vs. IFN-β1b, EC50 : 249±2 IU/ml p<0.01) (Fig.3 B). 
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Effects of type I IFNs, IFN-α2b and IFN-β1a, on cell proliferation 
After 6 days of incubation, IFN-α2b and IFN-β1a significantly suppressed the 
growth of H295 and SW13 cells in a dose-dependent manner (Fig.4 A,B). 
H295 was significantly more sensitive than SW13, as shown by the 
differences in IC50 after 6 days of treatment with IFN-α2b (57.0±2.3 IU/ml 
and 221.1.1±1.3 IU/ml, H295 and SW13, respectively; p<0.01) and IFN-β1a 
(5.4±1.3 IU/ml and 18.1±1.3 IU/ml, H295 and SW13, respectively; p<0.01). 
There was no statistically significant difference between the IC50 values of 3 
and 6 days for every IFN. After 6 days of incubation IFN-β1a induced in both 
cell lines a statistically significant cell growth inhibition already at very low 
concentrations (1 IU/ml, P<0.01, vs. control). 
Figure 3: Dose-dependent effect 
of two different IFN-β 
preparations on cell growth 
expressed as DNA content (A) 
after 6 days of incubation, and on 
apoptosis, expressed as DNA 
fragmentation  (B), after 24 hours 
of incubation, on H295 human 
adrenal carcinoma cells. 
Data are expressed as percentage 
of control and represent the 
mean±SEM. Control is set as 100 
percent.   
: IFN-β1a 
: IFN-β1b 
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The growth-inhibitory effect of IFN-β1a was significantly more potent than 
that of IFN-α2b, as shown by the higher maximal inhibition of proliferation 
induced by IFN-β1a, compared with IFN-α2b (H295: 96 + 7% and 35 + 2%, 
respectively, p<0.01; SW13: 85 + 7% and and 60 + 3%, respectively, p<0.01) 
after 6 days of treatment, as well as by the lower IC50 of IFN-β1a compared 
with IFN-α2b (p<0.01). In addition, the concentration used to obtain the 
maximal inhibition of proliferation is 100 IU/ml for IFN-β1a and 10 times 
higher (1000 IU/ml) for IFN-α2b. Comparable results were observed by a 
thymidine incorporation assay (data not shown). 
D
N
A
 
co
n
te
n
t 
(%
 
o
f  
co
n
tr
o
l)
0
25
50
75
100
125
D
N
A
 
co
n
te
n
t
(%
 
o
f c
o
n
tr
o
l)
0
25
50
75
100
125
Log IFN (IU/ml) Log IFN (IU/ml)
Log IFN  (IU/ml) Log IFN  (IU/ml)
D
N
A
 
fr
a
gm
en
ta
tio
n
( %
 
o
f  
co
n
tr
o
l)
100
200
400
600
D
N
A
 
fr
a
gm
en
ta
tio
n
( %
 
o
f  
co
n
tr
o
l)
100
200
400
600
0 1 10 100 1000 0 1 10 100 1000
0 1 10 100 1000 0 1 10 100 1000
A B
C D
 
 
 
 
 
 
 
 
Figure 4: Doses-dependent effect of interferon treatment on cell proliferation, expressed as 
DNA content (A, B), after 6 days of incubation, and on apoptosis, expressed as DNA 
fragmentation (C, D), after 24 hours of incubation, in human adrenal cancer H295 cells (A, C) 
and on SW13 cells (B, D). The mean DNA contents in control were: 7257±245 ng/well for 
H295 and 6870±326 ng/well for SW13. Data are expressed as percentage of control and 
represent mean ± SEM. Control is set as 100 percent.   
: IFN-β1a 
: IFN- α2b 
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To clarify the specificity of action of IFN-β1a we evaluated the effects on cell 
growth after a pre-absorption of IFN-β1a with neutralizing antibodies against 
IFN-β in H295 cells. The anti-tumor activity of IFN-β1a (5 IU/ml) was 
completely abolished by immuno-neutralization (fig.5). In fact, no significant 
difference has been observed between DNA contents of the control vs IFN-
β1a + neutralizing antibodies against IFN-β or neutralizing antibodies alone, 
while IFN-β1a alone induced a significant decrease in DNA contents 
compared to the control (p<0.01).   
 
 
 
 
Figure 5: Effects of IFN-β (5 IU/ml) on cell growth after 72 hours of incubation, alone and 
following overnight pre-absorption with neutralizing antibodies against IFN-β (IFN-beta Ab) 
at the dose of 40 µg/l All data are expressed as percentage of control. *: p<0.01 vs. control. 
 
 
 
 
Effects of type-1 IFNs, IFN-α2b and IFN-β1a, on apoptosis 
After 1 day of treatment with IFN-β1a and IFN-α2b we measured the DNA 
fragmentation to investigate the effect on apoptosis (fig.4 C,D). In H295, a 
striking dose-dependent induction of apoptosis was observed after IFN-β1a 
treatment (EC50: 5.0±1.4 IU/ml). The maximal increase of DNA 
fragmentation induced by 100 IU/ml of IFN-β1a was about 6 times higher 
compared with untreated control cells. IFN-β1a stimulated apoptosis in H295 
cells already at very low concentrations (1 IU/ml, p<0.01). A less effective 
dose-dependent induction of apoptosis was observed following IFN-α2b 
exposure of H295 cells (EC50: 249±2 IU/ml). The maximal increase of DNA 
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fragmentation was about 2.5 times compared to the control after 1000 IU/ml 
of IFN-α2b. Interestingly, no effect on apoptosis was observed after treatment 
with IFN-α2b and IFN-β1a in SW13. 
To study the role of caspases 3, 8 and 9 in the induction of apoptosis by IFN- 
β1a in H295 cells we tested if specific caspase inhibitors were able to block 
the IFN-β-induced DNA fragmentation. As shown in figure 6 the stimulation 
of apoptosis by IFN-β1a is completely blocked by Devd-cho, a specific 
inhibitor of caspase-3, while it is partially counteracted by the use of specific 
inhibitors for caspase-8 (Ietd-cho) and -9 (Lehd-cho). 
 
 
 
 
 
 
Figure 6: Effect of specific caspase inhibition on apoptosis induced by IFN-β in H295 cells. 
After 24 hours of preincubation with 10 µM of Devd-cho (caspase 3 inhibitor), Ietd-cho 
(caspase 8 inhibitor), Lehd-cho (caspase 9 inhibitor), the cells were incubated for further 24 
hours with 5 IU/ml IFN-β in the presence or absence of the caspase inhibitors. Apoptose is 
expressed as DNA fragmentation. Values are expressed as the percentage of control 
(untreated cells). +: compound present.*: P<0.05 vs. relative control group; **: P<0.01 vs. 
relative control group, ***: P<0.001 vs. relative control group; ^: P<0.01 vs. IFN-β without 
caspase inhibitors  
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Effects of type-I IFNs, IFN-α2b and IFN-β1a, on cell cycle    
We evaluated the effect of treatment with IFN-α2b (1000 IU/ml and 500 
IU/ml) and IFN-β1a (100 IU/ml and 10 IU/ml) on cell cycle distribution after 
3 days of incubation (Table 2). 
In the H295 and SW13 cells both IFNs induced a significant and dose 
dependent accumulation of cells in the S-Phase (IFN-α2b 1000 IU/ml and 
IFN-β1a 100 IU/ml: p<0.001 vs control in both cells; IFN-α2b 500 IU/ml and 
IFN-β1a 50 IU/ml: p<0.05 vs control in H295 and p<0.01 vs control in SW13 
cells), while no significant change in G1/G0 distribution was observed (table 
2). The accumulation of cells in S-phase after treatment with both IFNs was 
significantly higher in the SW13 compared with H295 cells. In addition, the 
proportion of cells in G2/M phase decreased significantly in comparison with 
the control in both cells lines. These data suggested that adrenal cancer cells 
exhibited a prolonged stay in S phase failing to transit into G2/M phases after 
treatment with type I IFNs. 
Finally, the cell cycle analysis revealed an increase in the percentage of H295 
cells with subdiplod DNA content (sub-G0 phase) after IFN-β1a (100 IU/ml: 
p<0.001: 50 IU/ml: p<0.05) and high dose of IFN-α2b (1000 IU/ml: p<0.05), 
confirming the induction of apoptosis mainly after IFN-β1a, as previously 
shown by the DNA fragmentation analyses. 
 
 
 
 
Biochemical effects 
The effect of both IFNs on forskolin induced cortisol production in H295 cells 
is comparable to the relative cell proliferation inhibition. In fact, we did not 
observe any significant difference between IC50 of cortisol (IFN-β1a: 8.4± 0.2 
pmol/l; IFN-α2b: 450 ± 390  pmol/l) and cell proliferation. This suggests that 
there is no effect on cortisol secretion and that the decrease in cortisol 
production is related to the decrease in the number of cells. 
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Effect of type-1 IFNs, IFN-α2b and IFN-β1a, on IGF-II transcription
 
The expression of IGF-II mRNA was dectectable in H295 cells (20±3 x 106 
copies mRNA IGF-II/ µg RNA), whereas it was undetectable in SW-13. 
In H295 cells the transcription of IGF-II gene seems to be modulated by the 
incubation with IFN-β1a. We observed a dose-dependent decrease in the 
number of copies of IGF-II mRNA after 3 days of treatment with IFN-β1a 
(fig 7). In contrast, IFN-α2b was unable to modify the expression of IGF-II 
gene in H295 cells (data not shown). 
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Discussion 
Type I IFNs, initially identified for their ability to modulate antiviral response 
of cells, are also implicated in cell differentiation, cell growth control, 
immune response, and play an important role in the anti-tumor defense 
(6,7,11,12). These cytokines modulate a variety of biological response after 
Figure 7: Effect on the IGF-2 mRNA 
expression after 72h of treatment with 
different concentrations of IFN-β (100, 
100, 10 IU/ml) on the H295 cells. IGF-2
 
mRNA is evaluated by quantitative RT-
PCR. The amount of relative copies IGF-
2
 
mRNA was calculated to the amount of 
total RNA. Data are expressed as 
percentage of control and represent 
mean±SEM. *: p< 0.01 vs. control 
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activation of a common receptor complex composed by two subunits: 
IFNAR-1 and IFNAR-2. IFNAR-1 is considered the signal subunit chain. 
There are three forms of IFNAR-2, which are differentially spliced products 
of the same gene. IFNAR-2a, soluble form, acts as a regulator of the free IFNs 
(21, 22).  IFNAR-2b, short form, is able to bind type-1 IFN but does not 
couple to signal transduction because it lacks the signal transduction tail (23); 
IFNAR-2c, long form, characterized by its long cytoplasm tail, constitutes 
together with the IFNAR-1 subunit the predominant active form of the type-1 
receptor complex. IFNAR-2c is capable to bind type I IFNs, but whith a lower 
affinity (20 fold less) than the dimeric IFN receptor complex (24).  
In the present study, we evaluated the anti-tumor effects of type I IFNs (IFN-
α2b, IFN-β1a) in the human adrenal cancer H295 and SW13 cells. The 
expression of mRNA and protein for the active subunits of type I IFN receptor 
(IFNAR-1 and IFNAR-2c) was detected by quantitative RT-PCR and 
immunocytochemistry, respectively, in H295 and SW13 cells. Both IFNs 
showed a dose dependent inhibitory effect on cell proliferation. The anti-
tumor activity of IFN-β1a was significantly higher than that of IFN-α2b in 
both cell lines, which is related to the higher induction of apoptosis in H295 
cells and S phase accumulation in both cell lines. The higher sensitivity to 
IFN-1βa may be explained by differences in the structure and affinity between 
IFN-α and IFN-β. There is only 35% sequence identity between both IFNs, 
and unlike IFN-α, IFN-β1a is glycosylated and includes a zinc ion (25, 26). 
These differences could generate differential interactions with the same 
receptor. In fact, although both IFNs induce tyrosine phosphorylation of the 
receptor subunits, IFN-β1a, but not IFN-α, induces the association of IFNAR-
1 and IFNAR-2c chains, indicating that the specificity of signaling for distinct 
type I IFN subtypes could be established by differential conformation of the 
receptor complex (26, 27). Finally, IFN-β has an higher affinity for the 
relative receptor than IFN-α (28). 
H295 cells were significantly more sensitive to IFN-β1a treatment compared 
with SW13. This could be a consequence of the IFN-mediated pro-apoptotic 
activity only in H295 cells, as shown by the increase in DNA fragmentation 
and in the percentage of cells in subG0 phase after the treatment with IFN. We 
evaluated the role of the activation of caspases in the induction of DNA 
fragmentation after IFN-β1a treatment in H295 cells. In the classical model, 
caspases are divided into initiator caspases (such as caspase-8, -9) and 
executioner caspases (caspase-3, -6, -7), according to their function and their 
sequence of activation. There are at least two major apoptotic pathways. The 
first involves the death receptor or extrinsic pathway, which is initiated by 
TNF-receptor family members that recruit adaptor and signaling molecules to 
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assemble the death-inducing signaling complex. This complex leads to 
activation of caspases 8 and/or 10. An alternative mitochondrial pathway 
involves activation of caspase-9 upon recruitment to the mitochondria by 
cytochrome c and apoptosis protease activation factor-1. More downstream, 
the initiator caspases lead to the activation of executioner caspases -3, -6, and 
-7, which in turn cleave specific proteins resulting in the DNA fragmentation 
(29, 30). In H295 cells the stimulation of DNA fragmentation by IFN-β1a is 
completely blocked by a specific inhibitor of caspase-3, while is partially 
counteracted by the use of specific inhibitors for caspase-8 and -9. On these 
bases, IFN-β1a seems to induce apoptosis through both the extrinsic and 
mitochondrial pathways in ACC. 
At present, two recombinant IFNs-β (IFN-β1a and IFN-β1b) are available as 
registered drugs. IFN-β-1a is produced in mammalian cells, with an amino 
acid sequence and glycosylation identical to that of natural IFN-β. In contrast, 
IFN-β1b is produced in Escherichia coli bacteria, and as bacteria lack the 
ability to glycosylate proteins, it is not glycosylated. Furthermore, IFN-β1b 
has one amino acid sequence different from the natural human IFN-β; it has a 
cysteine-to-serine substitution at position 17 and a deletion of the N-terminal 
methionine residue. We observed in H295 cells that the effects of IFN-β1a on 
cell proliferation inhibition and stimulation of DNA fragmentation were much 
more potent compared with IFN-β1b. This is in agreement with the 
observation that the absence of glycosylation in IFN-β-1b can reduce the 
biological activity (31). 
Finally, we evaluated the effects of IFN-β1a on IFG-II mRNA expression, the 
most important autocrine/paracrine growth factor for ACC. H295, but no 
SW13 cells express IGF-II. IGF-II mRNA was inhibited in a dose dependent 
manner by IFN-β1a after 3 days of incubation. This effect was not observed 
after incubation with IFN-α. It is well known that in ACC the up-regulation of 
the IGF-II system represents a main pathway involved in the pathogenesis, 
through the stimulation of the proliferation and inhibition of apoptosis (32). 
This could partially explain why only in H295 cells IFN-β 1a is able to induce 
apoptosis. 
In conclusion, this is the first study showing that type-I IFNs, particularly 
IFN-β1a, have a potent inhibitory effect on the proliferation of the H295 and 
SW-13 human ACC cells, This effect is mediated via the induction of 
apoptosis and/or a cell cycle arrest in the S-phase. Our findings support the 
clinical attractiveness to use IFN-β in the treatment of ACC, considering that 
IFN-β inhibited cell proliferation and stimulated apoptosis already at very low 
concentrations (1-10 IU/ml). In addition, IFN-β1a is able to inhibit at 
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transcriptional level the expression of IGF-II. Further studies are necessary to 
evaluate in vivo this promising drug, not only as a single compound but also 
in combination with the currently used cytostatic mitotane. 
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Abstract 
The mechanisms of tumor cell resistance to interferon-α (IFN-α) are at 
present mostly unsolved. We have previously demonstrated that IFN-α 
induces apoptosis on epidermoid cancer cells and EGF antagonizes this effect. 
We have also found that IFN-α-induced apoptosis depends upon activation of 
the NH2-terminal Jun kinase-1 (Jnk-1) and p38 mitogen-activated protein 
kinase, and that these effects are also antagonized by EGF. At the same time, 
IFN-α increases the expression and function of the epidermal growth factor 
receptor (EGF-R). Here we report that the apoptosis induced by IFN-α occurs 
together with activation of caspases 3, 6 and 8 and that EGF also antagonizes 
this effect. On the basis of these results, we have hypothesized that the 
increased EGF-R expression and function could represent an inducible 
survival response that might protect tumor cells from apoptosis caused by 
IFN-α via extracellular signal regulated kinase 1 and2 (Erk-1/2) cascades. We 
have found an increased activity of Ras and Raf-1 in IFN-α-treated cells. 
Moreover, IFN-α induces a 50% increase of the phosphorylated isoforms and 
enzymatic activity of Erk-1/2. We have also demonstrated that the inhibition 
of Ras activity induced by the transfection of the dominant negative Ras 
plasmid RASN17 and the inhibition of Mek-1 with PD098059 strongly 
potentiates the apoptosis induced by IFN-α. Moreover, the selective inhibition 
of this pathway abrogates the counteracting effect of EGF on the IFN-α-
induced apoptosis. All these findings suggest that epidermoid tumor cells 
counteract the IFN-α-induced apoptosis through a survival pathway that 
involves the hyperactivation of the EGF-dependent Ras -> Erk signalling. The 
selective targeting of this pathway appears to be a promising approach in 
order to enhance the antitumor activity of IFN-α. 
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Introduction 
Interferon-α (IFN-α) is a biological agent widely used in the therapy of 
several neoplasms such as myeloma, renal cell carcinoma, epidermoid 
cervical and head and neck tumors and melanoma (1–5). IFN-α, the first 
cytokine to be produced by recombinant DNA technology, has emerged as an 
important regulator of cancer cell growth and differentiation, affecting 
cellular communication and signal transduction pathways, and is also 
produced during the immunological control of tumor growth (5). However, 
inconsistent data have been obtained regarding the clinical effectiveness of 
IFN-α in the therapy of solid tumors. In fact, the benefit of IFN-α treatment is 
limited to some neoplasms while others are completely or partially resistant. 
The mechanisms of tumor resistance to IFN-α have been studied in vitro. The 
alteration of JAK-STAT components of the IFN-α-induced signalling can be 
indeed a mechanism of resistance to IFN. In fact, it has been shown that 
melanoma cell lines refractory to the antiproliferative effects of IFNs are 
deficient in STATs and that the expression of STATs can be restored by in 
vitro gene therapy (6). More germane to clinical practice is the possibility that 
IFN treatment could be improved by the concomitant administration of agents 
known to enhance JAK-STAT responses; the use of retinoids in combination 
with IFN-α in cancer therapy is a salient example (7,8). 
The way in which tumor cell growth is suppressed by IFN-α is not well 
known. A possibility is that cancer cells undergo apoptosis after exposure to 
the cytokine. In fact, it is reported that IFN-α induces apoptosis in human 
squamous cancer (9,10), glioma (11) and virus-infected cells (12). Therefore, 
it is likely that this cytokine acts, at least in part, through the triggering of 
programmed cell death. 
On the other hand, Epidermal Growth Factor (EGF) is able to protect 
eukaryotic cells from the onset of apoptosis (13–16). EGF acts through the 
binding to its specific receptor (EGF-R), a transmemembrane protein with a 
cytoplasmic tyrosine kinase domain (17,18). The phosphorylation of the 
intracytoplasmic tail allows the interaction of EGF-R with cytoplasmic factors 
that can induce Ras activation and the subsequent stimulation of the mitogen-
activated protein kinase (MAPK) cascade composed of three intracellular 
protein kinases (MKKK, MKK and MAPK), which are activated successively 
by phosphorylation events (17,18). Raf-1, stimulated after steric interaction 
with Ras, phosphorylates and activates an MKK whose main component is 
Mek-1. Mek-1 phosphorylates the MAPKs extracellular signal regulated 
kinase 1 and 2 (Erk-1/2) that translocate to the nucleus and phosphorylate 
gene transactivators, such as the serum response factor-1, that are involved in 
the regulation of cell proliferation (17,18). Moreover, it has been recently 
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reported that Erks mediate a strong antiapoptotic effect (19,20). For instance, 
Erk plays an important role in protecting cardiac myocytes from apoptotic 
death following oxidative stress (21). Protection of PC12 cell death by N-
acetylcysteine requires Erk activation (20) that is, moreover, involved in the 
phorbol myristate acetate-mediated inhibition of drug-induced apoptosis in 
tumor cells (22). 
We have reported that IFN-α increases the functional expression of the EGF-
R at the surface of human epidermoid carcinoma cells (23,24). 
Moreover, we have shown that IFN-α induces apoptosis in these cells through 
the triggering of a stress response that leads to the activation of NH2-terminal 
Jun kinase-1 (Jnk-1) (10). EGF also antagonizes these effects. On the basis of 
these findings, we have hypothesized that increased EGF-R expression and 
function could be part of an inducible survival pathway, which is activated in 
the tumor cells by exposure to IFN-α. In this paper, we have investigated the 
molecular basis of the counteracting effects of IFN-α and EGF on the 
apoptosis of human epidermoid cancer cells. Specifically, we have evaluated 
the involvement of the caspase cascade and of EGF-dependent signalling in 
the apoptotic and antiapoptotic events recorded in our experimental model. 
We have then studied the effects of IFN-α and EGF on the activity of Ras, 
Raf-1 and Erk-1/2. We have finally evaluated if the selective inhibition of Ras 
and Mek-1 could enhance apoptosis induced by IFN-α in order to provide 
direct evidence on the antiapoptotic activity of this pathway in our 
experimental model and to identify novel molecular targets to enhance the 
antitumor effects of this cytokine. 
 
 
Materials and Methods 
Materials 
DMEM, BSA and FBS were purchased from Flow Laboratories (Milan, Italy). Tissue culture 
plasticware was from Becton Dickinson (Lincoln Park, NJ, USA). IFN-α was a gift of 
Schering (Schering-Plough, NJ, USA). Receptor grade EGF and protein Sepharose were 
purchased from Sigma (St. Louis, MO, USA). Rabbit antisera raised against Raf-1 C-12, β-
actin, Erk-1 K-23 and Erk-2 MAb C-14 were purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA). Anti-pan-Ras MAb clone 10 was purchased from Calbiochem. 
 
Cell culture 
The human oropharyngeal epidermoid carcinoma KB cell line, obtained from the American 
Type Tissue Culture Collection, Rockville, MD, USA, was grown in DMEM supplemented 
with heat-inactivated 10% FBS, 20mM HEPES, 100 U/ml penicillin, 100 µg/ml 
streptomycin, 1% L-Glutamine and 1% sodium pyruvate. The cells were grown in a 
humidified atmosphere of 95% air/5% CO2 at 37°C. 
 
Western blot analysis 
KB cells were grown for 48 h with or without IFN-α and were thereafter exposed for the 
indicated times to 10 nM EGF at 37°C. For cell extract preparation, the cells were washed 
twice with ice-cold PBS/BSA, scraped, and centrifuged for 30 min at 4°C in 1 ml of lysis 
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buffer (1% Triton, 0.5% sodium deoxycholate, 0.1 NaCl, 1mM EDTA, pH 7.5, 10mM 
Na2HPO4, pH 7.4, 10mM PMSF, 25mM benzamidin, 1mM leupeptin, 0.025 U/ml aprotinin). 
Equal amounts of cell proteins were separated by SDS–PAGE. The proteins on the gels were 
electrotransferred to nitrocellulose and reacted with the different MAbs. 
 
Affinity precipitation of Ras 
KB cells were treated with IFN-α and EGF as described above. The cells were lysed in Mg2+ 
buffer containing 20mM HEPES, pH 7.5, 150mM NaCl, 1% Igepal CA-630, 10mM MgCl2, 
1mM EDTA and 2% glycerol. Then, 10 µl Ras binding domain (RBD) conjugated to agarose 
was added to 1mg of cell lysate and the mixture was incubated at 4°C for 1 h. The agarose 
beads were collected by microcentrifugation at 14,000 x g for 5 s and washed three times with 
Mg2+ buffer. The agarose beads were boiled for 5 min in 2 x Laemmli sample buffer and 
collected by a microcentrifuge pulse. The supernatants were run on 12% SDS-PAGE, then the 
proteins were electrotransferred on a nitrocellulose film. The nitrocellulose was incubated 
overnight with 1 µg/ml of anti-Ras Mab, clone RAS10 and with a secondary Mab, a goat α-
mouse HRP conjugated IgG, for 1.5 h. The film was washed with PBS/0.05% Tween 20 and 
detected by ECL, chemiluminescence’s technique (Amersham). 
 
Internucleosomal DNA fragmentation (ladder) 
For all apoptosis evaluation experiments (gel ladder and FACS analysis), both attached and 
suspended cells were collected prior to the processing. DNA fragmentation was measured 
after extraction of low molecular weight DNA. Briefly, 10 x 106 cells were resuspended in 
900 µl x Tris-EDTA buffer and lysed with 25 µl 20% SDS. DNA was precipitated in ethanol 
for 6 h in the presence of 5M NaCl. The high molecular weight fraction was sedimented by 
high-speed centrifugation, and the fragmented DNA was extracted from the aqueous phase 
with phenol and chloroform and then precipitated with ethanol. After resuspension in water, 
DNA was electrophoresed using 1.5% agarose gel and visualized by ultraviolet light 
following ethidium bromide staining. 
 
Evaluation of apoptosis by DNA-flow cytometry 
Cells were centrifuged and directly stained in a propidium iodide (PI) solution (50 µg PI in 
0.1% sodium citrate, 0.1% NP40, pH 7.4) overnight at 4°C in the dark. Flow cytometric 
analysis was performed using a FACScan flow cytometer (Becton Dickinson, San Jose, CA, 
USA) interfaced with a Hewlett-Packard computer (mod. 310) for data analysis. To evaluate 
cell apoptosis, PI fluorescence was collected as FL2 (log scale) by the CellFIT software 
(Becton Dickinson). For the evaluation of apoptosis after transfection with RASN17 and/or β-
galactosidase plasmids, cells were fixed in methanol and then incubated with an anti-β-
galactosidase MAb for 1 h at 4°C and labelled with an FITC anti-mouse rabbit antibody for 1 
h. Thereafter, the cells were stained with PI as described above. In the latter case, apoptosis 
and cell cycle analysis were performed on the whole cell population and on β-galactosidase 
expressing cells after appropriate gating. For the evaluation of intracellular DNA content, at 
least 10,000 events for each point were analyzed in at least three different experiments giving 
a s.d. less than 5%. 
 
MAPK assay 
KB cells were cultured and treated as described above. Then the cells were washed twice with 
ice-cold PBS, scraped and lysed for 1 h at 4°C in the following buffer: 10mM TRIS, 150mM 
NaCl, 2mM EGTA, 2mM DTT, 1mM sodium orthovanadate, 1mM PMSF, 10 µg/ml 
aprotinin, 10 µg/ml leupeptin and 1% glycerol. Equalized amounts of proteins from lysates of 
KB cells (50 µl) were incubated for 90 min at 4°C with 50 µl of protein A-Sepharose 
conjugated to 25 µg anti-Erk-1 or anti-Erk-2 MAbs. The suspension was centrifuged at 
14,000 x g, the supernatant discarded, and the immunoprecipitated washed twice with 250 µl 
of the following buffer: 20mM Tris-acetate, pH 7.0 (20°C), 0.27M sucrose, 1mM EDTA, 
1mM EGTA, 1mM sodium orthovanadate, 10mM sodium glycerophosphate, 50mM sodium 
fluoride, 5mM sodium pyrophosphate, 1% Triton X-100, 0.1% 2-mercaptoethanol, 1mM 
benzamidine, 0.2mM phenylmethylsulfonylfluoride and 0.5M NaCl. The immunoprecipitates 
were washed once with 250 µl of the following buffer: 50mM Tris-HCl, pH 7.5 (20°C), 
0.03% Brij-35, 0.1mM EGTA and 0.1% 2-mercaptoethanol. Then the immunoprecipitates 
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were incubated for 30 min at 30°C with 5 ml of a solution containing 1.2mM Mg++ ATP with 
200 µCi/ml of [γ32P]ATP and 15 µl of a solution containing a peptide that is specifically 
phosphorylated by MAPK (Amersham, Biotrak, Milan, Italy) (25). The reaction was stopped 
with the addition of 2.94% (w/v) ortophosphoric acid and red carmosin solution and then 
microfuged for 15 s. The reaction mixtures were spotted onto phosphocellulose filters 
(Whatman P81) and washed three times in 1% acetic acid. Filters were air-dried and then 
counted by liquid scintillation using Omnifluor/toluene (DuPont-New England Nuclear, 
Boston, MA, USA). 
 
Raf-1 kinase assay 
Assay for Raf-1 kinase activity was performed by immunocomplex kinase assay as already 
described for MAPK using anti-Raf-1 antiserum. H1 histone (10 µg) (Upstate Biotechnology 
Inc.) was used as substrate in 30 µl of buffer A containing 10 µCi of [γ32P]ATP, the reaction 
was allowed to proceed for 30 min at 30°C, and the proteins were separated by SDS-12.5% 
PAGE. 
 
Electroporation 
Cells were detached from confluent 100 mm- dishes. Cells (100x106) were incubated in 
appropriate electroporation vials with 800 µl of electroporation buffer (20mM HEPES, 
137mM NaCl, 5mM KCl, 0.7mM Na2HPO4 and 6mM glucose) and 15 µg of the RASN17 
DNA and/or 5 µg/ml β-galactosidase DNA in 20mM HEPES. Then cells were electroporated 
at 250 V and at 975 µF for 6 s. The cells were incubated at 37°C with or without 1000 IU/ml 
IFN-α for 24 h. After the incubation, the cells were processed for FACS analysis as described 
above. 
 
TUNEL technique 
For TUNEL assay, after washing in PBS supplemented in 0.1% BSA, cells were treated with 
an in situ detection kit, according to the manufacturers instructions (Boehringer Mannheim 
Biochemicals). Nuclei with fragmented DNA were visualized by a fluorescence microscope. 
 
Determination of caspase activity 
Cells were seeded and treated with 1000 IU/ml IFN-α a for different times and/or 10 nM EGF 
for 12 h. At the time of caspase determination, cells were lysed. For each reaction, 50 µl of 
cell lysate was added to 1ml reaction mixture composed of reaction buffer, DTT 10mM and 
the specific substrate peptide (DEVD for caspase-3, VEID for caspase-6, IETD for caspase-8 
and LEHD for caspase-9) conjugated to 7-amino-4-trifluoromethylcoumarin (AFC). The 
mixtures were incubated for 1 h at 37°C. The levels of free AFC were measured using a 
spectrofluorometer with an excitation wavelength of 400 nm and an emission wavelength 
range of 480–520 nm (peak at 505 nm). 
 
 
 
Results 
Effects of IFN-α and EGF on the apoptosis of human epidermoid cancer 
cells. 
We have found that IFN-α (48 h 1000 IU/ml) induced apoptotic DNA 
fragmentation in the KB cell line and that the exposure of IFN-α-treated cells 
to 10nM EGF for 12 h antagonized this effect (fig.1a). Before performing 
apoptosis detection assays, both attached and suspended cells were collected. 
In these experimental conditions, 30% of cells exposed to IFN-α for 48 h 
were apoptotic while only about 8% of cells treated for 48 h with IFN-α and 
exposed for 12 h to 10 nM EGF underwent to apoptosis (fig.1b). Interestingly, 
also the exposure to 10nM EGF alone for 12 h is able to induce apoptosis in 
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15% of the cell population (fig.1a and b). Such an effect is not surprising 
since apoptosis and cell proliferation are couplet processes, and EGF can 
induce apoptosis in squamous cancer cells. In order to identify the molecular 
effectors of the apoptosis induced by IFN-α, we have evaluated the 
expression of p53 and c-myc and the activity of caspases in KB cells. We 
have found that apoptosis induced by either IFN-α or EGF was paralleled by 
a significant increase of p53 and c-myc expression in KB cells, as evaluated 
with Western blot assay. The antagonism of EGF on apoptosis occurred 
together with the restoration of p53 and c-myc expression to basal levels 
(fig.1C). 
 
 
 
Figure 1: EGF antagonizes apoptosis 
induced by IFN-α in human epidermoid 
cancer cells. KB cells were seeded and 
treated with IFN-α and/or EGF as 
described in the Materials and methods 
section. 
(a) The internucleosomic DNA 
fragmentation was assessed as described 
in the Materials and methods section. 
(b) The percent of apoptotic cells, 
evaluated by FACS analysis, is shown as 
bars. CTR: untreated cells; IFN-α: 48 h 
1000 IU/ml; EGF: 12 h 10 nM; IFN-α + 
EGF: 48 h 1000 IU/ml IFN-α + 12 h 10 
nM EGF. The experiment was performed 
three times and S.E.s were always less 
than 5%. 
(c) Evaluation of the expression of p53, 
c-myc and β-actin. Proteins were 
extracted and run on SDS–PAGE as 
described in ‘Materials and methods 
section’. The experiment was performed 
at least three times and the results were 
always similar. CTR: untreated cells; 
IFN-α: 48 h 1000 IU/ml; EGF: 12 h 10 
nM; IFN-α+EGF: 48 h 1000 IU/ml 
IFN-α+12 h 10 nM EGF; VP-16: 18 h 
50 µM etoposide. 
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Figure 2: Modulation of caspases 3, 6, 8 and 9 by IFN-α and EGF. (b) KB cells were seeded 
and treated with 1000 IU/ml IFN-α for the indicated times. The specific caspase activity was 
determined with a fluorimetric assay as described in the ‘Materials and methods section’. The 
experiment was performed three times and S.D.s were always less than 5%. Bars, s.d. (b–d) 
KB cells were seeded and treated with 1000 IU/ml IFN-α for the indicated times. EGF (10 
nM) was added to the cells for the last 12 h of incubation alone or in combination with IFN-
α. The specific caspase activity was determined with a fluorimetric assay as described in the 
‘Materials and Methods section’. Caspase 3 (b); caspase 6 (c); caspase 8 (d); caspase 9 (e). 
1000 IU/ml IFN-α (); 10nM EGF (); IFN-α+12 h 10 nM EGF (). The experiment was 
performed three times and S.D.s were always less than 5%. Bars, S.D. 
 
We have thereafter studied the role of caspases in the modulation of apoptosis 
by IFN-α and EGF in our experimental model. KB cells were treated with 
IFN-α for 12, 24, 48 and 72 h and then the activity of caspases was evaluated 
with a fluorimetric protease assay. Caspases 6, 8 and 9 showed an activation 
peak after 24 h exposure to IFN-α (fig.2a). The activation peak of caspase 3 
was instead found after 48 h exposure to the cytokine. Moreover, the exposure 
of KB cells to 10nM EGF for 12 h was always able to antagonize the caspase 
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activation induced by IFN-α both at 24 h and 48 h (fig.2b-d). In fact, EGF 
completely abrogated caspases 6, 8 and 9 and caspase 3 activities. EGF alone 
also induced a slight increase of caspase stimulation, but the extent of 
activation was far lesser than that recorded in IFN-α-treated cells. Therefore, 
in our experimental model the IFN-α-induced apoptosis is correlated with the 
activation of the caspase cascade, and EGF was able to antagonize both 
apoptotic death and caspase activation. Moreover, the apoptosis recorded in 
KB cells exposed to EGF alone did not appear to be induced by a caspase 
pathway similar to that recorded in IFN-α-treated cells. 
 
 
 
 
 
 
Figure 3: Effects of EGF and IFN-α 
on Ras activity. (Upper gel) Affinity 
precipitation of Ras performed with 
the minimal binding domain of Raf-1 
conjugated with agarose as described 
in the ‘Materials and methods section’. 
CTR, untreated; IFN-α, 48 h 1000 
IU/ml; E10’, 10 min 10 nM EGF; I/E 
10’, 48 h 1000 IU/ml IFN-α and 10 
min 10 nM EGF; E1 h, 1 h 10 nM 
EGF; I/E 1 h, 48h 1000 IU/ml IFN-α 
and 1 h 10 nM EGF; Asp, minimal 
binding domain of Raf-1 incubated 
only with Mab raised against Ras 
without cell extracts. (Lower gel) 
Western blot assay for the expression 
of the total Ras protein. CTR, 
untreated; IFN-α, 48 h 1000 IU/ml 
IFN-α; E10’, 10 min 10 nM EGF; I/E 
10’, 48 h 1000 IU/ml IFN-α and 10 
min 10 nM EGF; E1 h, 1 h 10 nM 
EGF; I/E 1 h, 48 h 1000 IU/ml IFN-α 
and 1 h 10 nM EGF. The experiments 
were performed at least three different 
times and the results were always 
similar. (Bars) Quantitization of the 
intensity of the different bands with an 
appropriate apparatus (Bio-Rad) and 
expression as arbitrary units. CTR, 
untreated; IFN-α, 48 h 1000 IU/ml; 
E10’, 10 min 10 nM EGF; I/E 10’, 48 
h 1,000 IU/ml IFN-α and 10 min 10 
nM EGF; E1 h, 1h 10nM EGF; I/E 1 
h, 48 h 1000 IU/ml IFN-α and 1 h 10 
nM EGF; Asp, minimal binding 
domain of Raf-1 incubated only with 
Mab raised against Ras without cell 
extracts. 
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Effects of EGF and IFN-α on Ras activity 
We have previously shown that IFN-α induces growth inhibition paralleled by 
increased EGF-R expression and sensitivity to the growth-promoting effects 
of EGF in epidermoid cancer cells (23,24) Therefore, we have investigated if 
the activity of the Ras-dependent MAPK pathway was increased in IFN-α 
treated cells. This and all the following experiments were performed without 
serum starvation in order to set up more physiological experimental 
conditions. Moreover, EGF was added for short-term exposures in order to 
evaluate the responsiveness of each signalling component to its physiological 
ligand in untreated and IFN-α-treated KB cells. We have firstly studied the 
activity of Ras through the affinity precipitation of Ras with the minimal 
binding domain of Raf-1. We have found that the levels of activated Ras 
(linked to the minimal binding domain of Raf-1) were increased in IFN-α-
treated cells. In fact, the activated Ras levels were about two-fold higher in 
IFN-α-treated cells than in control cells, and the stimulation of Ras activity by 
exposure to EGF for 10 min was further enhanced in IFN-α-treated cells 
reaching levels 3.5-fold higher than untreated controls (Figure 3). At longer 
times of exposure to EGF, Ras activity decreased either in EGF- or EGF/IFN-
α treated cells (Figure 3). Therefore, in IFN-α-treated KB cells, the increased 
activity of EGF-R signalling was indeed couplet to enhanced Ras activity and 
was further stimulated by the addition of exogenous EGF.  
 
 
 
Effects of IFN-α and EGF on Raf-1 expression and activity 
We have evaluated the effect of IFN-α and EGF on Raf-1 activity by a kinase 
assay using histone H1 as substrate of Raf-1, and we have found that Raf-1 
activity is increased either by EGF or IFN-α and is potentiated after EGF 
addition for 10 min to KB cells exposed to IFN-α (fig.4). Moreover, we have 
determined Raf-1 levels by Western blotting, and found that they were almost 
unmodified by the different treatments (fig.4). These experiments demonstrate 
that an increase of basal and EGF-induced enzymatic activity of Raf-1 can be 
recorded downstream of the EGF->Ras signalling in IFN-α-treated cells. 
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Figure 4: Effects of IFN-α and EGF on Raf-1 activity and expression. KB cells have been 
cultured for 48 h in the absence or presence of 1000 IU/ml IFN-α with or without the addition 
of 10 nM EGF for the last 5 min as described in the figure by + and -. Raf-1 was 
immunoprecipitated and analyzed for kinase activity by immunocomplex kinase assay using 
histone H1 as substrate. Lane C1 indicated a control where the immunocomplex kinase assay 
was performed on untreated EGF-stimulated cells in the absence of the substrate. Lane C2 
indicated a control assay performed using nonimmune serum to immunoprecipitate untreated 
EGFstimulated cells. At the same time, the cells were also processed for the determination of 
Raf-1 expression as described in the ‘Materials and Methods section’. 
 
 
 
Effects of IFN-α and EGF on Erk-1/2 activity 
On the basis of the finding that IFN-α induced a hyperactivation of Mek-1, 
we have evaluated the effects of this cytokine on the activity of Erk-1/2, the 
downstream enzymatic targets of Raf-1. We found that the exposure of KB 
cells to IFN-α for short times (5 min-12 h) had no effects on MAPK activity, 
while they were maximally activated after 48 h of treatment with the cytokine 
(fig.5a, lower panel). The latter effect paralleled EGF-R upregulation, which 
reached a peak after 48 h of exposure to IFN-α (fig.5a, upper panel and see 
also ref. 24). Therefore, the timing of MAPK25 activation by IFN-α 
overlapped that of EGF-R upregulation, suggesting that the stimulation of 
MAPK activity could be a consequence of the increased surface expression of 
EGF-R with subsequent amplification of downstream signalling. We have 
subsequently evaluated the kinetics of Erk-1/2 activation by EGF in untreated 
and IFN-α-treated KB cells. We again found an almost two-fold increase of 
the two enzyme activities in 48 h 1000 IU/ml IFN-α-treated cells. In both 
untreated and 48 h 1000 IU/ml IFN-α-treated KB cells, the maximal 
activation of Erk-1/2 occurred after 10 min of exposure to 10nM EGF, as 
evaluated with an immunoconjugated kinase assay (fig.5b and c). However, 
the exposure to IFN-α caused an almost two-fold increase of the maximal 
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activation of Erk-1/2 induced by EGF (fig.5b and c). Therefore, 48 h exposure 
to IFN-α increased the activity of Erk-1/2 without affecting the sensitivity to 
further stimulation by exogenous EGF. 
 
 
 
 
 
Figure 5: IFN-α increases Erk-1 and Erk-2 activity in human epidermoid cancer cells. (A) 
upper panel) 125I-EGF binding on human epidermoid KB cells. KB cells were treated for 
different times with 1000 IU/ml IFN-α. At the indicated times, cells were processed for the 
determination of the 125I-EGF specific binding, as described in the ‘Materials and methods 
section’. The values were expressed as % of control. The experiments were performed three 
times and SDs were always less than 5%. (a, lower panel) KB cells were cultured for the 
indicated times in the absence or presence of 1000 IU/ml INF-α. Then the cells were 
processed for the determination of the expression and phosphorylation of Erk-1 and -2 
evaluated after blotting with an anti-MAPK and an anti-pMAPK specific Mab, respectively, 
as described in the ‘Materials and methods section’. The experiments were performed at least 
three different times and the results were always similar. (b and c) KB cells were cultured for 
48 h in the absence or presence of 1000 IU/ml IFN-α with or without the addition of 10 nM 
EGF for different times. Then an immunoconjugated kinase assay of (b) Erk-1 and (c) Erk-2 
was performed as described in ‘Materials and Methods section’. Untreated KB cells (); 
IFNα-treated KB cells (●). The experiment was performed three times and s.d.s were always 
less than 5%. Bars, s.d. 
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IFN-α enhanced the apoptosis induced by dominant negative Ras plasmid 
RASN17 in KB cells 
We have shown that the EGF-dependent Ras->Erk pathway was 
hyperactivated in cells exposed to IFN-α. In order to demonstrate that such 
signalling could indeed retain an antiapoptotic activity in the cells exposed to 
IFN-α, we have selectively inhibited Ras activity by a dominant negative 
mutant. KB cells have been cotransfected with a plasmid encoding for a 
dominant negative Ras RASN17 and with the E. coli β-galactosidase reporter 
gene. The cells were analyzed by FACS after PI labelling as described above. 
In all cases, the cotransfection resulted in specific green fluorescence in a 
fraction of the cell population owing to the expression of β-galactosidase (see 
fig.6 β-Gal NEG versus β-Gal POS). The latter effect allowed us the gating of 
nontransfected (G2) or transfected cells (G1) in order to perform cell cycle 
analysis (red fluorescence determined by PI labelling). We have found that β-
galactosidase expression alone did not cause apoptosis (2 and 6% of apoptosis 
either in nontransfected or β-galactosidase-transfected cells, respectively) 
(fig6A, G2 and G1). In the cells cotransfected with RASN17 and β-
galactosidase almost 29% of apoptotic cells were detected (fig.6B, G1), while 
only 2% of apoptosis was found in nontransfected cells (fig.6B, G2). The 
exposure of β-galactosidase-transfected cells to 1000 IU/ml IFN-α for 24 h 
induced apoptosis in 16% of the cell population (fig.6C, G1) against 14% of 
apoptotic cells in nontransfected population (fig.6C, G2). The treatment of β-
galactosidase and RASN17 cotransfected cells with 1000 IU/ml IFN-α 
induced an almost 76% of apoptosis (fig.6D, G1), while programmed cell 
death was found in only 13% of the nontransfected cell population (fig.6D, 
G2). We have performed these experiments after 24 h of exposure to IFN-α 
because at this time maximal β-galactosidase expression occurred. Moreover, 
almost 80% of cells were apoptotic after 48 h from the transfection with 
RASN17 (data not shown). In this experiment about 30% of the cell 
population was transfected with β-galactosidase plasmid. It was therefore 
demonstrated that the abrogation of Ras activity by a transfected dominant 
negative mutant sensitized tumor cells to IFN-α-induced apoptosis, indicating 
an antiapoptotic function of Ras in this experimental model. 
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Figure 6 IFN-α enhances the apoptosis induced by the dominant negative Ras plasmid 
RasN17 in KB cells. KB cells were seeded, electroporated with dominant negative Ras 
plasmid RASN17 and/or β-galactosidase plasmid, and treated with IFN-α for 24 h as 
described above. Then the cells were fixed in methanol, incubated with anti-β-galactosidase 
MAb and anti-mouse FITC rabbit antiserum and analyzed after DNA labelling with 
propidium iodide. Cell cycle analysis was performed after appropriate gating on cell 
population expressing β-galactosidase as described in the ‘Materials and methods section’. 
(a) Parental untreated cells (CTR); (b) RASN17 transfected cells (RASN17); (c) 24 h 1000 
IU/ml IFN-α-treated parental cells (IFN-α 24 h); (D) 24 h 1000 IU/ml IFN-α-treated RasN17 
transfected cells (IFN-α 24 h+RASN17). βGal NEG, cells exposed to an irrelevant mouse 
IgG and subsequently labelled with an anti-mouse FITC rabbit antiserum. βGal POS, cells 
exposed to an anti-β-galactosidase mouse IgG and subsequently labelled with an anti-mouse 
FITC rabbit antiserum. G1, gating of cells expressing β-galactosidase; G2, gating of cells not 
expressing β-galactosidase. The lower histograms show the analysis of cell cycle performed 
on the G2 and G1 population, respectively. The apoptotic cells were shown as a percentage of 
total cell population indicated by a bar. The experiments were performed at least three 
different times and the results always gave less than 5% s.d. In each experimental point 
10,000 events were analyzed. 
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Figure 7 The antiapoptotic effects of EGF are mediated by the selective activation of Erk. 
KB cells were seeded and treated with IFN-α and/or 50 µM PD098059 for 48 h and/or 10 nM 
EGF for 12 h. At the time of the experiment, cells were fixed and processed with TUNEL 
techniques as described in the ‘Materials and methods section’. The experiments were 
performed at least three different times and the results were always similar. (a) Control cells; 
(b) 48 h 1000 IU/ml IFN-α-treated cells; (c) 48 h 50 µM PD098059-treated cells; (d) 12 h 10 
nM EGF-treated cells; (e) 48 h 1000 IU/ml IFN-α and 12 h 10 nM EGF-treated cells; (f) 48 h 
1000 IU/ml IFN-α and 48 h 50 µM PD098059 treated cells; (g) 12 h 10 nM EGF- and 48 h 
50 µM PD098059-treated cells; (h) 48 h 1000 IU/ml IFN-α and 48 h 50 µM PD098059-
treated cells and 12 h 10 nM EGF. Insets: The cells were seeded and treated with the different 
substances as described above. At the time of the experiment KB cells were FACS analyzed 
after detachment and DNA labelling with propidium iodide as described in the ‘Materials and 
methods section’. The experiments were performed at least three different times and the 
results always gave less than 5% SD. In each experimental point, 10,000 events were 
analyzed. (I) The expression and phosphorylation of Erk-1 and -2 was evaluated after blotting 
with an anti-p-MAPK (upper gel) and an anti-MAPK-specific MAb (lower gel) in KB cells 
treated for different times with 50 µM PD098059. The experiments were performed at least 
three different times and the results were always similar. 
 
MEK-1 inhibitor PD098059 specifically abrogated recovery from IFN-α-
induced apoptosis by EGF 
Since Ras is implicated in the triggering of several different signal 
transduction pathways, we have verified that the integrity of the downstream 
Erk-targeted pathway was indeed required for the antiapoptotic effects of 
EGF (26). Therefore, we have evaluated if the specific inhibition of Mek-1 
could also potentiate the growth inhibition and apoptosis induced by IFN-α 
and if the Ras->Erk-1/2 pathway plays a crucial role in the survival of 
epidermoid cancer cells exposed to IFN-α. Only 5% untreated KB cells were 
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apoptotic as assessed by FACS and in situ TUNEL analysis (fig.7A). Again 
48 h 1000 IU/ml IFN-α induced 30% apoptosis and 12 h 10nM EGF 
antagonized this effect (only 8% apoptotic cells were recorded under these 
experimental conditions) (fig.7B and e and relative insets, respectively). In 
total, 50 µM PD098059 and 10nM EGF alone induced 35 and 15% apoptosis, 
respectively (fig.7C and D, respectively). PD098059 was again able to 
enhance the effect induced by IFN-α causing programmed cell death in about 
80% of cells, thus suggesting a supra-additive effect induced by the addition 
of MEK-1 inhibitor to IFN-α (fig.7F). Moreover, 50 µM PD098059 abrogated 
the anti-apoptotic effects of EGF in IFN-α-treated cells since an almost 30% 
of apoptosis was recorded in cells exposed to IFN-α, EGF and PD098059 
(fig.7H). On the other hand, PD098059 caused almost no effects on the 
apoptosis induced by EGF (fig.7G). Interestingly, PD098059 reduced MAPK 
phosphorylation almost completely already after 6 h in KB cells (fig.7I). All 
together, these data suggest that the antiapoptotic effects induced by EGF 
occurred through the activation of Erk, which is therefore the final target of an 
antiapoptotic kinase cascade. 
 
 
 
Discussion 
IFN-α is a cytokine that has shown a well-defined but still limited activity 
against human tumors (1–5) Resistance to IFN-α has been demonstrated to be 
in part based on receptor or post-receptor signalling defects in the tumor cells 
(6–8). However, the cancer cell escape from the antiproliferative activity of 
IFN-α and the mechanisms by which this cytokine causes direct antitumor 
effect remain still unsolved. Apoptosis induction appears to be a way by 
which IFN-α exerts its antiproliferative effects (9–12). It is well established 
that tumor cells overcome the natural propensity to undergo apoptosis with 
the overexpression and/or overactivation of growth factor-induced signal 
transduction pathways (13–15). EGF-R overexpression is a common event in 
epidermoid cancers and is considered an unfavorable prognostic factor (27). It 
has also been demonstrated that Erk-1/2 antagonize apoptosis in several 
experimental models (22,28–30). We have previously reported that IFN-α 
induces growth inhibition and increases the expression and function of EGF-R 
in human epidermoid cancer cells (23,24). Moreover, we have demonstrated 
that the growth inhibition induced by IFN-α is, at least in part, because of the 
apoptosis triggered by a stress response leading to the activation of JNK-1, 
and that EGF antagonizes growth inhibition, apoptosis and the biochemical 
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events induced by the cytokine (10). On the basis of these findings, we have 
hypothesized that the increased expression and function of the EGF-R could 
be part of a survival response that could protect tumor cells from the apoptosis 
triggered by IFN-α. In this paper, we have investigated the molecular bases of 
the counteracting effects of IFN-α and EGF on apoptosis. We have firstly 
studied the involvement of caspases in the execution of the apoptotic process. 
We have found that IFN-α induced an activation peak of caspases 6 and 8 
after 24 h, while the maximal activation of caspase 3 was recorded 24 h later. 
The differential timing of caspase activation is in agreement with the 
sequence of activation of these proteases during the apoptotic process and 
suggests an involvement of caspases in the execution of apoptosis induced by 
IFN-α (31). Our findings are, moreover, in agreement with the recent 
observations by Thyrell et al. (32), who found induction of caspase activity by 
IFN-α in apoptotic tumor cells. In our experimental conditions, we have 
found that the addition of EGF to IFN-α-treated KB cells completely 
antagonized apoptosis induction and the triggering of the caspase cascade, 
suggesting that the EGF-R signalling suppresses apoptosis, thereby 
antagonizing the activation of its executioners. These results appear also in 
line with the recent findings demonstrating the involvement of growth-factor-
dependent pathways in the protection from caspase activation induced by Bad 
overexpression. Moreover, it has been demonstrated that the EGF-R-
dependent pathway controls keratinocyte survival and the expression of the 
proapoptotic bcl-xL expression through a Mek-dependent pathway (30). 
We have then investigated the involvement of EGF-mediated intracellular 
signalling in the protection of epidermoid cancer cells from IFN-α-induced 
apoptosis. We have found that the EGF- and Ras-dependent MAPK cascade is 
hyperactivated in IFN-α-treated cells and could be further stimulated by the 
addition of EGF. In fact, we have demonstrated an increased activity and 
responsiveness to EGF stimulation of Ras, Raf-1 and Erk-1/2 in KB cells 
exposed to IFN-α. These findings suggest that the EGF-R function is 
preserved in IFN-α-treated cells, taking also into account the activation 
threshold of the EGF-dependent signalling. Interestingly, maximal MAPK 
hyperactivation occurred after 48 h from the beginning of the treatment with 
IFN-α. It must be considered that the maximal upregulation of EGF-R on the 
cell surface occurs with the same timing, suggesting that overstimulation of 
the MAPK pathway could be produced by the amplification of the EGF 
signalling owing to the increased expression of the receptor (23,24). We have 
previously described that other antiproliferative agents, such as cytosine 
arabinoside, 5aza-2’deoxycytidine and 8-chlorocAMP (8ClcAMP), also 
increase EGF-R expression on KB cells (33–35). On this basis, we have 
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hypothesized that the upregulation of growth factor receptors is a common 
event in growth-inhibited tumor cells and could represent a protective 
response towards the antiproliferative stimuli (36). Also in the case of 
8ClcAMP, the EGF-induced signalling MAPK is amplified likely as a 
consequence of the increased expression of EGF-R (35). However, MAPK 
activity is reduced in 8Cl-cAMPtreated KB cells, suggesting a selective 
inhibition of Erks or of a still unknown upstream activator induced by the 
drug (35). It has to be considered that chronic activation of Erk has been 
reported to induce apoptosis in eukaryotic cells (37–40). However, we can 
exclude that IFN-α-induced apoptosis occurs through the hyperactivation of 
Erks on the basis of both the timing of Erk activation and the effects of the 
combined treatment of KB cells with IFN-α and EGF. In fact, we have found 
that the exposure of IFN-α-treated KB cells to EGF did not simply induce a 
recovery of cell growth, but it also caused a proliferative effect much greater 
than that recorded in KB cells exposed to EGF alone (24). 
The involvement of the Ras->MAPK pathway in the protection of KB cells 
from the apoptosis induced by IFN-α is further demonstrated by both Ras 
inactivation by RASN17 transfection and Mek-1 inhibition by exposure to 
PD098059. In fact, the transfection of RASN17 in KB cells caused apoptosis 
as demonstrated by the FACS analysis performed on transfected cells and also 
potentiated the apoptosis induced by IFN-α. These data suggest that the 
integrity of Ras function was necessary to produce an anti-apoptotic signal 
that mediates a survival response in cells exposed to IFN-α via Erk-1/2 
activation. In fact, we have demonstrated that Ras-dependent survival 
signalling targets Erk-1/2 since the reduction of MAPK activity by PD098059 
enhanced apoptosis caused by IFN-α. An additional important finding is that 
PD098059 specifically abrogated the recovery from apoptosis induced by 
EGF in IFN-α-treated cells. A second important antiapoptotic pathway 
involves signalling via Akt/PKB (41,42). In fact, it has been demonstrated 
that Akt can be activated concomitantly or independently from Ras->Erk-1/2 
signalling by growth factors (43–45). Additionally, it has been reported that 
PC12 cells display a protective antiapoptotic pathway in response to hypoxic 
stimuli (46). The protection from apoptosis by Akt could be because of the 
regulation of mitochondrial physiology since Akt is involved in the regulation 
of bcl-related proteins such as Mcl-1 (43). However, the requirement of Akt 
for the protection from apoptotic events is highly variable depending upon the 
experimental model used (44,45,47). In our experimental conditions, we have 
demonstrated that PD098059 completely antagonized the antiapoptotic effects 
of EGF. Moreover, we have preliminarily found that the specific EGF-R-
associated kinase inhibitor ZD1839 (IRESSA) synergizes with IFN-α in 
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inducing the growth inhibition and apoptosis of several human epidermoid 
cancer cell lines, which is coupled to complete inhibition of Erk activity (A 
Budillon et al., manuscript in preparation). Therefore, our results suggest that 
the activation of Ras->Raf-1->Mek1- >Erk-1/2 signalling has a prominent 
role in the antiapoptotic effects exerted by EGF in epidermoid cancer cells 
exposed to IFN-α, providing evidence of the potential benefits of the 
molecular interference with this pathway. However, the occurrence of other 
survival pathways will warrant further investigations and we cannot presently 
completely exclude a role of the Akt pathway in the modulation of apoptosis 
of KB cells. 
Consistent with our results, additional findings have been recently reported on 
the interaction between the Ras->Erk pathway and the myc oncogene on 
apoptosis onset (48). In fact, it has been recently found that the activation of 
the Ras/Mek signalling suppresses myc-dependent apoptosis in cells with 
MAPK cascade amplification because of Ras activation (48). In our 
experimental model, we have also found increased expression of p53 and c-
myc in cells exposed to IFN-α while the EGF anti-apoptotic effects were 
paralleled by downregulation of myc and p53 expression. 
In conclusion, we have provided evidence that IFN-α makes the survival of 
human epidermoid cancer cells dependent on Ras/Erk signalling, which acts 
as a survival pathway. The specific disruption of the latter could be a useful 
approach to potentiate the antitumor activity of IFN-α against human 
epidermoid tumors as indicated by the results achieved by selective 
interference with Ras and Mek-1 function in cells exposed to IFN-α. 
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IFN-α is the first cytokine produced by recombinant DNA technology for 
clinical usage in the treatment of infectious as well as malignant diseases, 
through direct (cell growth inhibition) and indirect (immune stimulation) 
mechanisms. 
In clinical practice, IFN-α has been used in the treatment of several cancers 
(1-15). In Table 1, we provide a general overview of IFN-α activity in human 
malignancies.  
 
 
Table 1: IFN-α efficacy in human malignancies. RFS Relapse-free survival, OS 
overall survival, HR haematologic response, MS median survival 
 
    
Tumor Type Stage Clinical Effects Ref 
    
    
Melanoma adjuvant IIb, III Benefit in RFS and OS at 6.9 yrs 1 
    
Melanoma adjuvant IIb, III Benefit in RFS at 5.1yrs 2 
    
Melanoma adjuvant IIb, III Benefit in RFS and OS 3 
    
Metastatic renal cell cancer IV Benefit in 1-yr survival and MS 4 
    
Metastatic renal cell cancer IV Benefit in MS 5 
    
Chronic myeloid leukemia  Benefit in HR rate and OS 6 
    
Chronic myeloid leukemia  Benefit in OS 7 
    
Multiple myeloma  Benefit in RFS and OS 8 
    
Multiple myeloma  Benefit in RFS and OS 9 
    
 
 
 
However, the use of IFN-α treatment in oncology is limited by 3 factors: 
1. Several neoplasms are completely or partially resistant, even at high 
doses of IFN. 
2. High-doses of IFN-α produce important toxicity, and at least 40% of 
patients require dose reduction and/or recycling delay due to severe 
toxicity, such as granulocytopenia, liver toxicity, neurological 
disorders and fatigue. 
3. There are not molecular predictors of response potentially useful for 
deciding whether a patient should be treated with t
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On the other hand, the efficacy of other type I IFNs has been poorly explored. 
Few authors reported that IFN-β has greater antitumor effects than IFN-α on 
melanoma, squamous carcinoma, glioma, breast and hepatocellular cancer 
(16-20). For these reasons the first aim of the present thesis (chapter II, III, 
IV) was to analyze the in vitro effects of IFN-α and IFN-β, the role of the 
relative receptors and the mechanisms of action in the following human 
cancer cell lines: 
1. BON (neuroedocrine tumor of the pancreas) 
2. BxPC-3, MiaPaCa-2 and Panc-1 (pancreatic adenocarcinoma) 
3. H295 and SW13 (adrenocortical carcinoma). 
In all these cell lines, the IFN receptor is expressed, as shown by quantitative 
RT PCR analysis and immunocytochemistry. Besides, the antiproliferative 
effect of IFN-β seems to be clearly more potent than IFN-α. The direct 
antitumor activity of IFN-β is modulated through the induction of apoptosis 
and an accumulation of the cells in the late part of S phase. The pro-apoptotic 
activity and the cell cycle arrest after IFN-β treatment are more potent and 
earlier than after IFN-α. In adrenocortical carcinomas (chapter IV) and in 
carcinoid cells (data not shown) IFN-β could stimulate the apoptosis through 
the inhibition at transcriptional level of IGF-2 gene.  
Interestingly, the different expression and distribution of active subunits for 
type I IFN receptor (IFNAR-1 and IFNAR2-c) could predict, at least in 
pancreatic cancer cells (chapter III), the sensitivity to IFN treatment. In fact, 
at immunocytochemistry the staining for both subunits was high and mainly 
membranous in BxPC-3, the most sensitive cell line. While, Panc-1, the most 
resistant cell to IFN, showed a lower and preferential cytoplasmatic positivity 
for IFNAR-1, and about 60-70% of the cells were negative for IFNAR-2c. We 
need to confirm these data with a larger series of pancreatic cancer cell lines 
and primary cultures, but it is possible that the intensity, the subcellular 
localization and distribution of IFNs receptor could predict the response to 
type I IFNs treatment. In the case that this hypothesis will be confirmed, from 
a practical perspective, a selection of patients to treat with IFN-β could be 
decided on the basis of IFNAR-1 and IFNAR-2c positivity and localization in 
the tumor. 
The less potent effect of IFN-α compared to IFN-β could be related to the 
lower affinity for the relative receptor, but it is also possible that human cells 
have developed resistance mechanisms to avoid being killed by IFN-α, 
probably upregulating specific survival signalling pathways. In fact, IFN-α 
induces different survival pathways (fig.1) that protect tumour cells from 
different stress-producing events (i.e. viral infections). One of these survival 
pathways is mediated by phosphatidylinositol 3 kinase (PI3K) and by several 
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of its downstream targets (21). In detail, after IFN-α binding, the IFNAR-1 
subunit recruits and activates STAT-3 protein. The activated STAT-3 acts as 
adapter for PI3K, forming a final complex composed of IFNAR-1, STAT-3, 
p85 and PI3K (22). One of the targets downstream to PI3K is the serine-
threonine kinase Akt, which is important for the generation of antiapoptotic 
signals such as the phosphorylation, and consequent inactivation, of caspase-
9, Bad, and Forkhead transcription factor FKHRL1 (which modulates the Fas-
ligand gene expression). Another effect induced by IFN-α is the induction of 
the ubiquitin cross-reactive protein (ISG 15) and of two ubiquitin-conjugating 
enzymes (UbcH5 and UbcH8). A molecular target of these enzymes is the 
inhibitor of kB (IkB) protein, a cytoplasmic protein that binds and inactivates 
NF-kB. The family of NF-kB transcription factors regulates the expression of 
a wide spectrum of genes involved in immunity, inflammation, and cell 
growth, including apoptosis. Therefore, IkB degration activates Rel/NF-kB 
that triggers the transcription of genes involved in the antiapoptotic process. 
In parallel there is another survival pathway, activated by type I IFNs, called 
“noncanonical”, which involves the linkage of TNF receptor-associated 
factors (TRAFs) and NF-kB-inducing kinase (NIK) (23,24). 
 
 
 
 
Fig. 1 Escape mechanisms to the antitumour effects of IFN-α. Survival and antiapoptotic 
signalling are induced by IFN-α through the activation of different pathways. In detail, the 
following have been reported: the hyperactivation of the EGF-mediated Ras/Raf/Erk-1/2–
dependent pathway; the induction of the Akt and NFkB-dependent pathways through the 
activation of the STAT3/PI3 K–mediated signalling; and the stimulation of Shp2 that 
determines an increased response to peptide growth factors 
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You et al. (25) have studied other targets involved in the IFN-α–activated 
pathway, such as the Shp1 and Shp2 proteins. After IFN-α binding, Shp1 is 
associated to the IFN-α receptor, complexed to Jak1 and Tyk2. In this 
complex, it exercises a negative feedback by inhibiting the IFN-α–stimulated 
Jak/STAT pathways. Moreover, Shp2 has a positive effect on the mitogenic 
stimulation of Erk-1/2 and on the expression of platelet-derived growth factor 
receptor and, on the other hand, inhibits JNK under cellular stress (25). Other 
Jak/STAT pathway inhibitors have been recently identified, such as the 
suppressors of cytokine signalling (SOCS)-1 and 2 (26). These two proteins 
contain an SH2-domain and can inhibit Jak, thus playing a negative control on 
the Jak/STAT signalling. Other antiapoptotic factors are the protein inhibitors 
of activated STAT (PIAS) proteins. In detail, PIAS1 (27) inhibits the STAT-1 
DNA binding activity and the consequent induction of gene expression. 
Moreover, Ki-Ras can inhibit the expression of IFN-α–regulated genes 
providing a novel mechanism of tumour cell escape to the cytokine (28). 
In the chapter V, we showed another important survival pathway Epidermal 
Growth Factor (EGF)-dependent that IFN-α regulates in human 
oropharyngeal epidermoid carcinoma KB cell line. IFN-α is able to increase 
EGF-receptor expression and function and to activate its downstream targets 
that include the Ras/MEK1/Erk-1/2 pathway. This effect appears to protect 
the cells from apoptosis. Selective inhibition of this pathway at different 
molecular levels always results in increased apoptosis in cells exposed to IFN-
α. In fact, either the transfection of a dominant form of Ras RASN17 or the 
treatment of tumour cells with a specific MEK-1 inhibitor (PD098059) 
strongly potentiated the apoptosis induced by the cytokine, suggesting that the 
integrity of Ras function is necessary to produce an anti-apoptotic signal that 
mediates a survival response in cells exposed to IFN-α via Erk-1 and -2 
activation. An additional important finding is that PD098059 specifically 
abrogated the recovery from apoptosis induced by EGF in IFN-α-treated 
cells. Therefore, our results suggest that the activation of Ras->Raf-1->Mek1-
>Erk-1/2 signalling has a prominent role in the anti-apoptotic effects exerted 
by EGF in epidermoid cancer cells exposed to IFN-α providing evidence of 
the potential benefits of the molecular interference with this pathway. 
In conclusion, the devastating effects of IFN-β on cancer cells support the 
clinical attractiveness to use this cytokine in the treatment of endocrine and 
non-endocrine pancreatic tumors and adrenocortical carcinomas. In addition, 
tumors where the effect of type I IFNs is counteracted by escape mechanisms 
consisting in increase EGF-receptor expression and function, the activity of 
IFN could be potentiated by means of highly selective agents like the EGF-
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receptor inhibitor Gefitinib (IRESSA; Astra Zeneca, UK) or the dominant 
negative RASN17 (transfected with recombinant adenovirus). Future studies 
are necessary to evaluate in vivo these promising tools. 
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